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ABSTRACT
Despite good evidence for p53 dysfunction in human hepatocellular carcinomas, rather little is known of
the significance of p53 to normal hepatocytes, or whether p53 dysfunction has consequences that could
be relevant to early hepatocarcinogenesis. Therefore, the consequences of targeted p53-deficiency in
hepatocytes were examined for regulation of proliferation, apoptosis, ploidy and responses to DNA-
damaging agents. In order to complement and extend observations made in vivo, a method for primary
culture of mouse hepatocytes was established and evaluated. A modified form of Chee's medium gave
superior culture preservation compared with other proprietary media tested, and allowed serum-free
culture, providing liepatocyte selectivity and fully-defined conditions of culture under which the effects of
specific cytokines could be tested.
p53-deficiency was silent in normal liver and did not affect progression from diploidy to polyploidy in
the aging liver. However, in primary culture the absence of p53 resulted in increased hepatocyte
proliferation indices and decreased sensitivity to proliferation inhibition by TGFp. Moreover, p53-
deficient murine hepatocytes continued to survive and proliferate under conditions of minimal trophic
support that led to growth arrest and apoptosis ofwild type cells. In vivo, p53-deficient mice had
enhanced proliferative responses to both xenobiotic hepatomitogen and CC14-induced liver necrosis,
although lack of persistent proliferation showed that other control mechanisms are important.
There was no simple relationship between p53 and apoptosis following DNA damage, since uv
irradiation led to p53-independent apoptosis, even though p53 was stabilized and transcriptionally
activated— as assessed with a transiently transfected p53-specific reporter plasmid. By contrast, y-
irradiation injury to hepatocytes failed to produce detectable changes in either p53 immunopositivity or
transcriptional transactivation activity. Nevertheless, p53 did couple both uv and y-irradiation injury to
growth arrest, showing that agents producing different forms ofDNA damage can act differently through
p53, yet produce a common biological response. The observation has implications for how particular
dysfunctional mutations of p53 in carcinogenesis could alter hepatocyte responses to different DNA
injuries. Abnormal mitoses after y-irradiation of regenerating p53-null livers demonstrated
circumstances where loss of p53-dependent G| and G2 checkpoints may generate abnormal ploidy.
Indeed, the likelihood of mice to develop diffuse hepatic cytological atypia or morpholgically-atypical
foci in liver, after a single-dose of a hepatocarcinogen (diethylnitrosamine), was increased with
decreasing p53 gene-dose.
Thus p53 becomes important when hepatocytes are released from G0 and stressed, sensitizing them to
mitogen and cytokine regulators of cell cycle progression and apoptosis. Hence p53 deficiency is likely to
be significant in an environment of persistent regenerative stimuli and unfavorable trophic support, or in
the presence of other enabling genetic lesions. This model is relevant to human hepatocarcinogenesis,
which almost always occurs against a background of chronic hepatocellular destruction in hepatitis and
cirrhosis. In that context, by reducing the need for cytokine support and disabling DNA damage-induced
growth arrest, p53 deficiency should facilitate the expansion of preneoplastic clones in chronic liver
disease.
In summary, the 4 major findings of this thesis are that in murine hepatocytes (1) p53 sensitises
stimulated hepatocytes to cytokine regulators of proliferation and survival; (2) p53 is essential for normal
growth arrest, but not apoptosis, after exposure to DNA damaging agents (uv, y-irradiation); (3) after uv
and y-irradiation there are differences in p53 accumulation and transcriptional activation that suggest
multiple pathways to p53-dependent growth arrest after different genotoxic injuries; (4) reduction of p53
gene dose does not regulate normal nuclear polyploidisation, but after exposure to a carcinogen increases
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Many tissues grow or atrophy to meet variations in demand, and can restore deficits due
to injury. Regulated changes in cell number are critical to these activities, and are
achieved by control of proliferation, active cell death (apoptosis), and differentiation into
or away from the particular cell type. By contrast, the cancers are a group of diseases
characterised by dysregulated increases in cell number, and carcinogenesis is facilitated by
genetic lesions that relax the regulation of proliferation or apoptosis. The p53 tumour
suppressor gene regulates both proliferation and apoptosis in certain tissues, and is
commonly dysfunctional or deleted in human cancer.
The premise of this thesis was that the disease consequences of defective p53 could only
be understood for the cell type in which the studies were performed, and that different
environmental contexts could alter these consequences. The idea was to attempt to
develop a broad understanding of how loss of p53 affected proliferation, apoptosis and
carcinogenesis in a cell type relevant to human cancer, under different environmental
conditions.
The constraints of tissue specificity and relevance to human cancer required that primary
epithelial cells be studied, using the resource of p53-gene-targeted mice. Hepatocytes are
particularly suitable and interesting to study, since they are differentiated, yet
proliferation-competent, and the regulation of hepatocyte turnover is fundamental to
understanding inflammatory and neoplastic liver disease, liver failure and liver
carcinogenesis. Moreover there was evidence that defective p53 was common in human
liver cancer (although thought to be a late event) but almost no data on the role of p53 in
hepatocytes.
My reviews - written during the period of this thesis - of general aspects of apoptosis,
p53, and the relationship of p53 to apoptosis and cancer, are included as bound
submissions at the back of the thesis, and the contents are not repeated here. Therefore,
this chapter focuses on hepatocyte proliferation, apoptosis and carcinogenesis as 3 major
themes relevant to this thesis, and specifically considers the roles of the p53 protein in
these processes.
1.1.b The liver
The adult liver is composed of specialised epithelial cells and non-parenchymal cells
(including endothelium, Kupffer cells, Ito cells, fibroblasts). Together, these elements
form a structured multicellular community in which no single cell type is autonomous.
Receiving 2 blood supplies, the liver carries out unique synthetic, catabolic and regulatory
responsibilities that affect many aspects of physiology and are differentially distributed
within the liver acinus along the axis of vascular flow, producing zonal heterogeneity of
function and response to a signal. Whilst there is functional reserve, this is backed up by
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an enormous capacity to regenerate parenchyma, even after repeated insults. Conversely,
parenchymal mass decreases during states ofdecreased physiological demand, by extra
apoptosis and reduced generation of hepatocytes.
The mechanisms of liver-size homeostasis and plasticity in response to new environmental
demands are remarkably unclear. Physical constraints are important, as well as metabolic,
hormonal, and genetic factors '1'. The liver normally maintains a constant mass relative to
body weight, and may be regulated more by total parenchymal mass or volume than by
cell number. This is significant because hepatocytes are ofdifferent sizes, according to
their ploidy and whether they are binucleate cells— which contribute significantly to the
total cell population. Indeed, when the liver returns to normal size after partial excision or
after withdrawal of a pharmacological mitogen, the final cell number is not necessarily the
same as the original<2~4'.
In this section the models commonly used to study hepatocyte proliferation are described,
then the regulation ofproliferation and apoptosis are considered in turn. It is clear
throughout that the complexity is daunting, with factors often ambiguous in role
depending on context; these difficulties are compounded by differences between species,
strains and data obtained from different systems. Much new data in the field derives from
mice, whilst older material is largely from rat experiments, and the differences from
humans are often unknown. Moreover, the liver has to maintain differentiated functions
during proliferation, and it is difficult in many instances to clearly discriminate adaptive
changes during proliferation to those accomplishing the proliferative process.
1.2.a Hepatocyte proliferation
There are 4 major models used to study liver proliferation:
1.2 Hepatocyte turnover
Legend: models ofhepatocyte proliferation.
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1. Continuous basal renewal. In normal adult rat, one per 2,000-20,000 hepatocytes is
in S phase. Mice transgenic for certain hepatocyte mitogens can dysregulate this type
of turnover (e.g. TGFa-transgenic mice).
2 Compensatory hyperplasia after 70% partial hepatectomy (5) The 2 major liver
lobes are ligated and removed without disturbance to the remainder. The residual liver
lobes increase in size to restore liver mass; the original anatomy is not restored and
thus regeneration is not an appropriate term. There is no significant inflammation or
necrosis, beyond that related to the small surgical incisions to access the peritoneal
cavity. Thus, this model does not reflect the circumstances producing hepatocyte
proliferation in human disease processes (bar surgical resection). Nevertheless, this is
an exceptional model system of semi-synchronised response to a proliferative
stimulus: in rats, DNA synthesis begins after 12-16 hours and peaks at about 24
hours. For individual hepatocytes, S phase lasts about 8 hours; G2 4-6 hours; mitosis
30-60 minutes. In the first 35 hours most hepatocytes undergo one cell cycle; for
those entering a second cycle, Gi only lasts 6-8 hours. The majority of liver mass is
restored within the first 72 hours, and is completely restored by 7-10 days, after
which quiescence resumes. In mice, the peak ofDNA synthesis after partial
hepatectomy may occur a little later than in rats, at about 36 hours (6'7).
3. Regeneration after cytotoxic injury (e.g. viral infection, drug, ischaemia, immune
attack, metabolic injury). Hepatocytes are destroyed, with or without non-
parenchymal cell damage, and replaced by proliferation of neighbouring hepatocytes.
This model recapitulates more closely than partial hepatectomy the pattern of
damage-regeneration of human hepatitis and cirrhosis. A difficulty is to discriminate
changes specifically related to the insult from those pertaining to the regeneration
process.
A standard version of this model is CCl4-induced hepatocyte necrosis: intraperitoneal
injection of CC14 produces acute swelling and degeneration of hepatocytes in the
central regions of lobules (acinar zone 3)(8>. This is followed by necrosis that is fully
developed by 24 hours, then by regeneration and restoration of the normal liver
anatomy within 3-7 days. By contrast with partial hepatectomy, damaged regions of
lobules are repaired, but no new hepatic lobules are formed.
Unlike the acute necrosis produced by CC14, some transgenic mice have chronic, low
grade hepatocyte destruction that stimulates continuous regeneration (e.g. mice
expressing the Hepatitis B surface antigen transgene in hepatocytes <9)).
4. Primary hyperplasia. Exogenous mitogen causes hepatocytes to proliferate without
the stimulus of tissue loss, by contrast with 2 and 3 above. As a result, liver mass
increases. This model is also used to investigate hepatocyte apoptosis, which
increases after withdrawal of the mitogen, during the return to normal of liver mass
(the regressing liver model).
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One further model that is not well developed is that of altered
polyploidisation/binucleation. The majority of the postnatal increase in mouse liver weight
is not due to increase in cell number, but increased cell size related to binuclearity
(through acytokinetic mitosis) and polyploidy <2). Without these processes the total
hepatocyte number would need to be considerably increased to achieve a normal liver
mass.
1.2. a. 1 Hepatocyte neoformation
Hepatocytes are unusual in that they are differentiated cells, yet capable of proliferating,
and they are the normal source of new hepatocytes in adult liver. Hepatocytes are long-
lived (over 2 years in rats and mice (10)), so turnover is very low. There is a diurnal
variation in proliferation rate, related to feeding (1U2).
The proliferating hepatocytes in normal liver are distributed in a sporadic, fractal manner
(13). They produce microclones of daughter cells that are recruited into adjacent hepatic
plates (14). The fractal pattern of proliferation is retained after partial hepatectomy (15),
until sufficiently extreme resection stimulates virtually all residual hepatocytes to undergo
practically synchronous DNA synthesis <l6>. Indeed, the liver has an enormous capacity to
restore itself (17'18): after serial partial hepatectomies, rodent hepatocytes can undergo 12-
20 consecutive cell cycles (potentially producing over 1 million cells from each parent
cell) (15'18J9).
A second source of new hepatocytes is multipotential cells around portal tracts and in bile
ductules, and whose progeny (oval cells) can differentiate into hepatocytes, biliary
epithelium or even intestinal or exocrine pancreatic epithelium. <20). These multipotential
cells may represent facultative stem cells, whose contribution to hepatocyte neoformation
is normally negligible but can be made significant if hepatocyte regeneration is prevented
— for example by 5-AAF treatment — in combination with a strong stimulus to
regenerate, such as partial hepatectomy (2tl~23). in these experiments many oval cells die by
apoptosis and it is difficult to prove a contribution to hepatocyte formation, but
hepatocyte neoformation from oval cells is now accepted by most investigators (1(l-2()-22)
Oval-like cells have been reported in human liver disease (24), however, their significance
outside of special experimental circumstances is uncertain.
1.2.a.2 Molecular-genetic changes in hepatocytes after partial hepatectomy
The sequence of events linking excision of liver lobes (partial hepatectomy) to
recognition and response initiation by hepatocytes in the remaining lobes is unknown.
Nevertheless, specific changes occur in hepatocytes within minutes ofPHx that will now
be described.
The earliest molecular-genetic events after PHx do not require synthesis of new proteins
and are accomplished through the rapid activation of preexisting cytoplasmic
transcription factors that translocate to the nucleus, bind DNA and transactivate target
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genes (defined as primary response genes or immediate early genes). Two candidate
transcription factors to initiate immediate early gene transcription in hepatocytes are NF-
kB and STAT3.
NF-acB activity peaks and subsides to almost normal within the first hour after partial
hepatectomy(25). NF-/cB is the prototype of a family of dimeric proteins, formed by
products of the rel oncogene family. The active form is a p50/NF-/cBl-p65/RelA
heterodimer, that is activated by dissociation from an I/cB inhibitor. Several cytokines or
mitogens can activate NF-/cB, ofwhich TNFa may be important in liver regeneration
(26,27)
targets 0fNp./cB after partial hepatectomy are undefined but probably include
genes maintaining a differentiated phenotype, such as those involved in gluconeogenesis,
also constitutive hepatocyte transcription factors such as the C/EBPs (CAAT enhancer
binding proteins)(28>29).
STAT 3 (signal transducer and activator of transcription) shows increased DNA binding
activity within 30 minutes after partial hepatectomy, and this is sustained until 5 hours.
STAT 3 may therefore contribute to induction of a subset of immediate early genes that
are induced over a prolonged period during Gi. IL-6 and TNFa are activators of STAT3
that are likely to be important after partial hepatectomy, and appear to be required for a
normal proliferative response (27 30). STAT 3 is also activated by cytokines such as IL-1,
and by the hepatomitogen, EGF (29>. Immediate early gene targets of STAT 3 after partial
hepatectomy may include c-jun, c-myc and c-fos— involved in progression through Gi.
Hepatocytes induce expression of at least 70 immediate early genes within a couple of
hours after partial hepatectomy (31). The transition from quiescence (G0) to early Gi has
been defined by the appearance of certain of these gene products. The immediate early
genes include members of several transcription factor families (e.g.jun-fos, LRF-1, rel,
nuclear receptors, helix-loop-helix and zinc finger families). The Jun and Fos families are
probably important inducers of delayed early gene transcription through the AP-1
(activator protein) transcription factors formed by their products; individual members
show different patterns of activity during Gf for example, c-fos, c-jun, junB and junD are
expressed, but not fra-l,fra-2 orfosB (32). Jun is essential to hepatogenesis —
c-jun-deficient embryonic stem cells do not contribute to liver in chimaeras, by contrast
with all other somatic cell types <33> — and these gene families are probably essential for
regulation of hepatocyte proliferation and phenotype during regeneration. Other
categories of immediate early gene are still poorly understood, but intriguingly include the
hormone and potent hepatomitogen EGF (34)). It is of interest that maximum activity of
c-jun is probably dependent on early TNFa stimulation of hepatocytes (35), illustrating
that external stimuli can both trigger and modulate the immediate early response.
Approximately one third of immediate-early genes induced after partial hepatectomy is
induced only in the hepatocytes. A proportion is part of an adaptive response to maintain
metabolic homeostasis (e.g. increased gluconeogenesis) in the face of tissue loss, rather
than having primary involvement in proliferation. This reflects that for the hepatocyte to
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combine dual roles of differentiated function and proliferation requires intimate co-
regulation of these activities(36). Indeed at least some immediate early genes probably
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Figure I. Gene expression after partial hepatectomy (the bottom axis indicates hours after resection). Sequential
activation ofgenes during Gi provides multiple opportunities for strict control ofhepatocyte proliferation, by
ultimately regulating activation ofGj cyclins to start the irreversible step ofDNA synthesis. Adaptedfrom
4V
Many of the immediate early gene products are themselves transcription factors, so they
in turn induce a set of secondary response genes (delayed early genes, including p53), in
an amplifying cascade of transcription events during progression through Gi to S phase.
Specific and sequential expression of certain oncogenes and other cell cycle related genes
has been defined and correlated with the onset ofDNA synthesis and mitosis in the liver
remnant (Figure 1). The significance for the regulation ofentry to DNA synthesis by
hepatocytes will now be discussed.
1.2.a.3 Regulation ofmitogen responsiveness ofhepatocytes
The identification of specific, sequential gene transcription in the interval between partial
hepatectomy and DNA synthesis shaped the idea of regulated progression from
quiescence to a point where hepatocytes became irreversibly committed to DNA
synthesis. The observation that quiescent hepatocytes in normal liver were refractory to
mitogen stimulation ofDNA synthesis, but became responsive after stimuli insufficient by
themselves to produce significant proliferation (30% hepatectomy or low dose hepatic
collagenase perfusion<4X'491), led to the concept ofunresponsiveness that needed
"priming", and the proposal of2 key stages in the pre-replicative period after partial
hepatectomy (43,44): during the first 4 hours (characterised by c-fos, c-jun and c-myc
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expression) hepatocytes enter Gi and become "competent" to respond to mitogen
stimulation ("primed"). Thereafter "progression" occurs, controlled by paracrine or
autocrine mechanisms, correlating with transit from mid-Gi to S, and marked by
increasing p53 expression, ras expression coincides with the start of replicative DNA
synthesis and the period to mitosis.
Thus priming was conceived as a permissive process for mitogen responsiveness, whilst
commitment to DNA synthesis was assumed to occur during progression. The model
allowed for a ready but easily reversed stimulation of hepatocytes into the primed state
from which the likelihood of subsequent proliferation was tightly regulated by
environmental factors. In culture, hepatocytes become unresponsive to mitogens after a
few rounds of cell division, requiring replating or pharmacological agents (e.g. DMSO) to
regain sensitivity (50); this implies a cell internal regulator of the primed state that needs
"refreshing" periodically, to maintain a mitogen-responsive state.
Loyer has used a primary culture model, in which similar genetic changes occur as
following partial hepatectomy, to define a mitogen restriction point in mid-late Gi (42-
48 hours after isolation) (51>. Hepatocytes require mitogen (EGF or TGFa) to progress
beyond this point and begin DNA synthesis; without mitogen, they growth arrest. Thus
commitment to DNA synthesis must occur after the mitogen restriction point.
Although rather more poorly understood than soluble regulators of cell cycle progression,
cell-matrix interactions through specific receptors (e.g. integrin receptors) regulate
priming events in early Gi, while alterations in cell shape (itself determined by cell-cell
and cell-matrix interactions) may regulate progression through late Gi phase <52-53). The
interactions can have a comitogenic or inhibitory effect on hepatocyte proliferation (52 55).
These factors may be particularly relevant to true regeneration (i.e. tissue damage), in
which there are additional but little understood signals such as local electrolyte and
metabolic abnormalities, with altered cell-cell and cell-matrix contact (52-56).
1.2.a.4 Molecular genetic events in other models of regeneration andprimary
hyperplasia
Regenerating liver after CCU injury shows the same sequence and similar time course of
expression of c-jun, c-fos, c-myc, p53, c-Ha ras and c-Ki ras as occurs after partial
hepatectomy (41-57_62) These changes start in the lethally-damaged hepatocytes (in the
centers of lobules) 2-3 hours earlier than in the remainder, suggesting that the response to
injury overlaps with the immediate early events of proliferation (63). Kubin reported that
mdm-2 expression peaked 12 hours after CC14 injury (just before the onset of necrosis)
but did not increase after partial hepatectomy, and interpreted the increase as a response
in the injured cells to the drug-induced damage (57). TNFa is an important stimulus of
hepatocyte c-fos and c-jun expression after CC14 injury— just as after partial
hepatectomy — and is necessary for rapid repair and regeneration (26).
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Thus, despite the differences in the initial insult, partial hepatectomy and CCI4 treatment
have very similar effects on cell cycle-related gene expression in the residual hepatocytes.
By contrast, hepatocyte injury producing oval cell proliferation (Galactosamine
treatment, or 5-AAF pretreatment before CC14) showed a different pattern of oncogene
expression: there was delayed and prolonged expression of c-myc, c-fos and c-jun,
despite livers showing similar kinetics ofDNA synthesis (62).
Hepatocyte hyperplasia produced by xenobiotic mitogens involves different signal
transduction and transcriptional events from those after CCI4 or PHx (64-65). The particular
pathways vary, depending on the chemical class ofmitogen. Some mitogens may act
through non-parenchymal cells, for example by stimulating TNFa release (64'66). However,
in general, whilst hyperplastic DNA synthesis is followed by increased expression of c-
ras, there is no preceeding increased expression of c-jun, c-fos or c-myc, suggesting that
immediate early gene activation is not necessary for hepatocyte cell cycle entry
(60,61,64,65,67) Q^gj. differences with post-hepatectomy proliferation include the occurrence
of increased apoptosis in hyperplastic growth.
The molecular genetic differences between these models have biological significance:
induction of regenerative DNA synthesis is commonly used to fix the DNA damage
produced by a liver carcinogen, whereas hyperplastic DNA synthesis cannot fulfill this
purpose <68'69) (see section below). Taken together, these models increase understanding
of the complexities regulating hepatocyte proliferation, but show a need to select relevant
models when attempting to understand human disease processes.
1.2. a. 5 Late cell cycle events: acytokinetic mitosis andpolyploidy
Hepatocyte binuclearity and polyploidy are features of normal adult liver growth,
developing after weaning (2). In mice, hepatocyte polyploidisation occurs to a relatively
high degree, predominantly through repeated rounds of acytokinetic mitosis to produce a
binuclear cell, followed by nuclear fusion (thus doubling cell ploidy) in a subsequent cell
cycle (Figure 2) (2). By contrast, regeneration is non-binucleating: after partial
hepatectomy, mitoses temporarily become cytokinetic, so the proportion of binuclear
cells in the liver remnant decreases. However, average nuclear ploidy increases because
cytokinetic mitosis of the binuclear cell population produces mononuclear cells of
increased ploidy (Figure 3)(16,64). Once liver mass is restored, the normal pattern of cell
division resumes, and the proportion of binuclear cells slowly increases. By contrast with
regeneration, hepatocyte hyperplasia produced by certain xenobiotic mitogens can be
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Figure 2. The evolution ofpolyploidy in hepatocytes. Acytokinetic mitosis is followed in the next cell cycle by
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Figure 3. The change from polyploidising (acytokinetic) to non-polyploidising (cytokinetic) proliferation during
liver regeneration.
Acquisition of a polyploid nuclear DNA content is an irreversible event that involves
modulation of centrosome replication, and of the normal couplings of S to M phase and
M phase to cytokinesis. The observations described above show that proliferating
hepatocytes are capable of reverting to normal cytokinesis, suggesting that
polyploidisation is specifically regulated. Binuclear and polyploid hepatocytes are less
sensitive than diploid cells to physiological mitogens (EGF, insulin)<70), and are less likely
to go through multiple cell cycles during liver regeneration. Thus mice transgenic for
hepatic mitogens often show a relative preponderance ofdiploid cells <7,'72). However,
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both the regulation and the significance of polyploidy are still rather poorly understood
C73-76) jt js p0SSj[]3ie ^at polyploidising growth protects against the development of
neoplasia, through increased gene copy number (reducing the consequences of allele
mutation) or reduced capacity to proliferate. Indeed, preneoplastic nodules and
carcinomas in experimental carcinogenesis, human focal nodular hyperplasia and
hepatocellular carcinomas all show a predominance of diploid, non-polyploidising
hepatocytes (3'77). The switch to cytokinetic division during regeneration might preserve
the liver's capacity for self-renewal.
1.2.a. 6 Extracellular regulators ofhepatocyte proliferation
Mitogens & comitogens
Critical experiments showed that there are signals producing hepatocyte proliferation
after PHx, which:
1. begin within minutes (or, at least, there are electrophysiological (78"80> and biochemical
changes in residual hepatocytes).
2. are specific to liver, because no proliferation occurs in other organs (except a small
increase in DNA synthesis in exocrine pancreas (81)).
3. are blood borne, because there is concomitant proliferation of hepatocytes placed in
other body sites (tissue engrafts (82) and transplants of isolated hepatocytes (83)).
Moreover, the blood of normal rats is not mitogenic, but the blood of a rat subjected
to partial hepatectomy stimulates DNA synthesis in normal rat liver maintained in
parabiotic circulation (84'85).
4. involve blood-borne stimuli of extrahepatic origin, because when rats are maintained
in parabiotic circulation, removal of the liver from one rat induces DNA synthesis in
the other (84'85).
Although foetal hepatocytes continue to proliferate for a few days in culture (86), primary
cultures of adult hepatocytes require mitogen stimulation to proliferate. Culture studies
on primary hepatocytes maintained in chemically-defined medium have led to a
categorisation of mitogens as "complete" (those that stimulate hepatocyte DNA
synthesis) or "co-mitogens" (those that do not themselves stimulate DNA synthesis but
that increase the effect of complete mitogens). The term "complete" is slightly
misleading since these factors have little effect on hepatocyte proliferation in quiescent
liver, but efficiently stimulate DNA synthesis in primed hepatocytes.
Many agents have been reported to stimulate hepatocyte DNA synthesis, but only a few
have been shown to be important in vivo, and there are conflicting reports or only
associative data for several others (87). Interspecies differences (for example with
vasopressin <88'89) and members of the fibroblast growth factor family (90)) account for
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some discrepancies, and illustrate the difficulties of cross-species comparisons. Table 1
lists hepatocyte mitogens commonly recognised to be important in vivo. Table 2 lists co-
mitogens; other comitogens, such as angiotensin IIt91), neurotensin (92), hepatopoietin B
(93), remain uncharacterised or of uncertain importance in vivo, whilst many hormones
reported to facilitate DNA synthesis (pineal, oestrogens, glucagon) may only do so as a
side-effect of their general stimulation of cellular metabolism (l'87). Still others, such as
IGF-1, have only been shown to stimulate proliferation in co-culture
Complete mitogens. References.
Epidermal growth factor (EGF) (94)
Hepatocyte growth factor (HGF) (72)
Transforming growth factor a (TGF a) (95)
Tumour necrosis factor a (TNF a) (26)
Table I. Complete hepatocyte mitogens
Hepatocyte co-mitogens References.
Hepatic stimulator substance (HSS) to
Insulin (96)
Interleukin 6 (IL6) (30,97)
Noradrenaline (96)
Table 2. Hepatocyte co-mitogens.
Proliferation signals can be delivered to hepatocytes by hormonal (EGF), paracrine
(F1GF) or autocrine (TGFa) mechanisms. Of course, these factors do not act in isolation
and their effects are titrated against existing gene expression and micro-environmental
influences. Transgenic and gene-targeted mice are now a major resource to show how the
factors act in vivo, and what are the consequences of their dysregulation. This section
briefly describes factors thought to be the major players regulating and perhaps initiating
hepatocyte proliferation.
Hepatocyte growth factor (HGF) is a pleiotropic epithelial cell mitogen and the most
potent hepatocyte mitogen. In liver, HGF is secreted by Ito cells and so probably acts in
paracrine fashion, binding the specific receptor product of the c-met oncogene (98). During
liver regeneration, release ofHGF by the Ito cells may be stimulated by the cytokine
interleukin-6. HGF injection accelerates regeneration, and after a prolonged infusion even
induces proliferation in quiescent liver (99). Transgenic mice that overexpress HGF have
twice the normal baseline rate of hepatocyte proliferation, although little increase in
liver:body weight ratio, suggesting a shorter hepatocyte lifespan <72). The transgenic
hepatocytes continuously express c-jun and c-myc, suggesting that HGF helps to prime
hepatocytes, and there is a relative increase in diploid hepatocytes, in keeping with the
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increased cell proliferation (see polyploidy above). Indeed, HGF-transgenic mice recover
from partial hepatectomy in half the time of controls. Despite increased proliferation,
there is no increased susceptibility to hepatocellular carcinoma, in keeping with data that
HGF suppresses proliferation of several hepatocellular carcinoma cell lines (100).
Homozygous targeted germline-deletion of c-met or HGF is embryonic lethal; however,
the embryos show up to 55% reduction in liver size, consistent with a critical role for
HGF in hepatogenesis as well as proliferation of differentiated hepatocytes(101).
Transforming growth factor-a (TGFa) and epidermal growth factor (EGF) share
the same receptor (EGFR) which, like the HGF receptor, is a receptor tyrosine kinase.
Young TGFa-transgenic mice have enlarged livers with increased hepatocyte
proliferation rates (71). They also have an increased proportion of diploid hepatocytes —
the ploidy population most responsive to growth factor stimulation (see polyploidy
above). Like HGF-transgenic mice, the peak ofDNA synthesis after partial hepatectomy
is increased, suggesting increased numbers of hepatocytes responding (or greater
synchrony). By contrast with HGF-transgenic mice, the interval to DNA synthesis is not
shortened, suggesting TGFa may not actually prime hepatocytes, but act later in Gi.
The hepatomegaly of TGFa-transgenic mice resolves later in life due to increased
hepatocyte apoptosis (i.e. shorter lifespan), that may in part relate to the development of
chromosomal abnormalities and aneuploidy in a high proportion of hepatocytes. At 12-15
months 75% of TGFa-transgenic mice develop hepatocellular carcinomas, in striking
contrast to HGF-transgenic mice. The reason for this difference is not clear. In primary
culture, TGFa-transgenic hepatocytes readily replicate continuously without
transformation, and maintain a differentiated phenotype <1<)2).
TGFa-null mice show no liver abnormalities and regenerate normally <103'104)i presumably
reflecting redundancy with EGF. However, the converse does not hold: the major source
of circulating EGF in rodents is the salivary gland; excision of the salivary glands or
ligation of their venous drainage in rats delays and reduces the peak ofDNA synthesis
after partial hepatectomy, suggesting that endogenous TGFa secretion is insufficient to
compensate (105). This does not affect immediate-early oncogene expression in the liver
remnant (c-jun, c-fos, c-myc), further suggesting that EGFR signalling acts later in Gi to
permit DNA synthesis. Interestingly, in chimaeras, EGFR-homozygous-null embryonic
stem-cells contribute to formation of hepatocytes in the neonate but not adult(106). This
implies that EGFR signals are required for growth of postnatal but not embryonic liver.
As described earlier, EGF is an immediate early gene of hepatocytes, but the significance
of this observation is unknown.
Noradrenaline (Nor). Stimulation of hepatocyte ai-adrenergic receptors causes
downregulation of the growth arrest specific gene gas-6 in the first 4 hours after partial
hepatectomy, and is necessary for the normal peak ofDNA synthesis to occur (93'107 I09>
Noradrenaline stimulation of hepatocytes is also an effective antagonist of proliferation
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inhibitors such as TGFPi or activin (11(U11). Thus, although still little understood, there is
good evidence for neuroendocrine modulation of liver regeneration.
Inflammatory cytokines. In human liver disease, hepatocyte proliferation usually occurs
in a context of inflammatory destruction, in a micro-environment rich in inflammatory
cytokines. These molecules might be expected to influence hepatocyte proliferation and
the two cytokines thought to be most important to liver regeneration are tumour
necrosis factor-a (TNFa) and its inducible cytokine, interIeukin-6 (IL6). TNFa and
IL6 are released by macrophages, monocytes and endothelial cells after tissue injury or
exposure to toxins such as bacterial endotoxin (514). Indeed, normal liver is probably
continuously exposed to low concentrations of these cytokines, due to various gut
bacterial and other toxins in portal blood. Several lines of evidence show that
inflammatory cytokines are important to liver regeneration:
1. Animals with deficient inflammatory or immune environments show retarded liver
regeneration: for example, pathogen-free rats, which lack gut bacterial endotoxin (112),
or p2-microglobulin-deficient mice, which lack MHC class I and CD8 T cells <1L,).
Mice lacking endotoxin-responsive macrophages show decreased secretion ofTNFa
and IL-6 after partial hepatectomy, and have retarded liver regeneration (114).
2. IL6-deficient gene-targeted mice have severely impaired liver regeneration, leading to
necrosis and liver failure. This is associated with decreased activation of STAT3 and
decreased immediate early gene expression (AP-1, myc and cyclin D) after partial
hepatectomy. These biochemical and regenerative defects are corrected by a single
dose of IL6, which also promotes DNA synthesis in cultured hepatocytes (97). TNF
receptor I-deficient mice have similar defects in activation of transcription factors
STAT3 and AP-1 after partial hepatectomy, with reduced hepatocyte DNA synthesis
(27). These defects are partially corrected by IL6 (NFkB remains inactive), illustrating
the degree of overlap between cytokine signal pathways.
3. TNFa promotes DNA synthesis in primary cultures ofmouse hepatocytes (115>116) and
enhances EGF-induced hepatocyte DNA synthesis (117>. In vivo, TNFa rapidly
activates NF-kB (25), and is necessary for increased expression of immediate early
genes (c-fos, c-juri) and for increased DNA synthesis after CC14 injury (26) or partial
hepatectomy (35'118). Intravenous infusion ofTNFa into healthy rats increases
hepatocyte proliferation and liver mass (119'120).
Taken together, the data suggest that TNFa and IL6 prime hepatocytes for proliferation,
and are important for initiation of the regenerative response. Although most reports use a
post-hepatectomy model, these cytokines might be expected to be even more relevant to
inflammatory-necrotic regeneration such as in lobular hepatitis.
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Signal integration (Figure 4). Cytokines such as TNFa, IL6, y- and a-interferon bind
different receptor types from the receptor tyrosine kinases binding HGF, EGF and TGFa;
however, there are potential common targets for mitogen and cytokine signal
transduction pathways: for example, the STAT transcription factors implicated in
immediate early gene activation after partial hepatectomy, and the stress-activated protein
kinases (e.g. jun kinase) that in some cell types mediate growth arrest responses to
cytokines or uv-irradiation<36). Such cross-talk allows orchestrated reprogramming of
hepatocyte gene expression to balance regenerative demands with general metabolic
requirements, participation in the local acute phase response to injury, and the need to
perform systemic tasks such as synthesis of acute phase proteins (,2II22).
HGF, EGF/TGFct, HSS
C D E F
taraet aenes
Figure 4. Cartoon illustrating interaction and overlap between mitogen and cytokine signal transduction pathways
to influence expression ofoverlapping sets of target genes. The overlap allows redundancy between signals, and
interactive effects that are qualitatively different from the individual contributions. (36>I22'123\
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Extracellular inhibitors of proliferation (restoration & maintenance of
quiescence)
The regenerative response stops abruptly when liver mass has been restored. This has
been interpreted to imply an important role for specific extracellular inhibitors of
hepatocyte proliferation. At the same time, however, it is usually implicitly assumed that
the "default" state of hepatocytes is replicative quiescence and that stimulation is required
to cause proliferation. There is thus the expectation that the system returns itself to
quiescence when no longer stimulated. In fact, hepatocyte proliferation in the presence of
a mitogenic stimulus is self-limited, presumably by cell-intrinsic properties: thus in culture
adult primary hepatocytes become refractory to mitogen stimulation after 2-3 rounds of
cell division, unless "reprimed" periodically by replating or temporary exposure to
pharmacological agents such as DMSO or phenobarbital(50,124). Investigators have
regarded this phenomenon as one of "inadequate" (unphysiological) culture conditions
preventing continuous replication; however, the observation is entirely compatible with a
simple stimulus (mitogen) producing perturbation (cell cycle) but with inevitable return to
the set point by a self-organising system (see below)(125). Mice transgenic for growth
factors demonstrate the same phenomenon: although there may be increased basal
proliferation rates, almost all hepatocytes are still not proliferating (although capable, as
demonstrated after partial hepatectomy); the increased proliferation seen is entirely in
keeping with such a self-limited response to mitogen at the individual cell level. Certainly
there is no evidence that soluble growth inhibitors are involved in maintaining
refractoriness to mitogens in quiescent liver, or are necessary for resumption of
quiescence, or indeed are capable of maintaining quiescence after partial hepatectomy,
and such hypotheses seem a rather unnecessary overcomplication in this cell type.
It is possible that quiescence in the adult hepatocyte can be understood in the terms of a
self-organising system (l25). In a self-organising system, perturbation is followed by
oscillations but eventual return to the default state — a so-called stable setpoint or
stable limit cycle in state space (state space represents all the possible changes in the
system). Cell cycle progression and checkpoints are perhaps best understood using such
models (125 126) in hepatocytes, replicative quiescence may represent a stable set point in
state space. Stimuli to proliferate produce or represent perturbations that push the system
away from the stable state (into cell cycle). This is sufficient to generate some cycles in
culture but ultimately quiescence resumes as the system returns to the stable state. There
is thus no need for cell-external antiproliferative influences because the oscillations are
necessarily self limited. Nevertheless, some situations may demand suppression of
proliferation that would otherwise occur, and therefore require that specific extracellular
inhibitory influences can be brought to bear. These will now be discussed.
Extracellular regulators
It is of interest that factors that inhibit hepatocyte proliferation all have other important
functions in the regenerating or inflamed liver; it is possible that anti-proliferative actions
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on hepatocytes are not their primary effect. Moreover, these agents cause only temporary
growth arrest in mitogen-stimulated hepatocytes, rather than resumption of quiescence,
and none is able to prevent liver regeneration. Table 3 lists factors shown to suppress
mitogen-stimulated entry to DNA synthesis in primary culture. At present, only TGFpi is
widely recognised to be important. Some of these factors will now be discussed.
Mito-inhibitor. References.
Transforming growth factor B fnf (88)
Activin A (127)
Interleukin 1(3 (128)
Hepatic proliferation inhibitor peptide (129)
y interferon (116,130)
Table 3. Physiological inhibitors ofhepatocyte proliferation.
TGF/3,
Three TGFp isoforms are produced in liver, although most is known about TGFPi.
TGFP1-3 delivery to hepatocytes during liver regeneration was thought to be paracrine
031', however, recent work shows that TGFp expression can occur in hepatocytes as well
as Kupfifer cells, hepatic endothelium and Ito cells, and favours autocrine delivery as the
major mechanism during liver regeneration 1 lj2~l34). Extracellular TGFp is normally
inactive, sequestered by matrix binding proteins that control its bioavailability or
complexed to latency associated peptide on cell surfaces; the mechanisms of activation on
the hepatocyte surface are multistep and poorly understood, but may involve altered
interaction with the IGF-2 receptor (lj2).
The TGFp receptors are serine-threonine kinases, but the post-receptor events leading to
growth arrest in hepatocytes are not well-defined. In epithelial cell lines, TGFPi activates
inhibitors of cyclin-dependent kinases (p27k,pl, pl5ink2B and p21WAF1) to prevent
activation of the Gi cyclins and subsequent Rb phosphorylation (,35~l38). This produces
growth arrest in late Gi phase. Similar inhibition of pRb phosphorylation has been shown
in TGFPi-treated liver remnants after partial hepatectomy, and induction ofp21WA"
expression by TGFPi has been demonstrated in primary hepatocytes (7-137 l39). TGFPi does
not alter hepatic expression of c-myc or p53 (l); however, in other cell types p53 function
is important for effective TGFpi growth arrest(140), due to a co-operative but distinct
• • i WAF1 (141,142)action on p21 v .
TGFp i is the most potent inhibitor of hepatocyte DNA synthesis produced by different
mitogens, for example, EGF or TNFa (ll5-l43). In vivo, TGFPi produces a dose-dependent
reduction in the proportion of hepatocytes entering S phase if given 11 hours after (but
not if only administered simultaneously with) partial hepatectomy, suggesting it induces
growth arrest in late Gi, in keeping with an effect on pRb (,()4144). Flowever DNA
synthesis is only postponed (from 22 to 72 hours), and cannot be further blocked by more
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TGFPi. The rise in ai adrenergic receptor stimulation after partial hepatectomy inhibits
the anti-proliferative effects of TGFpi(U0).
TGFPi activity is negligable in normal adult liver, suggesting it has no role in maintenance
of quiescence. Transgenic mice expressing TGFpi show liver fibrosis, increased
hepatocyte apoptosis and increased hepatocyte proliferation. The proliferation is probably
secondary to the other hepatic disturbances, but shows that even supraphysiological
autocrine and paracrine TGFPi expression is insufficient to stop hepatocyte regeneration.
TGFPi homozygous-knockout mice die with systemic inflammatory disease within a
couple of weeks of separation from sources ofmaternal TGFPi (placenta and milk).
However there is no drastic change in liver function and no evidence of abnormal
proliferation <32). Thus the role ofTGFpi in the downregulation of hepatocyte
proliferation, although universally cited as important, may be rather limited and less
critical than other activities, for example, liver fibrosis and angiogenesis (132).
Activin A
Activin-A is an autocrine product of hepatocytes that binds a specific receptor and
inhibits mitogen-induction ofDNA synthesis in primary culture (l27). Hepatocytes (and
other cell types) also secrete follistatin, which binds and inhibits the actions of activin-A
(111). The importance of activin-A for hepatocytes in vivo is unknown — infusion delays
regenerative DNA synthesis, whilst follistatin administration accelerates regeneration
after partial hepatectomy, suggesting some endogenous activin activity (145). Although
activin-A is a member of the TGFP superfamily, it does not compete with TGFP for
receptor binding.
Interleukin 1(3
The TNF-inducible cytokine interleukin 1P also decreases mitogen-induced DNA
synthesis in culture, although less effectively than TGFPi<128).
y-interferon (ylfn)
ylfn receptors are expressed by hepatocytes in diseased but not normal liver<146). ylfn is
produced by activated T cells, and may be involved in immune hepatic injury (see
hepatocyte apoptosis). In primary culture, ylfn suppresses the induction of hepatocyte
DNA synthesis by mitogens (115'130( but whether this is important in vivo is not known.
Intracellular regulation
C/EBPa. Expression of the C/EBPa transcription factor decreased mitotic activity in a
hepatoblastoma cell line, and is reduced during liver regeneration (147). It is possible that
upregulation ofC/EBPa is important to restore quiescence, and although little is known
about its regulation, p53 or pRb are not required (147). Quiescence-associated genes such
as gas-6 are downregulated at the start of regeneration, however any role in the
restoration of quiescence is not understood {27).
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p21WAF1 is a cyclin-dependent-kinase inhibitor that arrests eukaryotic cell cycle
progression at multiple points, including late Gi. p21WAI1 rnRNA concentration is very
low in normal liver, but increases after partial hepatectomy during Gi and again after S
phase (7,148). The importance of p21WAF1 to downregulation of liver growth, at least when
expressed at high levels, has been shown in mice bearing a liver-specific p21WAF1
transgene (149). The mice had small livers with hypoplastic lobules and did not show the
normal compensatory hyperplasia of remaining lobes after partial hepatectomy. p21WAI 1 is
activated by a variety of upstream signals, including p53, however the post-hepatectomy
increase occurs in p53-deficient mice and so is p53-independent(7). Sawada found that
cultured hepatocytes from aged mice were more likely than those from young mice to
express p21WAF1 protein during late Gi phase, and has suggested that this accounts for the
age-related reduction in the capacity of hepatocytes to proliferate (150). Extracellular
stimuli that increase p21WAF1 mRNA concentration in cycling hepatocytes include protein
deprivation (by a p53-dependent mechanism), TGFPi and activin-A(7).
In summary, no extracellular physiological inhibitor can prevent liver regeneration or
induce quiescence. Defects in mitogens (eg Brattleboro rat(88), IL-6 deficiency <30)) have
more profound consequences for reduced liver regeneration than excessive levels of
TGFP — perhaps illustrating the intrinsic bias of liver homeostasis towards quiescence.
1.2.b Hepatocyte apoptosis
Many of the same players are identified as regulators of hepatocyte death, proliferation,
proliferation-inhibition and acute phase responses; the context appears to determine how
a particular change in stimulation affects hepatocytes. It is therefore relevant that culture
studies are assessing hepatocytes in cell cycle, in contrast to studies of hepatocytes in
vivo, where this is not always the case.
1.2. b. 1 Occurrence in normal adult liver
Hepatocyte apoptosis is rare in the normal adult liver and has a prevalence of 0.001-
0.005% in mice or rats (151>. The incidence of apoptosis shows a circadian rhythm in
rodents, being reduced after feeding (152). Apoptotic hepatocytes are rapidly engulfed by
Kupffer cells, sinusoidal endothelium and adjacent hepatocytes; this is the form in which
they are usually identified in tissue sections. The mean duration of histologically
appreciable hepatocyte apoptosis was estimated to be 169 minutes (95% CI 137 - 222
minutes) and found to be similar for hepatocytes of preneoplastic foci(153). The apoptotic
hepatocytes are usually identified in the 2 rows of cells closest to the central vein (154'155);
but whether this reflects an increased incidence of cell death in centrilobular hepatocytes
is not clear. Genetic marker studies show that hepatocytes do not migrate towards the
central vein as they age ("streaming liver" hypothesis)(156>, therefore suggesting that
centrilobular hepatocytes are shorter-lived than their neighbours, or that the kinetics of
disposal are different. Alternatively, since Kupffer cells are avid scavengers of apoptotic
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bodies <157) (often only appreciable by electron microscopy (153)), the observation may
reflect relocalisation ofKupffer cells within the lobule.
1.2.b.2 Execution ofhepatocyte apoptosis
There are no ultrastructural or biochemical features to suggest that apoptosis of
hepatocytes differs in any unique way from apoptosis of other cell types. Nuclear DNA is
cleaved to 30-50 and 200-250kbp fragments by a Mg (but not Ca++)-dependent process
<158). However, nucleosome 180bp fragments are often not detectable in apoptotic
hepatocytes, therefore "DNA ladders" have low sensitivity as a marker of apoptosis in
this cell type (159'160).
Specific recognition and engulfment of apoptotic hepatocytes may be facilitated by
altered expression of cell surface carbohydrate receptors. In a rat liver regression model
(lead nitrate) hepatocyte apoptosis correlated with increased expression of
asialoglycoprotein receptors on hepatocytes and galactose receptors on non-parenchymal
cells (157-161). Endothelial scavenging of apoptotic bodies is increased by IL-1; this may
improve the liver's capacity to deal with increased cell destruction in hepatitis or
endotoxaemia <!62). Nevertheless, in animal models, extensive hepatocyte apoptosis is
followed by increasing serum concentrations of hepatocellular enzymes, indicative of cell
lysis (16 ,"165). in these circumstances saturation of clearance mechanisms has allowed the
apoptotic hepatocytes to undergo autolysis, causing leakage of hepatocellular enzymes
into extracellular fluid. This probably also accounts for the observation of "necrosis" in
tissue sections (163"165). In a regressing liver model a 20-fold increase in apoptotic rate was
estimated as sufficient to saturate clearance mechanisms <164).
1.2.b.3 Extracellular regulators ofhepatocyte apoptosis
Physiological demands
Apoptosis is the characteristic mechanism by which cells are eliminated from organs
during periods of decreased physiological demand. Whether apoptosis is involved in
involution of the liver after pregnancy or lactation is not reported; however, in rats
reduction of trophic signals by hypophysectomy produced increased hepatocyte apoptosis
and liver involution (166). Nutritional status also regulates liver turnover: caloric restriction
increases hepatocyte apoptosis, suppresses proliferation and reduces liver size (152 167);
normal feeding returns the rates of apoptosis and proliferation to normal(152). The
pathways signalling these changes have not been defined, but the observation that calorie
restriction also makes hepatocytes resistant to xenobiotic mitogens suggests that diffuse
changes in cellular responsiveness accompany any reduction in trophic stimuli(152). By
contrast, the prevalence of apoptosis was shown to be significantly reduced during the
first 96 hours after partial hepatectomy <168).
The two responses of atrophy and compensatory proliferation can be produced
concurrently, in the model of hepatic portal vein branch ligation: the affected lobe, distal
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to the ligated portal vein branch, shows a wave ofhepatocyte apoptosis in the first
postoperative week, predominantly affecting centrilobular cells, and rapidly shrinks; the
other lobes show hepatocyte proliferation in the first few postoperative days ( l69,l70).
Again, the signalling pathways triggering apoptosis are unknown; there is no evidence
that hypoxia is a significant factor (171).
In summary, rates of cell death in liver can change to meet fluctuations in physiological
demand and are regulated in complementary fashion to proliferation rates.
Specific signal factors that trigger hepatocyte apoptosis
Hepatocyte apoptosis in disease: the role ofcytokines
There is good evidence that apoptosis is the critical mechanism ofhepatocyte destruction
in immune hepatitis (e.g. the response to virus-infected hepatocytes, autoimmune
hepatitis, transplant rejection) (172"175)? and also under conditions producing acute liver
failure during septic shock (l76~179)- Apoptosis is signalled through specific surface
receptors, triggered by soluble or cellular ligands. The soluble ligands include cytokines
and hormones, whilst cellular ligands include fas ligand. Apoptosis can also be triggered








Table 4: physiological triggers ofhepatocyte apoptosis. For references, see text.
Many of the key players that can trigger hepatocyte apoptosis, can also regulate
hepatocyte proliferation and the synthesis ofacute phase proteins that characterise the
systemic response to tissue injury or infection. Moreover, similar or overlapping
intracellular pathways are usually proposed to mediate these different activities. Thus, the
effects of any particular physiological agent are likely to be strongly conditioned by the
prevalent microenvironment: some agents may even have opposite actions, depending on
concentration and context <l80,. TNFa and fas ligand have emerged as dominant triggers
of hepatocyte death in liver disease.
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Tumour necrosis factor-a, interferon-y,interleukins -If and -6
TNFa directly triggers hepatocyte apoptosis, signalling through the TNF receptor 1
(TNFR1). The TNF receptors (1 and 2) are normally expressed at low levels on
hepatocytes, and expression increases in inflammatory liver disease. TNFR1 can signal
very different downstream events in hepatocytes, including proliferation (see earlier),
synthesis of acute phase proteins and apoptosis. The pathway to apoptosis involves
recruitment of a protein (TRADD) that in turn binds a protein (FADD) which signals
directly to the apoptotic protease cascade (m"'83) (Figure 5). TNFR1 separately signals
activation of Jun kinase, p38 MAP kinase and the transcription factor NFkB (which is
inhibitory for apoptosis), demonstrating a divergance between pathways to proliferation
and apoptosis (,8, l82). There is some evidence that TNFa may also signal engagement of
apoptosis through activation ofmembrane acid sphingomyelinase, to release ceramide.




Figure 5. Fas and TNFRI signal pathways to apoptosis in hepatocytes
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TNF (a or (3) is a dominant and final trigger of liver apoptosis in mouse models of sepsis-
induced liver failure produced by bacterial endotoxin <163>173'176'184) Mice deficient in the
TNF 55kDa receptor are resistant to endotoxin-induced liver failure (184'185). However,
pre-sensitisation of hepatocytes is necessary for TNFa to produce apoptosis: in animal
models, hepatocytes are sensitised by pre-exposure to killed bacteria(186) or
transcriptional inhibitors (163); viral infection may also sensitise hepatocytes to TNFa- or
Ifny-triggered apoptosis (187'188) in clinical septic shock, ischaemia due to endothelial
injury may produce sensitisation U89>. By contrast, interleukin-ip (IL-ip) (or inhibitors
of translation) inhibits the ability of endotoxin or TNFa to trigger apoptosis (176'190). IL-ip
effects may be mediated through nitric oxide synthesis in hepatocytes (19I>192); although
others have found nitric oxide (which is also induced by TNFa and interferon-y) to be
hepatotoxic (193).
TNFa is also critical to apoptosis in the model of immune liver injury after T cell
activation by concanavalin A (Con A) or anti-CD3 antibody injection <173>176'194>195> n0
presensitisation is necessary in the Con A model of liver injury, but unlike the models of
sepsis-associated liver failure, it is not clear whether TNFa or interferon-y are the final
triggers of hepatocyte apoptosis, and both appear to be required (130'195'196) jL-6 prevents
the liver injury, by reducing TNFa and interferon-y secretion, but can also act directly on
hepatocytes to inhibit apoptosis (195). Other factors that may be important to modulate
hepatocyte responses in the cytokine milieu include HGF, which inhibits interferon-y
cytotoxicity(130). Fas receptor stimulation (see below) is not necessary in models of
TNFa-induced liver failure and apoptosis, since those responses are intact in fas-defective
(lpr) mice and hepatocytes cultured from them <197>. By contrast, TNFa was found to
suppress rodent hepatocyte apoptosis in primary culture <515).
Taken together, the data show that TNFa can signal different downstream events, whose
realisation is context-dependent. In this way the role ofTNFa to trigger hepatocyte
apoptosis in septicaemia or immune hepatitis is reconciled with its role in promoting
hepatocyte proliferation during regeneration.
Fas ligand
Hepatocytes constitutively express the fas receptor (CD95) which, when stimulated in
mice, triggers pan-lobular hepatocyte apoptosis within a few hours (165). By contrast with
TNFa, the fas-triggered apoptosis does not require pre-sensitisation in vivo. In culture,
human hepatocytes are also sensitive to fas-triggered apoptosis, whereas cultured mouse
hepatocytes require inhibition of transcription or translation to achieve high levels of fas-
triggered apoptosis, suggesting the presence of short-lived inhibitors of the apoptotic
pathway (198 199)
Little is known about the regulation of fas expression by hepatocytes. Regulation of fas
mRNA splicing may determine the amount of fas expressed on the hepatocyte surface
(200), whilst release of a soluble form of fas may reduce cell-surface fas activation, by
competion for fas ligand (analagous to the release by hepatocytes of soluble TNF
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receptor) was able to prevent endotoxin-induced hepatocyte apoptosis and animal death
due to liver failure (186).
The signal transduction steps linking fas stimulation to apoptosis include binding to the
receptor "death domain" by an intermediary protein (FADD) that recruits a CED 3-like
cysteine protease (caspase 8 FLICE MACH) (Figure 5). This initiates a protease cascade that
engages apoptosis (201"203). FADD also mediates TNFa-triggered apoptosis, and injection
of tripeptide inhibitors of caspases reduced both fas- and TNFa-triggered liver apoptosis
in mice (183-203> However, the signals can be differentially regulated: hepatocytes ofmice
with an SV40 T antigen transgene are resistant to induction of apoptosis by fas
stimulation in vivo and in primary culture, but retain sensitivity to TNFa-mediated
apoptosis (204). The mechanism of this effect is not known. Fas may trigger more than one
pathway to apoptosis in hepatocytes, involving different subclasses of serine proteases
(202)
Fas is important for the normal regulation of adult liver size, presumably through
apoptosis of redundant hepatocytes: mice with targeted deletion of fas develop
considerable liver enlargement after 8 weeks that reaches 160% of normal weight by 16
weeks . The enlargement is due to hyperplasia of liver lobules, and perhaps also
hepatocyte hypertrophy or polyploidisation, although only nuclear enlargement is
documented (205).
Fas is also likely to be important in the pathogenesis of human liver disease.
Observational studies in human chronic hepatitis C infection, hepatitis B-associated
cirrhosis and acute (predominantly virus-induced) liver failure show association of
hepatocyte destruction with liver infliltration by lymphocytes that express fas ligand
099,206) pag expression by hepatocytes was also shown to be upregulated in the areas of
lymphocytic infiltration in hepatitis C infection (207). Most intriguingly, hepatocytes
express fas ligand in alcoholic liver disease, suggesting the possibility of autocrine
apoptosis (fratricide) as a disease mechanism (199>.
Cytotoxic T cells (Tc cells) kill target cells by perforin-granzyme-mediated lysis, or by
stimulating target cell fas receptors with fas ligand (208). Deficiency of perforin, or
inhibition of target cell fas stimulation, were each alone sufficient to prevent fulminant
hepatocellular injury in similar mouse models of the Tc cell immune response to hepatitis
B virus infection <186-209>. Moreover, inhibition of hepatocyte TNF receptor stimulation (by
injection of a soluble TNF receptor) also prevented hepatocyte apoptosis and animal
death in the same model<186>. Thus multiple mechanisms contribute to immune-mediated
hepatocyte apoptosis (TNFa, fas, perforin), and although they are independent, blockade
of any one can be sufficient to prevent fulminant hepatic injury, suggesting that at
individual cell level there is a threshold level of hepatocyte stimulation/injury for




TGFPi does not produce significant hepatocyte apoptosis in normal rats or mice, when
injected at a dose sufficient to suppress regenerative hepatocyte proliferation (151-210).
However, a similar dose increases apoptosis of rat hepatocytes that have been stimulated
by xenobiotic mitogen (cyproterone acetate) or culture: in a regressing rat liver model
(after cyproterone acetate treatment), TGFPi increased apoptosis throughout the liver
lobules, in dose-dependent fashion <164). Apoptosis increased from within 2-3 hours of
treatment up to the final 9 hours timepoint. Apoptosis is more delayed in primary cultures
treated with TGFPi — appearing from about 30 hours after treatment, and peaking at
about 48 hours (211-212). This may reflect that the apoptosis is triggered when hepatocytes
are in late Gi phase of the cell cycle (see below) <139-213).
These observations have led to the idea that stimulated hepatocytes synthesize inactive
TGF|3i that when activated can trigger autocrine suicide (fratricide) in sensitised cells. In
rats, most apoptotic hepatocytes — but almost no others — were immunopositive for
pre-TGFPi, and a smaller proportion were also positive for mature TGFPi<214). Paracrine
suicide is also possible, triggered by TGFPi from non-parenchymal cells: cultured
myofibroblasts derived from Ito cells secreted TGFPi into culture medium, which was
then able to induce apoptosis of hepatocytes (215).
The intracellular events leading to TGFpi-induced apoptosis in hepatocytes appear to be
closely linked to those producing Gi growth arrest, mediated through effects on the
retinoblastoma gene product, pRb and the E2F-1 oncogene <137'139) The factors
determining the threshold between growth arrest and apoptosis are unclear, but results
from other cell types suggest that cells become susceptible to apoptosis only during a
critical window during late Gi that is after the point at which TGFpi produces growth
arrest (21,-216) in hepatocytes, TGFPi increases the proportion of dephosphorylated pRb,
which inactivates the E2F-1 oncogene to produce growth arrest and suppress hepatocyte
apoptosis (139). However TGF(3i also reduces pRb expression in hepatocytes, which could
allow activation ofE2F-1; inappropriate E2F-1 activation in Gi produces hepatocyte
apoptosis (139). Thus TGF(3i itself, or other unidentified events in TGFPi-growth arrested
hepatocytes, may lead to E2F-1 -triggered apoptosis. The balance between hepatocyte
growth arrest and apoptosis can be regulated by extracellular factors: EGF decreases
TGFPi-induced apoptosis in culture (although HGF does not)(2,7>.
Activity of one or more cysteine proteases (caspases) is necessary for TGFPi-induced
apoptosis of primary hepatocytes, as shown by use of specific cleavage site inhibitors (218).
DNA cleavage to 300kbp and/or 50kbp fragments occurs in TGFP^induced hepatocyte
apoptosis, but there are conflicting reports as to whether further, internucleosomal
cleavage occurs (159-160'219-221)
TGFpi produces apoptosis of stimulated rat hepatocytes, but possibly not ofmouse
hepatocytes (151). Results from mice bearing a TGFPi transgene that is expressed in
hepatocytes are difficult to interpret in the context of regulation of hepatocyte apoptosis,
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since the liver microenvironment is so disturbed — increased liver fibrosis, hepatocyte
apoptosis and mitosis — as well as numerous inflammatory and fibrotic lesions in other
organs (222). Similarly, the TGF(3i-homozygous-null mouse is not yet sufficiently well
investigated to provide data on hepatocyte apoptosis (223~225). in human liver biopsies,
TGF(3i immunopositivity was demonstrated in hepatocytes of regenerative cirrhotic
nodules, and in fulminant hepatitis, but not in hepatocytes of normal liver (226); its
significance for apoptosis is unknown.
Activin-A
Activin-A produces profound centrilobular hepatocyte apoptosis when infused into
normal mice and rats at nanomolar concentration. Apoptosis is apparent within 6 hours,
and is sufficient to reduce liver weight by 30% within a day (227-228). The reduction in liver
weight continues for about 3 days (to half normal weight), after which the liver becomes
refractory to activin-A and starts to regenerate. Indeed by 2 weeks, liver-body weight
ratios were significantly greater than normal (227'228). In vitro, activin-A produces a similar
increase in apoptosis to TGFPi, although requiring 10-fold concentration compared with
TGFp!(227).
By contrast with its effect on normal liver, activin-A administered after partial
hepatectomy delays DNA synthesis instead of triggering apoptosis (229). This may be due
to extracellular signals that regulate the hepatocytes' response to activin: in culture,
hepatocytes treated with activin-A in the presence of liver mitogens EGF or
noradrenaline, undergo growth arrested instead of apoptosis (111). Physiological inhibitors
of activin-A also block its induction of apoptosis (follistatin completely, inhibin partially)
in addition to blocking its growth arrest effect(1I1).
Thus activin-A is a potentially important autocrine regulator of hepatocyte apoptosis,
whose effects are dependent on local environment and hepatocyte cell cycle status.
Nevertheless, the importance of endogenous activin in the liver remains unknown.
Extracellular matrix
There are empirical descriptions that hepatocyte primary cultures "survive" longer when
cultured on specific extracellular matrix proteins than on tissue culture plastic, however,
there is no data on rates of apoptosis. Matrix proteins have been shown to influence rates
ofDNA synthesis in culture (54-55\ and this may account for the extended lifespan of the
culture. Flowever anoikis (i.e. dependence on specific cell-matrix signals for survival)(516)
is likely to be a property of hepatocytes, which survive only briefly as single cells in
suspension culture (87). Moreover, different substrata influence autocrine secretion of
TGFpi by hepatocytes in culture l230), providing a further indirect mechanism to regulate
apoptosis, albeit one of unknown significance.
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Microcystin, okadaic acid (243)
Dimethylsulphoxide (DMSO) (218)
Pravastatin (244)
a-amanatin (via TNFa) (245)
Furan (246)
Staurosporine, polymyxin B (247)
Phorbolmvristate acetate (247)
Table 5. Non-physiological agents that trigger hepatocyte apoptosis.
Survival factors
The mechanisms by which specific agents can decrease basal or induced hepatocyte
apoptosis is poorly understood. The physiological factors are predominantly also
mitogens or co-mitogens, whilst the xenobiotic agents were identified through their use
as promoters ofexperimental rat fiver carcinogenesis -— many also have a weak, transient
mitogenic effect on hepatocytes (151).
Insulin and insulin-like growth factors (IGFs)
The decrease in the incidence of heptocyte apoptosis in rats after feeding 1152,167i, suggests
a direct effect ofnutrients or anabolic hormones such as insulin. Portal vein ligation
rapidly produces apoptosis without evidence of critical ischaemia'169,170), perhaps
similarly illustrating a requirement for trophic survival factors. Serum-withdrawal from
culture medium produces apoptosis ofprimary hepatocytes (247), indicating that soluble
factors are necessary for hepatocyte survival. Empirically, certain hormones, particularly
insulin and EGF, are described to increase culture longevity, apparently independently of
proliferation(87). However, a direct effect on the incidence ofapoptosis has not been
tested. Overexpression of receptors for EGF or insulin in hepatoma cell fines, and of an
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activated HGF receptor in hepatocytes in vivo, has been reported to inhibit apoptosis
(248,249)
The insulin-like growth factors (IGF1, IGF2) can substitute for serum to reduce
apoptosis in hepatocyte cell lines expressing a N-myc-transgene (2,0'251), and may also
inhibit TGFPi-induced apoptosis (2"2'. The specific receptor(s) involved is unclear, since
insulin and IGF1 can activate each others' receptors, as can IGF1 and IGF2. Hepatocytes
constitutively express insulin and IGF2 receptors, however the IGF1 receptor is
expressed by adult hepatocytes only during regeneration <253).
Other survivalfactors
Several other physiological agents are known to inhibit hepatocyte apoptosis. They are
discussed in other sections of this introduction and are listed in Table 6. Pharmacological
agents shown to inhibit hepatocyte apoptosis are listed in Table 7.
Physiological survival
factor (in primary culture)
Apoptotic stimulus Reference
EGF/TGFa TGFp, activin-A (111,217)
Follistatin, inhibin activin-A (227)
Fructose (ketohexoses) Bile salts (254)
Glucagon "spontaneous" apoptosis (255)
HGF, activated c-met ylfri (130,249)
L-carnitine "spontaneous" (256)
Noradrenaline activin-A (111)
Table 6. physiological agents that inhibit hepatocyte apoptosis in primary culture.
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Pharmacological survival factor Reference
a-chlorocyclohexane






Table 7. pharmacological agents that inhibit hepatocyte apoptosis in vivo or primary culture.
1.2.b.4 Intracellular regulators of hepatocyte apoptosis
Signal transduction pathways that trigger hepatocyte apoptosis after surface receptor
stimulation have already been discussed for TGFp, TNFa and fas. This section considers
more general aspects of intracellular regulation of hepatocyte apoptosis, not necessarily
tied to a particular pathway.
Apoptosis of hepatocytes is energy dependent(262). However, studies investigating the
requirement for protein or RNA synthesis have produced contradictory results
063,243,262,263) Qjven suppression of these activities is invariably incomplete and the
pharmacological agents used to determine these requirements can themselves produce
apoptosis, the data are difficult to interpret. Moreover, the state of the hepatocytes
themselves and the system under test are factors, as illustrated by the easy triggering of
hepatocyte apoptosis by fas stimulation in vivo, but the requirement for inhibition ofRNA
synthesis to get the same effect in primary culture. Taken together, the data show that
there are a variety of susceptible and resistant states for hepatocyte apoptosis, which are
changeable, and determined by patterns of gene expression.
Protein phosphorylation
Phosphorylation-dephosphorylation reactions have many functions in intracellular
signalling. The use ofpharmacological inhibitors to dissect these complex and delicate
cascades is hampered by the low specificity of the inhibitors, at both the biochemical and
the subcellular compartmental level(264). Thus the phosphatase inhibitors okadaic acid
(serine/threonine phosphatase inhibitor) or microcystin, produce rapid hepatocyte
apoptosis <243), whilst the protein kinase inhibitors staurosporine or polymyxin, or protein









(218,247) c0iiective]y^ these data are difficult to interpret beyond showing that sufficiently
severe disruption of normal intracellular signal pathways can (still) trigger hepatocyte
apoptosis.
Oncogenes
The finding in other cell types that forced oncogene expression triggers apoptosis, unless
there is co-stimulation by survival factors, has been extended to hepatocyte cell lines
forced to overexpress an N-myc transgene (250). Thus hepatocytes share with other cell
types fundamental protective mechanisms that prevent autonomous oncogene activation.
There is also increased hepatocyte apoptosis in double transgenic TGFotlc-myc mice,
although the precise basis for the increase is less clear (265>. However, forced
overexpression experiments may reveal important protective mechanisms relevant to
tumour suppression, but may not represent a normal signalling pathway to apoptosis.
Indeed, c-myc has not been shown to regulate hepatocyte apoptosis triggered by
physiological signals.
c-jun (but not c-fos) has been suggested to regulate hepatocyte apoptosis in an
ischaemia-reperfusion model, based on its temporal and spatial expression patterns in the
injured liver (266). However, it is difficult to separate causal from casual associations
relating to the tissue response to injury. An association of c-fos induction with TGFP-
induced apotosis has been reported (217), but again the correlation may not reflect cause.
Intracellular proteases
Caspase activation is a prevalent and necessary phase preceeding hepatocyte apoptosis
triggered by a variety of different signals, many ofwhich have already been discussed,
and which include TGFPi(218), fas antibody (183-202>203'267( TNFa (182'183), and also re-
oxygenation of hypoxic hepatocytes (268).
Serine protease activity may be required for hepatocyte apoptosis after bile acid exposure
(269), and also for hepatocyte chromatin cleavage to 50kbp fragments (270). Serine
proteases may also be important in TNFa-induced apoptosis, although this has not been
shown for hepatocytes (271-272).
Inhibitory regulators of apoptosis
NFkB
NFkB activation can determine whether a cell is stimulated or dies in response to certain
agents, ofwhich TNFa is the best understood. TNFa activates NFkB which induces
genes that suppress apoptosis, in addition to functions such as induction of antiviral
proteins. Target genes ofNFkB that suppress apoptosis include the zinc finger protein
A20 and possibly manganese superoxide dismutase (273). IfNFkB is deficient or not
activated, the cells instead undergo apoptosis. This mechanism is important for survival
ofmacrophages, fibroblasts, and hepatocytes — mice deficient in the p65re/a subunit of
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NFkB die in utero with massive liver apoptosis, due to lack of inducible, NF-/cB-
regulated pathways(274).
Thus, activation ofNFkB has to be prevented or its effects blocked, for stimuli such as
TNFa to trigger apoptosis. This may explain why stimuli such as TNFa (or fas activation
in cultures) do not trigger hepatocyte apoptosis unless RNA or protein synthesis are
inhibited (see earlier), blocking the protective actions ofNFkB (163). More authentic
stimuli that sensitise hepatocytes to killing by TNFa include hepatitis B virus infection
(187). Viral infection of hepatocytes subverts cellular protein and RNA synthesis, perhaps
preventing NFkB from acting. Thus there is selective, cytokine-triggered killing of virus-
infected hepatocytes, whilst adjacent non-infected cells respond normally with NFkB-
induced expression of antiviral genes (273). Other cytokines, such as IL-ip, activate NFkB
and so may raise the level of protection against apoptosis induced by TNFa, although this
has not been formally tested in hepatocytes (130'163).
Thus NFkB is part of a pathway that induces anti-apoptotic genes and that can be
manipulated to alter the balance between cytokine-mediated stimulation and cell killing.
Intriguingly, ionising radiation can activate NFkB, suggesting that regulable
autoprotective mechanisms might also be induced after DNA damage <I23'273)
bcl-2family
The bcl-2 family of proteins are believed to directly influence the activation of apoptotic
caspases (275). Most data on members of the bcl-2 family in liver are observational or of no
determined physiological significance, although BAG-1 may be important. BAG-1 is a
bcl-2-binding protein that cooperates with bcl-2 to inhibit apoptosis (276). The HGF
receptor binds BAG-1, and overexpression ofBAG-1 in liver progenitor cells protects
against apoptosis (277), suggesting a mechanism for the survival factor effects signalled
through the HGF receptor (130-249) However, bcl-2 or BAG-1 were not able to suppress
apoptosis of hepatoma cell lines, produced by expression of a Wilms tumour 1 (WT-1)
splice variant(248).
Transgenic bcl-2 overexpression in hepatocytes inhibits fas-triggered apoptosis (27°79(
but how this occurs, and whether the observation has physiological significance, are
unknown, given that adult hepatocytes do not normally express bcl-2 and have not been
shown to induce it <254-280-284> bcl-2 and the related antiapoptotic protein A1 are expressed
at low levels in human foetal and mouse embryonic hepatocytes, respectively, suggesting
differential expression of this protein family in developing and adult liver (285-286)
Several other members of the bcl-2 family have been identified in adult hepatocytes,
including bax, bcf\L bclxs and other uncharacterised Bax and Bcl-2 cross-reactive proteins
— no significance has been attached to these observations (284'286'287) bax protein levels
were shown to increase after partial hepatectomy, whilst bcl-2 and bclxL protein levels did
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Hepatitis viralproteins
Hepatitis C virus (HCV) core protein inhibits apoptosis induced by DNA damage or c-
myc overexpression in genital tract cell lines (288), however its effect on hepatocyte
apoptosis has not been reported. The HCV NS3 protease inhibits actinomycin D-
triggered apoptosis ofNIH3T3 fibroblasts, by a mechanism that was suggested to be
p53-dependent and p21WAF1-independent, however again this has not been evaluated in
hepatocytes <289).
1.2.b.5 Ploidy and apoptosis
The possibility that hepatocyte ploidy populations have differential susceptibility to
apoptosis has received little attention. This could be of interest since diploid cells differ
from polyploid cells in responsiveness to mitogens and may be more susceptible than
polyploid cells to carcinogenesis (see earlier). In primary hepatocytes, apoptosis
produced by inhibition ofRb expression led to proportionately greater loss of diploid
compared with tetraploid cells (41% vs 11% reduction), suggesting that diploid .
hepatocytes are more likely than polyploid cells to undergo apoptosis (139). Increased liver
polyploidy produced by administration of a xenobiotic mitogen (lead nitrate) did not
reverse after withdrawal of the mitogen, despite considerable apoptosis during regression,
further suggesting that polyploid cells are not more sensitive than diploid to undergo
apoptosis <4).
1.3 p53 in the liver
1.3.a Normal liver
Little is known about how p53 functions in normal liver. In adult liver, p53 is virtually
undetectable and levels of the p53-responsive gene, p21WAF1, are low, together suggesting
that p53 has no constitutive role, for example in the maintenance of replicative quiescence
(7'37). This is confirmed by observations that mice made germline-deficient in p53 have
normal, quiescent liver <290~293). Indeed, the transcription factor C/EBPa is an important
determinant of quiescence in many cell types, including liver, and does not require p53
(29,147)
After partial hepatectomy, p53 mRNA and protein concentrations increase transiently
from 12-15 hours, during late Gi, and return to basal level by 18-24 hours (37). No
significance has been attached to this change, which has been largely ignored in
subsequent papers on the regulation of liver regeneration. Tsukada reported that
hepatocytes from p53-deficient mice did not differ from wild type in growth
characteristics in primary culture; however, no data was presented (294). p21WAFI
expression after partial hepatectomy is normally independent of p53; however p53-
dependent induction of p21 can occur, for example, if mice are protein-deprived before
partial hepatectomy — presumably, this is a stress response (7).
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The role of p53 in hepatocyte apoptosis is also unknown; Columbano found that
cycloheximide treatment that was sufficient to cause hepatocyte apoptosis, also increased
hepatocyte p53 mRNA levels. However, there was no increase of p53 expression during
apoptosis associated with liver regression after mitogen-withdrawal<295). Thus there is no
direct evidence that p53 is involved in physiologically-triggered liver cell death.
1.3.b Liver after DNA damage
Hepatocytes increase p53 concentration after exposure to agents that damage DNA
(Table 8), and mice deficient in nucleotide excision-repair show extensive hepatocyte p53
immunopositivity, together suggesting a role for p53 in hepatocyte responses to DNA
damage, similar to other tissues (296). By contrast with other genotoxins and its effects on
some other tissues, y-irradiation does not increase p53 protein or mRNA concentration in
hepatocytes (283<297-298) However, hepatocytes do sense y-irradiation because there is
induction of the GADD45 gene and the DNA repair enzyme 06-alkylguanyl transferase
(299,300)
The only biological response shown to be regulated by p53 in hepatocytes is the recently-
demonstrated mitogen-resistant Gj/S arrest after DNA damage (uv-b irradiation,
diethylnitrosamine, mitomycin C) or actinomycin D (301>302). The growth arrest can be
reversed by antisense p53, demonstrating p53-dependence. The association of increased
p53 protein or mRNA concentrations with increased hepatocyte apoptosis after uv-c, 2-
acetylaminofluorene or portal vein ligation, implied that hepatocytes show p53-dependent
apoptosis, but casual association was not excluded (169-232). The association of p53 protein
increase and induction of apoptosis by prostaglandin was shown to be casual using
hepatocellular carcinoma cell lines with and without functional p53 (303).
The identification of a pathway linking p53 to DNA excision-repair proteins in fibroblasts
(304), and observations of p53-dependent excision-repair in different cell types (305~312)
(Prost S., Bellamy C.O.C., Clarke A.R., Wyllie A.H., Harrison D.J., submitted), suggest
the possibility that p53 could regulate DNA repair in hepatocytes. However, no studies
have addressed this issue directly; the induction by y-irradiation of the DNA repair
enzyme Or,-alkylguanyl transferase is p53-dependent; however, since the enzyme does not
repair DNA strand breaks (the DNA lesion of y-irradiation), the data is only suggestive of
a role for p53 in hepatocyte DNA repair (300>. The frequency of spontaneous mutations in
liver was not increased in mice heterozygous or null for p53, compared with wild type
(assessed on the basis of inactivating mutations in a lac transgene)<313).
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Stimulus. Detection. Study. Reference.
Partial hepatectomv protein. mRNA In vivo, rats (37)
Carbon tetrachloride mRNA In vivo, rats (57)
Portal vein ligation mRNA In vivo, rats (169)
SV40T transgene protein In vivo, mice (314)
ERCC-1 deficiency protein In vivo, mice (296)
uv-b irradiation protein Culture, rats (301) (232)
uv-c irradiation
Diethylnitrosamine injury protein In vivo, rivulus (315)
Culture, rats (302)
Mitomycin C protein Culture, rats (301)
2-acetylaminofluorene protein Culture, rats (232)
Cadmium mRNA In vivo, mice (316)
Copper mRNA In vivo, rats (317)
Actinomycin D protein Culture, rats (301)
Peroxisome proliferator mRNA In vivo, rats (318)
Table 8. Stimuli that increase p53 protein/mRNA levels in primary hepatocytes.
1.3.c p53 in hepatocarcinogenesis
Liver carcinoma is the fourth commonest cause of cancer death world-wide <319'.
Mutations in the p53 tumour suppressor gene, usually with loss of the residual wild type
allele, are frequent in human hepatocellular carcinomas (HCC) and correlate positively
with increasing histological grade of carcinoma and early recurrence, suggesting that
defective p53 function is ofpathogenic significance and confers increased clinical
aggression <320"322). Studies of intratumour heterogeneity have suggested that p53
mutation and allele loss are late events in human hepatocellular carcinoma, mediating
tumour progression but occurring after carcinogenesis (323'324). However, several lines of
evidence indicate that p53 dysfunction can precede hepatocarcinogenesis and have a
pathogenic role. First, abnormal accumulation ofp53 protein has been observed in
hepatocytes ofpatients with cirrhosis and liver cell dysplasia, high risk lesions for
carcinoma development (325~327). Second, exposure to Aflatoxin Bl, a dietary mutagen and
a cofactor in human hepatocarcinogenesis, is associated with a characteristic point
mutation in p53 (328). This mutation has been demonstrated in non-neoplastic hepatocytes,
particularly in areas ofhigh aflatoxin exposure where hepatocellular carcinoma is
prevalent(329). Third, dysfunctional p53 is probably more common in hepatocellular
carcinoma than appreciated from standard genetic screens of "hotspot" regions, because
of both mutation distribution(330,331' and functional inactivation without mutation (332_334).
Functional inactivation of p53 is best characterised for chronic hepatitis B infection.
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Hepatitis B virus is the major aetiological agent of human hepatocellular carcinoma; the
Hepatitis B X protein heterodimerises with and inactivates p53 in vitro and in vivo, and in
transgenic mice, this is temporally and spatially associated with the development of
hepatocellular carcinoma from preneoplastic lesions, providing strong evidence that p53
dysfunction is relevant to hepatocarcinogenesis (335~337).
p53 mutation profile in human hepatocellular carcinoma
The prevalence and spectrum of p53 mutations in hepatocellular carcinoma is strongly
influenced by geographic location. Dietary exposure to Aflatoxin B1 is associated with a
characteristic G-T transversion mutation in p53 (Ser249) (338'339) that can be identified in
over half of hepatocellular carcinomas in areas of high exposure risk, such as Qidong
(China) and Mozambique, but less than 1/25 hepatocellular carcinoma in low exposure
areas <340). Individual susceptibility to the aflatoxin-induced Ser249 mutation correlates
postitively with particular mutant alleles of hepatic detoxifying enzymes (341).
hepatocellular carcinoma p53 mutations have been categorised into geographic groups: G
to T transversions (including Ser249) predominate in the sub-Saharan Africa and
Southeast Asia continent, whereas the majority of p53 mutations in hepatocellular
carcinomas from Europe/North America are G to A transitions. By contrast, the mutation
spectrum in hepatocellular carcinomas from Southeast Asia islands is a mixture of base
substitutions, deletions and insertions (342)
In regions of little Aflatoxin B1 exposure, p53 mutations are still prevalent; however,
about one quarter of the mutations lie outside the most commonly evaluated exons 5-8,
and most of those (>70%) generated stop codons or frameshifts that would probably be
missed by immunohistochemical screening (330). Therefore, the true prevalence of p53
mutation in hepatocellular carcinoma is difficult to estimate. Nevertheless, there is
considerable geographic variability, for example, in Japan (19% <343), 32% <344), or 65%
when multiple nodules were evaluated (321)); in the United States (45% <345)); in Taiwan
(33% (346)); Germany (15% (347), 10/22 (348)); France (16% (349)); Great Britain (11% (350),
9% (351)); Alaskan natives (0/7 (352), 0/13 (353)); Australia (0/15 (354)).
In summary, p53 mutation is prevalent in hepatocellular carcinomas; the geographic
heterogeneity ofmutation prevalence and mutation profile may reflect patterns of
exposure to different risk factors for hepatocellular carcinoma.
Consequences of p53 mutation
A few studies have evaluated the functional consequences of p53 mutation in hepatocyte
cell lines. The Ser249 p53 mutation is the prevalent, but not exclusive, mutation
produced by Aflatoxin B1 in human hepatocytes, and its common identification in
hepatocellular carcinoma presumably reflects a selective advantage for affected cells (355).
Human p53ser249 is transactivation-deficient, and in human hepatocellular carcinoma
cells showed the strongest dominant negative inhibition of wild type p53 transactivation
activity compared with a panel of p53 mutants (356-l57) p53ser249 may also have novel
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gain-of-function properties, since it enhanced survival (colony formation) and mitotic
activity of the p53-deficient human hepatocarcinoma-derived cell line, Hep3B (HBV-
positive). However, p53ser249 did not increase the weak tumorigenicity ofHep3B —
postulated to be because TGFP-induced apoptosis was retained (356).
A murine p53 mutant (Ser246), equivalent to the human Ser249 mutant, was transfected
into a hepatocyte cell line and shown to reduce serum-dependence for growth, and to
increase colony formation and cellular pleomorphism. However, the mutant did not
transform the cell line ("58>. Thus the human and murine equivalent mutations appear to
have similar properties in hepatocyte-derived cells. Interestingly, the phenotype of
p53ser246 was specific to hepatocytes — not seen in transfected murine fibroblasts—
emphasising the limitations ofmodelling genetic lesions in irrelevant cell types. Moreover,
the phenotype was also mutant-specific— not seen using a p53vall35 mutant that is well
described in other cell systems as a temperature-sensitive, dominant-transforming
oncogene (359)).
Taken together, the data suggest there are p53 mutant-specific effects, on hepatocyte-
specific growth factor pathways, perhaps acting through altered transcriptional activation.
The data suggest that p53 dysfunction can augment clonal growth in carcinoma
progression, perhaps through manipulating sensitivity to growth factors, and leave open
the possibility of a similar contribution to carcinogenesis.
p53 dysfunction is not essential for hepatocarcinogenesis: human hepatocellular
carcinoma-derived cell lines, HepG2 and 2215, have wild type p53 that appears to be
functionally intact, as assessed by basal transactivation of a reporter gene, increased p53
and p213VAF1 protein concentrations after exposure to DNA-damaging agents (uv,
doxorubicin), and inhibition ofDNA synthesis <360>. However, by contrast with the effects
of y-irradiation on normal rodent hepatocytes, y-irradiation increased p53
immunopositivity in the HepG2 cells and a murine hepatocellular carcinoma cell line
(36o,36i) jt js nQt cjear tjjs difference is due to a malignancy-associated change in p53
regulation, or has a more trivial, methodological explanation.
Liver carcinogenesis in genetically modified animals
Germline p53-deficiency in mice, either heterozygous or homozygous, did not predispose
to spontaneous or carcinogen-induced hepatocarcinogenesis (y-irradiation,
diethylnitrosamine, dimethylnitrosamine), at least not before the mice succumbed to
lymphomas or sarcomas (292,293,362'363). Moreover the number and size of phenotypically
altered foci, and the relative proportions of hepatocellular carcinoma and hepatocellular
adenomas were not significantly different between wild type and p53-heterozygous mice
exposed to a single dose of diethylnitrosamine at 12 days (293>. In a different model, mice
bearing a mutant p53 transgene that dominantly inactivates wild type function and that is
specifically expressed in hepatocytes (and choroid plexus), also lived a normal lifespan
without liver disease (364). Thus there is no evidence that p53 dysfunction alone in
otherwise normal liver influences hepatocarcinogenesis. This suggests that the
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development of hepatocellular carcinoma in HBX-transgenic mice, discussed above,
involves properties ofHBX additional to inactivation of p53. The idea is supported by the
increased susceptibility ofHBX-transgenic mice to diethylnitrosamine-induced
hepatocellular carcinoma, not shown in simple p53 deficiency (365).
The SV40 T antigen binds and inactivates p53, as well as affecting other proteins,
particularly members of the pRb family. Mice bearing an SV40 T antigen transgene that is
expressed in hepatocytes, show abnormal hepatocyte proliferation, dysplasia, and develop
phenotypically-altered foci and hepatocellular carcinoma from within a few weeks of birth
(314,366-368) ^^ence 0f hepatocellular carcinoma is upto 100%, depending on
background strain. However, comparison with p53-deficient mice suggests that transgene
effects on gene products such as the pRb family are critical to hepatocarcinogenesis.
A few animal models of hepatocarcinogenesis recapitulate the disease sequence of
chronic hepatocellular destruction, inflammation and compensatory regeneration that
preceeds human hepatocarcinogenesis. However, p53 function is not usually evaluated.
Mice carrying a hepatitis surface antigen transgene, whose overexpression in hepatocytes
leads to chronic hepatocyte destruction, regeneration and eventually hepatocellular
carcinoma, did not show p53 mutation in the carcinomas <369). However, neither was any
abnormality detected in a large number of other oncogenes and oncosuppressor genes
that were evaluated. This suggests the model may have special features that replace the
selective advantage of oncogene or oncosuppressor mutation. Mice with a c-myc
transgene, or a TGFa transgene, expressed in hepatocytes, and double transgenic c-
myc/TGFa mice show accelerated hepatocarcinogenesis. However, no p53 mutations
were found in hepatocellular carcinomas developing in these mice (370).
In summary, where it has been evaluated, p53 mutation has not been identified in
transgenic mouse models of hepatocarcinogenesis, in the hepatocellular carcinomas that
develop. The HBX model of functional inactivation remains the best evidence for a
contribution of p53 dysfunction to hepatocarcinogenesis in these models.
Hepadnaviral models of hepatocarcinogenesis
Woodchucks and ground squirrels infected with the species hepatitis virus and/or
exposed to aflatoxin Bl, did not show p53 mutation in the hepatocellular carcinomas that
developed <371).
Chemical hepatocarcinogenesis
Genetic background is a critical determinant of rodent susceptibility to
hepatocarcinogenesis, and studies are frequently performed in strains known to be
susceptible, and in the more susceptible gender. Whether this strategy could reduce any
selective advantage from p53 mutation is not known. Most studies have failed to identify
p53 mutations in chemically-induced hepatocellular carcinomas from mice (372"375) 0r rats
(376). However, Smith reported immunohistochemical evidence for abnormal p53 in a high
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proportion ofmurine hepatocellular carcinomas induced by choline-deficiency (377) or
diethylnitrosamine (377), whilst Lilleberg found abnormal restriction fragments suggesting
mutant p53 in hepatocellular carcinoma from rats treated with Aflatoxin B1 (378).
Aflatoxin B1 treatment of non-human primates, mice, rats, or ducks does not produce an
analagous p53 mutation to that in humans, although it is an extremely potent animal
hepatocarcinogen; however, other p53 mutations have been reported in animal, Aflatoxin
B1-induced hepatocellular carcinomas <328'378~380). The reason for the species difference is
uncertain, but in humans, the Ser249 mutation has been linked to specific mutant alleles
of detoxifying enzymes, which may not occur in other species (341).
By contrast with animal hepatocellular carcinoma in vivo, p53 mutations were rapidly
acquired when cells from the carcinomas were cultured, indicating a specific selective
advantage under culture conditions, which is clearly not relevant, or suppressed, in vivo
(374)
1.4 Chemical carcinogenesis in the liver
The field of hepatocarcinogenesis is large, and the discussion here will be limited to issues
pertinent to the experimental data that will be presented on diethylnitrosamine (DEN)
carcinogenesis.
Liver is commonly used to study the stepwise development of cancer. Strategies of
chemical carcinogenesis involve a carcinogen (a DNA-damaging agent such as
diethylnitrosamine), which may be combined with a regenerative stimulus such as partial
hepatectomy, and/or long term administration of a tumour promoter (e.g.
phenobarbitone). Intriguingly, hyperplasia induced by direct mitogens cannot substitute
for the regenerative stimulus of partial hepatectomy or CCl4, to support initiation of
carcinogenesis by carcinogens (381). This remains unexplained (64). Carcinogenesis
protocols are many and varied, but can be categorised according to the possible target
population, into protocols producing oval cell proliferation (e.g. 5-acetylaminofluorene
with choline deficient diet) and those in which oval cell proliferation is not a feature, but
development of carcinoma is preceeded by phenotypically altered foci and nodules (e.g.
diethylnitrosamine with partial hepatectomy).
1.4.a Phenotypically altered foci
A variety of convenient phenotypic changes that occur after carcinogen treatment and
before development of malignancy, are used to identify putative mutated cells and their
progeny (so-called "altered foci"). The relation between altered foci and subsequently
developing carcinomas is uncertain, although there is a positive correlation. Only a tiny
proportion of foci (0.04-0.1% ( ,82)) may progress to neoplasms, and there is no evidence
that they represent an obligate, homogeneous or irreversibly-altered population in the
progression towards cancer (383-384) Indeed, different phenotypic markers identify
overlapping, but not congruent, subsets of cells (385>. There is some evidence that foci are
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clonal, but this may not be universal(386>. Nevertheless, studies of altered foci have
revealed interesting changes that will now be discussed.
In early carcinogenesis, altered foci increase in size (cell number) only very slowly, if at
all<151), perhaps at comparable rates to the microclones contributing to normal fractal
replenishment of liver (14,15)5 although a direct comparison has yet to be reported.
However, there is a critical alteration in the hepatocytes constituting the foci, such that
their average lifespan is dramatically curtailed, accompanied by a manyfold (5-1Ox)
increase in cell turnover (proliferation and apoptosis)(151). Foci are thus regions of altered
population kinetics in which numerous short-lived hepatocytes are generated to fill a
relatively stable volume of liver. One feature of a shorter-lived cell population is that its
size changes much more rapidly for similar relative changes in apoptosis or proliferation
rates. Indeed, calorie restriction sufficient to eliminate 20% of normal liver cells by
reducing DNA synthesis and increasing apoptosis, reduced the size and number of foci by
a total volume of 85% in the same period, and halved the incidence of carcinomas after
return to normal feeding - suggesting that many initiated cells had been eliminated (152).
Conversely, pharmacological inhibition of hepatocyte apoptosis by phenobarbitone (or
other tumour promoters such as nafenopin) rapidly increases the size of altered foci
(257,387). tjie egfect js reversed on withdrawal of the tumour promoter. Although such
tumour promoters also stimulate cell proliferation, the effect is transient and not sufficient
to account for the promoting effect, which correlates better with the inhibition of
apoptosis (15U84).
Compared with altered foci, the rates of proliferation and apoptosis in neoplastic nodules
and in hepatocellular carcinoma are progressively increased (151-388>; whether this could in
part reflect a subset of newly generated hepatocytes that are very short-lived, or a more
generalised reduction in the lifespan of lesional hepatocytes, is unknown.
Genetic marking studies have shown that the sporadic, fractal pattern of hepatocyte
proliferation becomes disturbed after carcinogen treatment (5-acetylaminofluorene with
choline deficient diet, or diethylnitrosamine with partial hepatectomy): proliferation
becomes concentrated in fewer sites that consequently produce larger cell clusters (389). In
part this may be due to carcinogen-induced damage causing cycle arrest ofmany cells.
The clusters could not be linked to phenotypically altered foci. The data are preliminary,
but it is tempting to speculate that the subsequent development of nodular liver disease is
an extension of this process.
1.4.b Diethylnitrosamine hepatocarcinogenesis
Diethylnitrosamine (DEN) is an alkylating hepatocarcinogen that produces a variety of
DNA adducts, ofwhich 04ethyldeoxythymidine is the most slowly removed from
hepatocyte DNA, and is probably the most significant(390). High doses ofDEN
(200mg/kg) produce liver necrosis; lower doses (l-20mg/kg) are not appreciably
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cytotoxic, but a single neonatal exposure is sufficient to produce hepatocellular
carcinomas (see
Table 9). The morphology and kinetics ofDEN-induced liver lesions are well described in
mice (39l,392). Mathematical modelling indicated that at least 2 critical time-dependent
events were required for the development of atypical foci, and 4 for carcinomas. The
probabilities of initiation of foci and carcinomas differed by more than 3 orders of
magnitude, suggesting qualitative differences in the initiating event required, and so foci
cannot necessarily be considered as early biological steps in carcinoma development.
Dose of DEN (single exposure at 15 days):
0.625mg/kg 5mg/kg
Atypical foci 26 12
Hyperplastic nodules 46 21
Hepatocellular adenomas 55 30
Hepatocellular carcinomas 65 46
Table 9. Time (weeks) to 50% incidence of liver lesions in male B6C3Fmice, after a single intraperitoneal dose of
DEN at 15 days, (adaptedfrom <3>l-392>)
Specific genetic lesions can modulate DEN-induced hepatocarcinogenesis: a retroviral
vector that expressed activated Ki-ras, produced increased proliferation of infected
hepatocytes, and accelerated hepatocarcinogenesis (393). By contrast, TGFa-deficient mice
exposed to DEN failed to develop the large liver lesions that were produced in wild type
mice, suggesting a role for TGFa in promotion (104'. DEN accelerated liver carcinogenesis
in HBX-transgenic mice, illustrating cooperativity between chemical and virus-associated
• (372)
carcinogenesis .
1.4. b. 1 p53 and diethylnitrosamine hepatocarcinogenesis
After exposure to DEN, hepatocytes show unscheduled DNA synthesis, indicating that
excision repair is stimulated (394). Specific adducts are also removed by O6 alkyl
transferase activity. Flowever, the repair is imperfect: mutation frequency in a reporter
transgene was still increased in "normal" mouse liver, one year after a dose ofDEN (395).
The DNA damage caused by DEN stimulates a p53 response: cultured hepatocytes from
rats exposed to DEN showed p53-dependent Gi/S cell cycle arrest when exposed again
to DEN. Flowever, the p53 response was much diminished in cells that were presumed to
be from atypical foci (immunopositive for glutathione S transferase P), showing that cells
in foci respond abnormally to further genetic injury <302). Goodwin reported abnormal,
persistent p53 immunopositivity in occasional hepatocytes 3 weeks after a necrogenic
dose ofDEN; this could reflect a response to persistent damage f3,5).
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Despite the evidence for a p53 response to the DNA damage that DEN produces in
hepatocytes, p53 mutation has not been found in mouse hepatocellular carcinomas
produced by single-dose DEN treatment; moreover— as discussed earlier — p53-
deficiency did not accelerate hepatocarcinogenesis after single dose DEN treatment at 15
days <293'372'373'375). Smith combined DEN treatment with a methyl-deficient diet in rats,
and demonstrated mutant p53 atypical foci that developed — but restricted to the larger
foci. This suggests either that p53-mutant foci grew larger than others, or that p53
mutation occurs late in the clonal expansion of initiated cells (396).
In summary, DEN produces a p53 response in normal hepatocytes, but although this
response may be muted in atypical foci, there is no evidence that p53-deficiency is
sufficient to facilitate carcinogenesis.
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2. Aims
The hypothesis underlying this thesis is that p53-deficiency in hepatocytes alters the
regulation of hepatocyte turnover in ways that might be relevant for liver carcinogenesis.
By comparison ofwild type with p53-deficient hepatocytes — where possible in vivo and
in vitro — the experiments described sought to identify whether and how p53 regulates
hepatocyte turnover and responses to DNA damage.
Specific aims were:
1. To establish and evaluate a system that allowed primary culture ofmouse hepatocytes
in defined conditions.
2. To study the consequences of p53 deficiency for hepatocyte proliferation, ploidy and
apoptosis.
3. To establish the involvement of p53 in the responses of hepatocytes to DNA damage,
and the particular downstream responses regulated through p53 in this cell type.
4. To compare the consequences for wild type and p53-deficient livers, of exposure to a
liver carcinogen.
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3. Materials and methods
3.1 Primary hepatocyte culture
3.1.a Gene-targeted mice
Generation of the homozygous p53-deficient mice used in these experiments has been
described <397). Mouse E14 embryonic stem cells (derived from strain 129/Ola) bearing a
targeted deletion of exons 2 through 6 of the p53 gene were injected into blastocysts to
generate germline chimaeras, which were bred to homozygosity. The targeting construct
consisted of a fragment from within intron 1 of the p53 gene, ligated to a pgk-neo
cassette and a 5kb fragment that incorporated exons 7-11 of the p53 gene. The neo
cassette contained numerous STOP codons in all 3 reading frames to prevent downstream
transcription of the truncated gene.
To establish mouse p53 genotypes, DNA was prepared from tail biopsies and selectively
amplified by polymerase chain reaction, using a primer for intron 7 (common to both
genotypes), and primers specific for exon 6 (wild type) and the neo construct.
Mice used in the experiments described here were outbred on a mixed background,
segregating for 129, Ola and Balb C. For each experiment the mice were age and sex-
matched, and were littermates if possible. p53 genotype was rechecked on tail biopsy
after killing. Unless otherwise stated, hepatocytes were cultured from adult male mice of
6-10 weeks age. The mice were housed in plastic cages in a room with a 12 hour day-
night cycle and controlled temperature and humidity. They were given a standard diet and
water ad libitum.
3.1.b Isolation ofmurine hepatocytes
3. l.b. 1 Two step retrograde perfusion ofadult mouse liver
The perfusion apparatus was sterilised and cleaned before and after use by running
through 70% absolute ethanol/tissue culture grade water followed by tissue culture grade
water. All reagents and equipment in contact with the hepatocytes were cleaned to tissue
culture grade standard and sterilised. Perfusions were carried out under still air conditions
and once hepatocytes were isolated all subsequent handling was performed in a sterile
laminar flow tissue culture hood (class 2) using sterile technique.
Young adult mice weighing 20-25g were anaesthetised with pentabarbitone (300mg/kg
i.p.). Once deeply anaesthetised (deep reflexes lost), the mouse was prepared for surgery
and the skin sterilised with alcohol. The abdominal cavity and thoracic contents were
displayed by a midline incision and reflection of peritoneum and the anterior thoracic
cage. The hepatic portal vein was identified and a loose ligature placed around the
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thoracic inferior vena cava (Figure 6). The inferior vena cava was cannulated by inserting
a polyethylene cannula (0.4/0.8 or 0.5/1.0 mm i.d./o.d.) through an incision in the right
atrium, and the cannula was secured in position by the ligature. The hepatic portal vein
was transected. Oxygenated perfusion medium (Appendix) at 37°C was pumped through
the cannula (8.5mls/minute) for at least 5 minutes. The liver clears immediately as blood
is flushed into the portal vein by incoming perfusate. The perfusate was then changed to
oxygenated digestion medium (Appendix) and perfusion continued for a further 10-15
minutes, until fissures form spontaneously or with mild pressure on the liver surface.
During this time the liver typically enlarges to almost twice normal size, and any
structural detail visible through the capsule is lost. The perfusion was then terminated; the
digested liver, still held intact by its capsule, was excised and the gall bladder discarded.
The liver was placed into a sterile plastic tissue culture dish and the capsule snipped open
with sterile scissors. Flepatocytes were then gently but thoroughly mechanically
dissaggregated from the fibrous stroma using a "brushing" action from hilum to
periphery, along the branching strands of fibrous supporting tissue. This produces a thick,
homogeneous cell "soup", consisting of isolated hepatocytes, small clumps of
hepatocytes, the intact fibrous stroma and some non-parenchymal cells. Depending on the
type and batch of collagenase used and the quality of the digestion, it was sometimes
necessary to continue the digestion for a further 10-15minutes in fresh digestion medium
at 37°C in a conical flask within an orbital incubator set at 90-100rpm.
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3.1.b.2 Purification and removal ofdamaged cellsfrom the hepatocyte isolate
Ice cold plating medium (Appendix) was then added to the cell suspension. This was
gently aspirated up and down a wide-bore pipette (2mm orifice) 10-15 times to further
break up small clumps, and then filtered through a 250pm mesh into an ice cold beaker.
The suspension was made up to 50ml with ice-cold platingmedium and centrifuged (50g
for 5 minutes, at 4°C). The supernatant, containing debris and non-parenchymal cells, was
discarded. The cell pellet — more than 90% hepatocytes on morphology— was then
further purified and damaged cells removed by centrigugation through Percoll:
Isopyknic centrifugation in Percoll
The protocol was adapted from that ofKreamer et al(398) for rat hepatocytes, and exploits
the observation that damaged cells will float and murine hepatocytes will pellet, in a dense
(p = 1.055 gem"3), isotonic, Percoll gradient.
The hepatocyte pellet was resuspended in 6ml ice-cold plating medium and 8ml cold
Percoll stock solution (Appendix) and spun at 50g for 10 minutes at 4°C. After discarding
the layer of floating cells (dead cells, non-hepatocytes and debris) and the remainder of
the supernatant the cell pellet (99% hepatocytes as assessed by morphology under phase
contrast illumination) was resuspended in ice-cold plating medium to 5mls, for estimation
of viability and yield.
3. Lb.3 Assessment ofhepatocyte viability andyield
The trypan blue exclusion method was used to estimate hepatocyte viability. Cells with
damaged membranes admit the dye and are easily differentiated from non-staining cells by
light microscopy. Trypan blue has a greater affinity for serum protein than cellular
protein, so the assays were performed in serum-free solutions.
Immediately after gentle resuspension (hepatocytes settle very rapidly in suspension) a
20pf aliquot of hepatocyte suspension was added to a mixture of 40pl of 0.5% Trypan
blue in isotonic saline (prefiltered at 0.2pm) with an equal volume of sterile PBS at pH
7 .4. One drop of the well mixed suspension was allowed to flow by capillary action into a
tightly coverslipped improved Neubauer haemocytometer (chamber depth 0.1cm), filling
but not overflowing the measuring compartment. The cell number in five 1mm2 blocks
was then counted and trypan blue negative cells expressed as a proportion of total to give
an estimate of hepatocyte viability. The viable hepatocyte yield was calculated from the
number of trypan blue negative cells in the known volume assessed (5xl0"4 cm3), allowing
for the sample dilution (5-fold) and original volume (5ml).
3.1.c Primary hepatocyte monlayer culture
3. I.e. I Plating offreshly isolated hepatocytes
Freshly isolated, purified hepatocytes in suspension were diluted as necessary with
plating medium and plated out at the required density (usually 0.2-0.4xl05/cm2) on
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coated tissue culture plastic (either Lab Tek Permanox chamber slides or Nunc culture
ware). Culture surfaces were normally precoated with fibronectin, although in some
experiments rat tail collagen was evaluated (Appendix). Before attachment hepatocytes
were evenly distributed over the culture surface by gently agitating the dish from side to
side then backwards and forewards. This was important to avoid otherwise inevitable
aggregation of hepatocytes at the center of the culture wells. Cultures were then left at
37°C for 40-60 minutes to allow hepatocytes to attach, incubating either in air or 5%
C02/95% air depending on the plating medium formulation.
3.1. c.2 Routine culture maintenance
After the attachment period, plating medium and unattached cells were aspirated and
replaced by fresh modified Chee's culture medium (Appendix). Cultures were incubated
in a humid atmosphere of 5% C02/air at 37°C and the medium changed the next day and
at least every 2 days afterwards. The medium was kept <2mm deep to maintain optimum
oxygen tension (60mm Hg) (399>.
3.2 Cell biology and in vivo studies
3.2.a Drugs
3.2.a.l 1,4 bis 2-(3,5dichloropyridyloxybenzene) (TCPOBOP)
In order to evaluate proliferative (hyperplastic) responses of hepatocytes in vivo, mice
were exposed to a chemical mitogen that had been previously used in our laboratories to
produce liver hyperplasia, 1,4 bis 2-(3,5dichloropyridyloxybenzene) (TCPOBOP, a gift
from Dr G. Smith, Dundee) (400). Male mice aged between 29 and 33 days were given a
single intraperitoneal (i.p.) injection of 3mg/kg TCPOBOP, suspended in corn oil.
Control animals received corn oil only. For assessment ofDNA synthesis BrdU labelling
agent (Amersham, 0. lml/lOg body weight) was administered as a single i.p. bolus 18
hours before the animals were killed by cervical dislocation. Liver and body weights were
recorded, and liver tissue was processed for DNA analysis by flow cytometry (section
3.2.g). The remainder was divided and fixed in buffered 10% formalin for routine
histological analysis and in methanol for BrdU immunohistochemistry (section 3.2.f.2).
3.2. a. 2 Induction of liver regeneration by carbon tetrachloride
Mice received an intraperitoneal injection of 0.5ml/kg CC14 (approximately lOOpmol),
mixed 5% v/v in corn oil, or corn oil alone (negative controls). This was administered at a
fixed time of day (midday) in order to control for any confounding circadian effects on
liver regeneration <401). Two hours prior to killing, mice received an i.p. bolus of 3mg/ml
BrdU labelling agent (Amersham, 0. lml/lOg body weight). The mice were then killed at
various timepoints by cervical dislocation. Liver and body weights were recorded. The
liver was divided and fixed in buffered formalin for routine histological analysis and in
methanol for BrdU immunohistochemistry (section 3.2.f.2).
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3.2.(l3 Exposure ofmice to the hepatocarcinogen diethylnitrosamine
Mice were given a single intraperitoneal bolus of diethylnitrosamine (DEN) (10 or
50mg/kg, diluted 1/1000 in corn oil) at twelve days of age. Ten weeks after treatment the
mice were killed by cervical dislocation and necropsied. In addition to any lesions, the
liver, one lung, one kidney, one submandibular gland, the pancreas, thymus and spleen
were excised and fixed in buffered 10% formalin. The colorectum and the distal 15cm of
small intestine were excised and flushed with water prior to mounting en face and fixing
overnight in methacarn (4:2:1 methanol:chloroform:acetic acid). The fixed bowel lengths
were then wound into a "swiss roll" which was subsequently paraffin embedded edge on
and sectioned, producing a continuous spiral of bowel from proximal to distal ends on a
single section. Lesion type and number were recorded by simultaneous microscopic
analysis of 5pm haematoxylin and eosin-stained sections by two observers (myself and Dr
AR Clarke) at a double headed microscope. Assessments were made without knowledge
of the genotype or treatment.
Livers were scored for the prescence and number of phenotypically-altered foci and
nodular lesions (hyperplastic, adenomatous or carcinomas), according to established
criteria<391). They were also scored for the presence of diffuse cytological changes that
were present in hepatocytes throughout the liver. These changes were termed diffuse
atypia. Diffuse atypia was defined as increased variability in the sizes of hepatocyte nuclei
(many ofwhich appeared enlarged), with easily identified irregular nuclear contours in
some hepatocytes. No attempt was made to discriminate different degrees of severity of
diffuse atypia, although there was variation between livers scored as positive.
3.2.b Cytokines
Aliquots of stock solutions of each cytokine were stored at -20°C until required.
3.2.b.l Transforming growth factor Pi (TCiFfj)
A stock solution of lpg/ml (40nM) transforming growth factor (3i from human platelets
(Sigma) with 50pg/ml human serum albumin was prepared in 4mM HC1 containing
lmg/ml bovine serum albumin. This was diluted in culture medium to the desired
concentration. Control cells were treated similarly but without TGF-(3i.
3.2.b.2 Insulin
A stock solution of 300pM Bovine pancreatic insulin (Life Technologies) in culture
medium was diluted to lOOnM. Control cells did not receive this supplement.
3.2.b.3 Dexamethasone
A stock solution of 100pM dexamethasone (Sigma) was prepared by 27-fold dilution in
culture medium of a lmg/ml solution of dexamethasone in absolute ethanol. This was
added to culture medium to a final concentration of 30nM. Control cells were similarly
treated but without dexamethasone.
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3.2.b.4 Epidermal growth factor (EGF)
A stock solution of 25pg/ml EGF from mouse submaxillary glands (Sigma) was prepared
in PBS containing 0.5% bovine serum albumin and added to culture medium to a final
concentration of 25ng/ml. Control cells were treated similarly with medium containing an
equivalent volume of bovine serum albumin in PBS.
3.2.c Irradiation
Mice and cultures were y-irradiated by a Cs137 source at 0.33 Gy/minute. Unirradiated
controls were otherwise transported and handled identically, uv-c irradiation (254nm)
was administered to cultures after complete removal of culture medium, using a
Spectrolinker XL-1500 (Spectronics Corporation) preset to the required flux (J/m2).
3.2.d Evaluation of apoptosis
3.2.d.l Electron microscopy
Culture medium was removed and hepatocyte monolayers fixed in situ by ice cold 3%
glutaraldehyde in 0.1M sodium cacodylate. After detachment by scraping the cell pellets
were prepared for transmission electron microscopy by standard methods. These entailed
postfixation by cacodylate buffered 1% osmium tetroxide, dehydration through graded
alcohols and impregnation by grades of araldite, which was then polymerised at 56°C.
50nm sections were cut and stained by uranyl acetate and lead citrate, ready for viewing
on a Phillips CM 12 Transmission Electron Microscope. An additional 1pm section was
cut and stained by toluidine blue for light microscopic examination.
3.2.d.2 Fluorescence microscopy
Monolayers of hepatocytes on Permanox chamber slides (Lab Tek) were fixed in ice cold
90% ethanol/10% formalin for at least 1 hour. The cells were then exposed to 0.2M
acetic acid for 1 minute before staining by acridine orange (1 Opg/ml in PBS). Excess stain
was rinsed off in water before coverslipping and viewing under uv light.
3.2. d.3 Light microscopy
Cultured monolayers fixed at 4°C overnight by Bourn's solution (Appendix) were
Feulgen-stained by exposure to 5M HC1 for 40 minutes, rinsing in tap water, incubating
in Schifif solution (Appendix) for 1 hour, followed by three 5-10 minute washes in tap
water. Cells were counterstained by 1% aqueous light green, air dried, mounted in
cedarwood oil (Sigma) and coverslipped.
3.2.e Recognition of apoptosis
The morphology of apoptosis was easily recognised by light microscopy in fixed,
Feulgen-stained hepatocyte monolayers on chamber slides, and was confirmed by electron
microscopy (Figure 7).
Figure 7. Morphology ofhepatocyte apoptosis, showing nuclearfragmentation and cytoplasmic condensation with blebbing
a, apoptotic hepatocyte in mouse liver (paraffin section, haematoxylin and eosin, original magnification x600);
b, apoptotic hepatocyte in primary culture (toluidine blue 200nm plastic section, original magnification x400);
c, apoptotic hepatocyte in primary culture (Feulgen stain, original magnification x400);
d, apoptotic hepatocyte in primary culture (transmission electron micrograph).
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The use of chamber slides gave improved optical resolution at high magnification when
compared with conventional tissue cultureware. Bourn's fixative was selected from a
variety of formalin, formalin/alcohol and alcoholic fixative mixtures as giving the best
nuclear morphology with a crisp nuclear membrane. Feulgen staining provided slightly
crisper, more detailed nuclear morphology than acridine orange staining, avoiding
problems of cytoplasmic autofluorescence and RNA fluorescence that lent a slight
haziness to hepatocytes. Moreover, the problems of rapidly-fading fluorescence were
eliminated and counting by light microscopy was less fatiguing than by fluorescence in a
dark room.
In order to compare the relative sensitivity to detect apoptosis using these stains, acridine
orange-stained monolayers were restained by the Feulgen method, and the results of
counting similar areas of the culture slide compared (Figure 8). The results showed that
compared with acridine orange, Feulgen staining had a similar sensitivity to detect
apoptosis. The figure also shows that counts of the same culture slide were consistent in
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Figure 8: Running means for apoptotic index in culture, and comparison ofacridine orange with Feulgen staining.
Cultures ofhepatocytes derivedfrom the same mouse andplated onto 4 culture slides (A-D) were stained with
acridine orange and countedfor apoptosis, then Feulgen-stained and recounted. Slides A and B
coated; slides C and D uncoated.
The variability in apoptosis counts between slides C and D was a feature ofcultures on uncoated slides, where
heterogeneity ofcell survival over the culture surface was increased comparedwith coated slides (i.e. dispersed
aggregates ofdying cells, better survival toward the edges ofthe chamber slides), so requiring higher counts to
achieve running means (the mean apoptotic indices ofC and D are converging only by 1200-1300 cells
counted).Fibronectin-coated slides were usedfor all experiments described in Results.
Key: Red lines show counts with acridine orange staining; black lines depict counts after Feulgen staining (slides A




The two primary antibodies used to label p53 protein were pAb421 (Oncogene Science),
a mouse monoclonal IgG2a that binds an epitope near the C-terminus, and CM5 rabbit
polyclonal antiserum, that recognises seven distinct epitopes distributed throughout the
p53 protein <402).
p53 immunohistochemistry was performed on formalin-fixed low temperature paraffin
sections on polylysine coated slides after steam exposure in a pressure cooker for 10
minutes, according to the recommended protocol supplied with the CM5 antiserum
(Novocastra, UK). Hepatocyte cultures on chamber slides were fixed in ice cold
acetone/methanol (1:1 v/v) for 10 minutes and stored dry at -80°C. Positive nuclei were
visualised by an avidin-biotin peroxidase labelling procedure, summarised below:
After rehydration, the slides were exposed to 1% hydrogen peroxide for 10 minutes,
washed in PBS, then incubated for 10 minutes in 20% serum, 0.5% Tween 20 in PBS.
Endogenous biotin was blocked using a kit (Vector laboratories), according to the
manufacturer's instructions. Paraffin sections were incubated in CM5 for 1 hour at room
temperature, whilst chamber slides were incubated with primary antibody in a humid
chamber overnight at 4°C. pAb421 was diluted 1/1000 in PBS containing 5% rabbit
serum and 0.5% Tween 20. CM5 was diluted 1/1500 for labelling cultured cells and
1/300 for paraffin sections. Negative controls omitted the primary antibody. After
washing in PBS, the appropriate secondary antibody was applied for 30 minutes, either
biotinolated rabbit anti-mouse F(ab')2 (Dako) at 1/400 dilution or biotinylated sheep anti-
rabbit (Dako) at 1/500 dilution. Avidin-biotin horseradish peroxidase complex (Dako)
was used as the final labelling step and the chromogen was Liquid DAB
(Diaminobenzidene) with DAB enhancer (Biogenex), each applied according to the
manufacturers' instructions. Slides were then counterstained, mounted and coverslipped.
3.2.f2 5-Bromo-2'-deoxyuridine (BrdU)
Cultures plated onto Lab Tek Permanox chamber slides were exposed to medium
containing 40pM BrdU for 3 hours, after which they were fixed overnight at 4°C in 70%
ethanol/PBS. Cells that had incorporated BrdU into DNA were labelled by an indirect
peroxidase immunocytochemistry technique, as follows:
Chamber slides were exposed to 1% H202 in distilled water for ten minutes, then rinsed in
PBS and incubated in 5M HC1 for 1 hour, followed by three 5-minute washes in PBS to
restore neutrality. Cells were then incubated in 20% normal rabbit serum with 0.5%
Tween 20 in PBS for 10 minutes. This was blotted off and cells incubated for 1 hour in
purified monoclonal rat anti-BrdU IgG2a (Sera Lab) diluted 1/100 in 5% normal rabbit
serum/Tween 20/PBS. Negative control slides omitted the primary antibody. After two
five minute washes in PBS, the slides were incubated for 30 minutes in affinity isolated
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horseradish peroxidase-conjugated rabbit anti-rat IgG (Sigma) that had been adsorbed in
normal mouse serum and was diluted 1/50 in Tween 20/PBS. Excess antibody was then
removed by three 5 minute washes in PBS. Positively stained nuclei were visualised by
Liquid DAB Chromogen with DAB enhancer (Biogenex), used according to the
manufacturer's instructions. Slides were counterstained with haematoxylin and light
green, air dried, mounted in cedarwood oil and coverslipped.
Immunohistochemistry was performed on methanol-fixed low temperature paraffin
sections preincubated in 5M HC1 for 1 hour, using a standard avidin-biotin peroxidase
procedure (section3.2.f. 1). The primary antibody was the rat anti-BrdU monoclonal
(Sera Lab) and the secondary a biotin-labelled goat anti-rat immunoglobulin (Dako).
Negative controls omitted the primary antibody.
For evaluation of BrdU positivity in experiments utilising TCPOBOP (see section3 .2.a. 1)
700 hepatocytes (sufficient to achieve a stable running mean — see Appendix) were
counted from at least seven randomly selected fields and the results expressed as a
percentage (BrdU labelling index). BrdU positivity in experiments utilising y-irradiation
or CC14 was expressed as positive cells per 20 randomly chosen high power (x400) fields
(running mean achieved at 14 high power fields, Appendix).
3.2.f3 Immunofluorescence
Indirect immunofluorescence was performed on hepatocyte cultures using polyclonal
antisera to murine albumin (rabbit IgG, Nordic Immunological Labs Ltd), murine
fibrinogen (goat IgG, Nordic Immunological Labs Ltd) and a purified mouse monoclonal
IgG2a antibody to P-galactosidase (Oncogene Science).
Hepatocyte cultures on chamber slides were fixed in ice cold acetone/methanol (1:1 v/v)
for 5 minutes and stored dry at -80°C until use. After rehydration in PBS indirect
immunofluorescence was performed by incubation in primary antibody for 30 minutes
followed by three PBS washes and incubation in the appropriate fluorescein isothionate-
conjugated (FITC) secondary antibody for 30 minutes. After further washes in PBS,
aqueous mounting and coverslipping, slides were viewed under uv illumination from a
mercury lamp using a dichroic filter appropriate for FITC (green) fluorescence.
3.2.g Flow cytometric evaluation of nuclear ploidy
Fresh liver tissue for DNA analysis was collected, dissaggregated and nuclei stained by
propidium iodide as described by Vindelov (403'404). This method produces clean, single
nuclei essentially devoid of residual cytoplasm, as confirmed by examination ofwet
preparations and cytospins. Ten thousand nuclei from each sample were analysed for
DNA content by a Coulter EPICS CS flow cytometer, measuring fluorescence emitted by
each nucleus at 610nm (red fluorescence) in 488nm Argon laser light. The gate was set to
red fluorescence and the results of each analysis were viewed as a histogram of recorded
red fluorescent events. The total red fluorescence emitted by each nucleus is
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proportional to the amount ofbound propidium iodide. Since propidium iodide binds
stochiometrically to DNA the integral red fluorescence recorded by the flow cytometer
for each nucleus is proportional to DNA content. The histograms of red fluorescence are
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Figure 9. Histogram oflinear red fluorescence for propidium iodide-stainedfresh hepatocyte nuclei. Peaks F, G, H
represent DNA contents of2n, 4n and 8n respectively.
3.2.h Transient transfection of primary hepatocytes
Under appropriate conditions, eukaryotic cells can take up exogenous DNA, and a
portion of this DNA becomes localised in the nucleus. This phenomenon has been widely
exploited to obtain both transient and stable expression of various genes. A wide variety
ofmethods have been developed to facilitate this process, ofwhich one of the most
efficient and reproducible in mammalian cells utilises liposomes containing cationic and
neutral lipids [FelgnerPL1987],
The mechanism by which cation-liposomes mediate transfection ofDNA into animal cells
is incompletely understood. Negatively charged phosphate groups ofDNA associate with
the positively charged surface of the liposome, forming a lipid-DNA complex. Residual
positive charge on the liposome causes it to associate with cell surfaces, following which
there is evidence for both endocytosis of the whole complex by the cell and for fusion of
the liposome-DNA complex with the plasma membrane, releasing the DNA directly into
the cytoplasm 1405 4H6)[FelgnerPL 1987], Several synthetic cationic lipid formulations are
available ofwhich, for primary hepatocytes, Lipofectin has been reported to be the most
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effective, or at least equally effective when compared with other lipids (405"407) The
requirement for transfection to occur under serum-free conditions was not a problem in
the present culture system.
3.2.h.l Plasmids transfected
pCMVP (Clontech) is a mammalian expression vector designed for the constitutive
expression of P-galactosidase from the Escherichia coli lacZ gene in mammalian cells,
under the control of the human cytomegalovirus immediate early promoter/enhancer. This
promoter was selected since it has been shown to give greater expression of reporter
genes in lipofected primary hepatocytes when compared with several other promoters
(408)
pRGCAFosLacZ is a reporter plasmid for transcriptionally active wild type p53. It is
based upon the pBSK plasmid into which has been cloned oligonucleotides containing
two copies of a p53 RGC binding site, a transcriptionally inactive mutant murinefos
promoter, the lacZ gene (open reading frame), and the small t intron with the
polyadenylation signals of SV40 (409). Wild type p53 binds strongly to the RGC elements
and stimulates expression of P-galactosidase. pRGCAFosLacZ and a negative control
plasmid pAFosLacZ, which is identical except lacking the RGC fragment necessary for
p53 binding, were the kind gift of Professor S.H. Friend, (Dept. of Paediatrics, Harvard
Medical School, USA).
Figure 10. pCMVf)plasmid. key: CMV e/p, cytomegalovirus immediate early promoter enhancer; SV40 sd/sa, SV40
splice donor/splice acceptor; LacZ, fi-galaclosidase gene; SV40polyA, SV40polyadenylation signal; Ampr,
Ampicillin resistance gene.
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Figure 11. p53 reporter plasmid and control plasmid. Key: SV40 t-polyA, small t intron and polyadenylation
signals ofSV40; LacZ, /3-galactosidase; AFos, mutant murine Fos promoter; RGC, ribosome gene clusterp53
binding site; Ampr, Ampicillin resistance gene.
Plasmid preparation
Plasmid DNA (approximately lOng in not more than lpl TE) was introduced into
competent Escherichia coli (e.g. 40pl strain DH5a) by incubation on ice for 20 minutes
followed by heat shock at 42°C for 40 seconds and chilling on ice for 2 minutes. The
bacteria were then incubated for 1 hour at 37°C with 160pl of SOC medium (Appendix)
in an orbital incubator at 220 rpm in order to allow expression of antibiotic resistance by
the transformed bacteria. Using a sterile glass spreader the organisms were then
inoculated onto LB agar plates with appropriate antibiotics (Appendix) and cultured at
37°C for 16-20 hours. Several single colonies were then isolated and individually cultured
in 20mls LB medium with the appropriate antibiotic in the orbital incubator at 220 rpm
and 37°C until cloudy (approximately 3 hours). Aliquots of each culture were stored at -
80°C in 50% glycerol, whilst the remainder was pelleted by centrifiigation at 6500 rpm
for 5 minutes. Plasmid DNA was prepared from each of these mini-cultures, using the
QIAprep Spin Plasmid Kit (Qiagen). These mini-preparations of plasmid DNA were done
to allow verification of plasmid identity by restriction enzyme digestion and gel
electrophoresis, before larger scale preparation of the plasmid. The large scale
preparation was done with QIA Tip-100 or Tip-2500 kits (Qiagen) from a 100ml or a
500ml bacterial culture (up to 16 hours incubation in antibiotic-supplemented LB
medium). In each case the manufacturers' instructions were followed. Essentially, the
Qiagen kits utilise alkaline lysis of bacteria with denaturation of proteins, plasmid and
chromosomal DNA, followed by separation of soluble, renatured plasmid DNA from
complexed chromosomal DNA, protein and detergent. The plasmid is then highly purified
by selective binding to a resin, followed by washing and subsequent elution. Purified
plasmid from these procedures was desalted and concentrated by precipitation in
isopropanol, centrifugation and washing of the pellet in ice-cold 70% ethanol. The air-
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dried plasmid pellet was resuspended in 1ml tissue culture grade PBS. Plasmids were
stored in this form at -80°C.
Verification of piasmid identity
Purified plasmid DNA (>lp.g) from the mini-preparations was digested in sterile
microfuge (Eppendorf) tubes containing a mixture of the appropriate restriction
endonuclease (Promega or Boehringer Mannheim) with the recommended buffer diluted
in DDW. Digestion was usually carried out at 37°C for at least 1 hour. Enough enzyme
was used to ensure complete digestion (1 unit of enzyme completely digests lpg of
plasmid DNA in 1 hour at 37°C). The volume of enzyme in the final reaction mixture was
adjusted to keep glycerol from the stock enzyme solution less than 5% v/v, in order to
prevent interference by the glycerol with enzymatic activity.
In order to characterise the prepared plasmids, plasmid DNA and the products of
restriction enzyme digestion were separated on agarose gels, along with a reference
kilobase ladder molecular weight marker (Life Technologies). Gel electrophoresis
separates DNA fragments of different sizes and conformation (supercoiled, nicked
circular or linear) because of their different migration rates through the gel toward the
anode in an electric field. Ethidium bromide in the gel intercalates into double stranded
DNA, allowing visualisation under uv light of fluorescent bands corresponding to
migrated DNA fragments of various sizes. Preparation of 1% agarose gels in TBE and
electrophoresis followed the protocols of Sambrook et al(410). Samples were mixed with \
volume of gel loading buffer (Appendix) and loaded into the wells of a gel submerged in
TBE. Electrophoresis was continued until the bromophenol blue marker had migrated
across 80-90% of the gel. Plasmid fragment sizes were estimated by reference to the
kilobase ladder marker.
The concentration ofDNA in plasmid preparations was estimated by measuring the
optical density (OD) at A,=260nm of a 1:100 diluted sample, using a Genequant II
spectrophotometer (unit OD26o=50|j.g DNA/ml). OD26o/OD280 ratios were used as a
measure of sample DNA purity.
3.2.h.2 Cationic liposome-mediated transfection
Lipofectin Reagent (Life Technologies) was used as the vehicle for transfection ofDNA
into hepatocytes. Lipofectin is a 1:1 (w/w) liposome formulation of the cationic lipid N-
[l-(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium chloride (DOTMA), and dioleoyl
phosphotidylethanolamine (DOPE) in water.
Primary hepatocytes were plated into fibronectin-coated 24 or 12 well tissue culture
dishes at a density of 0.2-0.3 x 105/cm2 and transfection was generally performed after 48
hours culture. The monolayers were fed with fresh, serum-free modified Chee's culture
medium a few hours prior to transfection. The quantities of reagents given here have been
optimised for a single 24 well chamber (1.90cm2), and were scaled up appropriately for
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larger well sizes. Lipofectin reagent (6pl of lmg/ml) was diluted into lOOpl serum-free,
antibiotic-free culture medium and incubated at room temperature for 45 minutes. This
suspension was then mixed gently with lOOp.1 of serum-free, antibiotic-free medium
containing purified plasmid DNA (lpg) and incubated for a further 45 minutes at room
temperature. The mixture was then made up to 300pl with serum and antibiotic-free
medium, and layed over hepatocytes in place of the existing culture medium. The cultures
were incubated at 37°C in a humid 5% C02/95% air atmosphere for 6 hours, whereupon
the DNA-containing medium was replaced with 500pl standard culture medium.
3.2.h.3 Effects of irradiation on p53 reporter plasmid expression
Primary hepatocytes were cultured for at least 40 hours on fibronectin-coated 12 well
culture dishes and then transfected with pCMVP or pRGCAFosLacZ or pAFosLacZ
plasmids, according to the protocol described in section 1. 24-48 hours later the cultures
received either uv-c (0 or 10J/m2) or y-irradiation (0 or 15Gy) as described in section
3.2.c. The culture medium was changed after a further 48 hours if the cells were not yet
harvested for estimation of P-galactosidase activity (section 3.2.i.3).
3.2.i Cytochemical staining
3.2.L 1 Tetrazolium dye assay ofculture growth and survival
Microculture tetrazolium assays depend upon the reduction of exogenous tetrazolium
salts to coloured formazans by mitochondrial succinate dehydrogenase in living cells. The
present protocol is based on a modification by Carmichael(4U) to the assay originally
described by Mossmann (412), utilising 3-(4,5-dimethylthiazol-2-yl)-2,5-dyphenyl
tetrazolium bromide (MTT).
Hepatocytes cultured in Permanox chamber slides or 24 well tissue culture plates were
incubated under normal culture conditions for 3 hours in culture medium containing
lmg/ml filtered MTT (from a lOmg/ml stock solution in medium). After this time the
medium was discarded and cultures washed with PBS. The PBS was aspirated and the
culture wells allowed to dry. DMSO was then added (lOOpl/ 1.9cm2 well) and mixed
briefly to ensure that all the formazan dye was solubilised. Aliquots were then transferred
to a 96 well ELISA plate and the absorbance read at 490nm (negative control omitting
MTT) by an ELISA plate reader (MR 5000, Dynatech).
3.2.L2 In situ staining oftransfected hepatocytesfor f3-galactosidase activity
After removal of culture medium and rinsing with PBS, cells were fixed by 0.05%
glutaraldehyde in PBS for 5 minutes at 4°C. The fixative was discarded and cells washed
three times in PBS, leaving the second wash on for at least 10 minutes. Monolayers were
then incubated at 37°C in 5-bromo-4-chloro-3-indolyl P-D-galactopyranoside (X-gal)
solution (Appendix) overnight, using sufficient volume to cover the cells. Positive cells
were easily visualised under light microscopy by their strong, blue colour (Figure 12).
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Figure 12X-gal staining ofpCMVfi-transfected hepatocyte primary cultures.
3.2.L3 Quantitation of )3-galactosidaseactivity by colorimetric assay
p-galactosidase activity in transfected hepatocytes was quantified using the Beta-
Galactosidase Enzyme Assay System with Reporter Lysis Buffer (Promega), following
the manufacturer's instructions. Firstly, cell extracts were prepared by rinsing the
monolayers with PBS and then incubating in Reporter Lysis Buffer, appropriately diluted
in water, using sufficient to just cover the cells (eg: lOOpl for one chamber of a 24 well
plate). After 15 minutes incubation at room temperature the dishes were scraped clean,
the resultant lysate vortexed, centrifuged in a microfuge at 4°C for 2 minutes (13,000
rpm), and the supernatant stored at -80°C until use.
The cell extracts were then assayed for P-galactosidase activity by measuring the amount
of yellow hydrolysis product (o-nitrophenol) generated from ONPG substrate (o-
nitrophenyl-P-D-galactopyranoside). Untransfected hepatocytes were used as a negative
control for the assay. A 30p.l aliquot of each cell extract was incubated with an equal
volume of 2x Assay buffer, containing the ONPG substrate, in a 96 well plate for 30
minutes to 3 hours, until a yellow colour was appreciable. A standard curve for
P-galactosidase activity was also prepared over a range of 0-5.0 milliunits, according to
the manufacturer's instructions, using the P-galactosidase supplied (1unit/pl; one unit of
enzyme hydrolyzes lpmol ONPG per minute at pH7.5 and 37°C.) Standard curve assays
were incubated in parallel with and for the same length of time as the test sample extracts
The reaction was then stopped by mixing in 90(j.l 1M Na2C03 and the absorbance at
420nm read by an ELISA plate reader (MR 5000, Dynatech).
To account for variability in the number of cells recovered from each well for estimation
of P-galactosidase activity, the protein concentration of each cell extract was estimated.
A known aliquot of each cell extract (usually 20pl, but this was altered if necessary to
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keep the final absorbance within the linear range of the standard curve) was diluted into
800|il distilled water, mixed with 200pl of Protein Assay Dye Reagent (Biorad) and
incubated at room temperature for 10-60 minutes. The negative control used Lysis
Buffer. A standard curve was constructed using a bovine serum albumin 2mg/ml standard
solution (Biorad), diluted to final concentrations of l-8pg/ml and incubated in parallel
with the test samples. The absorbance was then read at 595nm.
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4. Optimisation of hepatocyte isolation and
culture
Primary hepatocyte culture offers an oppurtunity to complement and extend observations
made in vivo, by combining the use of authentic hepatocytes (i.e. not cell lines) with the
ability to regulate and control the hepatocytes' environment. For a fully-defined culture
environment, it is necessary to use serum-free culture medium. This chapter describes the




Production of a single cell suspension from liver requires that intercellular junctions be
disrupted and cell-to-matrix adhesion abolished. Current techniques for the isolation of
viable hepatocytes are based on original studies on rats. Early attempts using mechanical
disruption generally produced non-viable cells in low yield and have been superceded by
protease enzyme-based isolation methods, ofwhich collagenase has remained the most
widely used enzyme since its introduction by Howard in 1967 <413). Howard reported the
isolation of intact rat hepatocytes representing 3-5% of the original liver using a
collagenase/hyaluronidase solution injected into hepatic sinusoids, followed by incubation
of thin liver slices in further enzyme solution. This was the first unequivocal
demonstration that the preparation of suspensions of intact hepatic parenchymal cells was
possible.
In order to obtain better exposure of the liver connective tissue to enzyme and better
survival of hepatocytes during digestion, Berry and Freind perfused the liver through the
hepatic portal vein with oxygenated, balanced saline solution containing
collagenase/hyaluronidase (4I4). This gave hepatocyte yields representing 30-50% of the
original liver. Adequate separation of parenchymal cells from each other requires
exposure to a Ca* -free medium in order to irreversibly disrupt intercellular calcium-
dependent junctions, but the collagenase activity necessary to digest the extracellular
hepatic matrix is calcium-dependent. Therefore Seglen devised the two-step perfusion,
whereby perfusion of the liver with a Ca++-free medium is followed by perfusion with a
calcium-enriched collagenase-containing medium (415). Although numerous minor
refinements have since been introduced (416), the collagenase perfusion technique has
remained essentially as described by Seglen. It is now common practice to obtain yields of
rat hepatocytes between 40-50% of the theoretical maximum yield, and with trypan blue
exclusion routinely exceeding 95%.
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4. I.clI Murine hepatocyte isolation
Only Klaunig has published a systematic comparison of different techniques for the
isolation ofmouse hepatocytes (417). Other authors have reported particular variations of
the one-step method ofBerry and Friend or the two-step method of Seglen, applied to
mouse hepatocyte isolation (4,8 425) Both hepatic portal and retrograde (i.e. abdominal or
thoracic inferior vena caval) perfusion techniques have been tested, with no consistently
preferred technique emerging. Klaunig favoured portal perfusion, however this gave
lower yields than retrograde techniques unless intermittent pressure was allowed to build
up within the liver during perfusion by occluding the perfusate outflow, a procedure
considered by Berry to be damaging to the cells (87). The greatest yields were reported by
Renton, using a retrograde technique similar to that described here (418). However there is
difficulty in comparing different authors' results, because of frequent failure to report
yields and viabilities and uncertainties about nutritional state, weights, gender and strains
of mice used. In general, yields are proportionately lower than for rat livers and many
groups report trypan blue exclusion of only 80-90%, a level unacceptable for rat
hepatocyte isolation and which suggests greater fragility ofmouse compared with rat
hepatocytes <87). Furthermore, incomplete dissagregation causing cell clumping seems to
be a more frequent problem for murine hepatocytes, even using batches of collagenase
known to be satisfactory for use on rat livers (R. Schulte-Hermann, communication).
4. l.a.2 Changes to hepatocytes during isolation
Although hepatocyte responses are conveniently studied in primary culture, phenotypic
changes may affect the interpretation or relevance of results for hepatocytes in vivo. It is
therefore important to consider the effects on hepatocytes of isolation and culture. This
section reviews the changes to hepatocytes during isolation, before discussing the chosen
method of isolation; phenotypic changes in culture are reviewed in the section on
monolayer culture.
The original report of one-step liver perfusion, by Berry and Friend, described the
ultrastructural changes that occurred in the rat liver, and others have added little to that
report. Klaunig has since described the ultrastructure ofmouse liver during 2-step
perfusion, which is similar to the changes described by Berry and Friend (417). Perfusion
with Ca +-free solution has little effect on hepatic architecture: sinusoids swell and there
is partial denudation of sinusoid lining cells. Hepatocytes themselves show only swelling
of endoplasmic reticulum and partial separation at areas of interdigitation, although
junctional complexes remain intact. However perfusion with collagenase solution causes
gross architectural disruption: hepatocyte plates break down as hepatocytes separate into
single cells or small aggregates, held together by the tight junctions around bile canaliculi.
Desmosomes are cleaved, forming hemidesmosomes which are endocytosed. Isolated
cells separate by physical shearing of tight and gap junctions or by tearing off blebs of
cytoplasm from their neighbor around the junctions. The resulting defects in membrane
integrity appear to reseal quickly, and excess water entering the cell is probably exported
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via the Golgi apparatus. However, there is substantial loss of cellular potassium during
perfusion (up to 60% of total<414)). With the loss of intercellular contacts, the hepatocyte
cytoskeleton disperses, however this change is reversed in monolayer culture when cell
junctions are reestablished and much of the polarity of the native cell can return (426).
Foy has recently added to these morphological assessments by magnetic resonance
imaging of rat liver during perfusion ex vivo to measure intrahepatic flow, pH and ATP
levels (427). Hepatic perfusion with Ca++-free solution was homogeneous and did not
significantly reduce intracellular pH or ATP levels. By contrast, perfusion with
collagenase solution led to dramatically disrupted intrahepatic flow within 3 minutes
(multiple unperfused foci), associated with profound decreases in intrahepatic ATP
concentration (undetectable by 6 minutes), and pH (nadir 6.79). These effects were not a
direct effect of collagenase on hepatocytes, but were probably related to local ischaemia
due to poor local perfusion. Thus, despite minimal intracellular ultrastructural injury,
hepatocyte isolation inflicts considerable, albeit brief, metabolic stress to the cells. This is
apparently tolerated quite well: the ability to synthesize glucose from lactate is retained to
50% of the level in situ (414). The gluconeogenic assay is a searching test ofmetabolic
integrity, since the anabolic process involves both mitochondrial and cytoplasmic
compartments (428).
Most of these changes appear to be temporary if the stress is not prolonged. However an
important consequence of isolation is shift of hepatocytes from replicative quiescence
(Go) into Gi phase of the cell cycle. In vivo, adult hepatocytes are largely unresponsive to
mitogens and become competent only after a "priming" stimulus that causes them to
progress into Gi. Such stimuli include partial hepatectomy, necrosis, metabolic stress or
any disruption of extracellular matrix or cell-cell contacts. Even sublethal concentrations
of collagenase, infused through the hepatic portal vein in vivo, are sufficient as a priming
stimulus for mitogen responsiveness (49), and it has been demonstrated that isolation into
culture of primary hepatocytes causes expression of immediate early genes fos,jun and
myc that mark entry to Gi(51). Therefore primary cultured hepatocytes are a system
representative of a stimulated liver ("primed for regeneration") rather than quiescant
liver.
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4.1.b Surgical method for hepatocyte isolation
Figure 13:Routes for liver perfusion
The present technique of retrograde 2-step perfusion under terminal anaesthesia, was
based on the studies cited above. It was also possible to perform perfusion on mice that
were killed by cervical dislocation, 30-60 seconds after injection of heparin (Multiparin,
100 units) into the tail vein. Anterograde (portal venous) and retrograde (vena caval)
routes ofperfusion (Figure 13) were tested with this protocol and each yielded viable
hepatocytes (Table 10). However, despite heparinisation, intrahepatic venous or sinusoid
thrombosis was a recurring problem that resulted in poor perfusion of a particular
segment or of the peripheral liver. Occasionally the entire liver did not perfuse.
Furthermore, hepatocyte clumps (5-20 hepatocytes in aggregates, often including dead
cells) were relatively more frequent in the final isolate, reducing the quality of the
preparation. Therefore this approach was abandoned in favour ofperfusion under
terminal anaesthesia, in which circulation continued almost until perfusion was started,
thus preventing intrahepatic stasis and thrombosis. Retrograde perfusion through the
inferior vena cava and hepatic veins was selected as the route ofchoice, primarily because










retrograde 23 19 14 23 90
perfusion
portal perfusion 6 20 17 27 89
Anaesthetised:
Collagenase a 16 13 17 14 88
Collagenase I 40 26 27 33 93
Collagenase IV 18 30 25 37 93
Table 10: Hepalocyte yields and viabilities for different perfusion protocols
4.1.c Choice of collagenase
The type and batch of collagenase are major factors affecting the quality and yield of
isolated hepatocyte preparations (4L'There is unpredictable batch-to-batch variability
that is due to uncertainty about which components of "crude" collagenase are essential
for satisfactory cell separation; different ratios of various non-collagenase protease
activities (clostripain, tryptic, caseinase etc.) are present in "crude" collagenase, removal
ofwhich can substantially decrease the quality of cell separation achieved. These preclude
definitive statements about the suitability of a particular collagenase for perfusion without
prior testing on the particular species of interest. For mouse liver perfusion, Boerhinger
collagenase h gave relatively poor yields and was also not recommended by others
(personal communication). Collagenase a (Boerhinger) has proved satisfactory for mouse
perfusion by others (personal communication) but gave dissapointing yields with mice
used here (Table 10). Better results were obtained using Sigma Collagenase I and IV.
These were similar in terms of viable hepatocyte yields produced (Table 10), however
collagenase IV generally gave fewer hepatocyte aggregates. The inclusion ofDNAse I in
the digestion medium was also effective to reduce the prevalence ofaggregates.
Continued incubation in digestion medium ex vivo for 10-15 minutes, as suggested by
Seglen t415) was found to be useful if the initial perfusion digestion was not optimal, or
after collagenase I perfusions— to decrease aggregation without compromising cell
viability.
4.1.d Perfusate composition
The value of continuously oxygenating the perfusate was not specifically evaluated and
was reported by Klaunig to be unnecessary (417). However of a series of otherwise
comparable isolations utilising collagenase I the average viable hepatocyte yield with
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means over 99% of freshly plated cells in monolayers were identified as hepatocytes.
Immunofluorescence cytoplasmic positivity for fibrinogen and albumin was also
demonstrated as further confirmation of cell phenotype.
Figure 14 phase contrastmicrograph ofhepatocytes in primary culture
4.1.g Precision of cell counting
It is standard practice to evaluate the yield of hepatocytes using a haemocytometer,
however there are potential sources of error. The occurrence of cell doublets and
aggregates in the hepatocyte isolate causes departure of the sample from the Poisson
distribution, resulting in underestimation of the true count (overdistribution error). The
number of cells counted also affects precision: the particular dilution of cells used here
(see Methods, section 3.1 b.3) was chosen so that approximately 500 cells would be
counted (representing a yield of 25 million); this gives a reasonably precise estimate
without being impractical(431>. If smaller numbers of cells were counted (250-300),
repeated counts from the same hepatocyte isolate were found to differ more than
expected from random fluctuation (e.g. 295, 322, 259, 260; p=0.02, %2 test) and therefore
to provide unreliable estimates of the true yield. In practice, the average of 2 independent
fillings of the haemocytometer was used to estimate yield.
4.2 Monolayer culture
Maintenance of a differentiated phenotype in cultured hepatocytes is obviously important
for data to remain relevant to hepatocytes in vivo. This section discusses some of the
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phenotypic changes that can occur in cultured hepatocytes and factors that affect those
changes. The results of attempts to optimise culture conditions for primary hepatocytes
will then be presented. In particular, serum-free culture was desirable — firstly, because
5-10% serum in culture medium does not promote differentiated function; secondly, to
allow fully-defined conditions of supplementation with cytokines to be tested; and thirdly
to prevent growth of contaminant cell populations.
4.2.a Background discussion
Hepatocytes can be plated onto tissue culture plastic and maintained for a few days in any
of several "off the shelf' simple culture media, such as Leibowitz LI 5 or Dulbecco's
modified Eagle's medium, supplemented with 5-10% serum. The major problems
associated with this "simple" monolayer culture of primary hepatocytes are shortened cell
survival time, including detachment from monolayers after 4-5 days, and alterations in
gene expression and differentiated function that rapidly depart from the in vivo state.
Such alterations include decreases in gluconeogenic enzymes, cytochromes P-450,.
NADPH cytochrome P-450 reductase, cytochrome bs, and associated drug metabolising
activities; reduced synthesis and secretion of albumin and other serum proteins, shifts in
isoenzyme expression patterns away from those typical of hepatocytes and increased
expression of proteins found in foetal liver (e.g. a-fetoprotein and y-glutamyl
transpeptidase). There is also increased expression of genes for some cytoskeletal
proteins such as actin and tubulin [reviewed by (432'433)], The changes do not necessarily
indicate "dedifferentiation" of the hepatocytes; several liver-specific enzyme activities are
hormone-dependent and can be restored with the appropriate hormone supplement.
However fundamental changes in gene expression do occur in simple cultures that reflect
greatly diminished transcription of the relevant genes (434). Variables known to influence
these changes include cell density, matrix attachment and composition, culture medium
composition, heterologous cell interactions and the source animal species. An exhaustive
investigation of these factors was not possible, however the effects of varying substratum
and medium composition were tested and will first be briefly discussed.
4.2. a. 1 Cell substratum
Use of culture-ware coated with adsorbed matrix protein greatly enhances cell
attachment, particularly in serum-free media, and also promotes DNA synthesis,
depending on the particular matrix protein (54'55). Matrix films probably have little
additional effect on preservation of differentiated function, although use of collagen gel
"sandwiches" with hepatocytes intercalated has been reported to greatly improve survival
and albumin secretion <435). Complex biomatrices such as "Matrigel" also greatly improve
functional preservation, but contain many undefined components in addition to the
cocktail of known cytokines (e.g.TGF(3) and matrix proteins (e.g.laminin). Until recently
it was thought that such biomatrices were essential for preservation of phenotype in vitro,
however several reports now indicate that highly supplemented culture media are capable
of preserving many hepatocyte functions at levels comparable to those in vivo, with only
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simple substrata such as collagen-coated tissue culture plastic (436). This is particularly
true for primate hepatocytes (437).
4.2. a.2 Culture medium
Medium formulation is a major determinant of both culture survival and maintenance of
hepatocyte phenotype. The literature on the subject is large, confusing and almost entirely
devoted to rat hepatocytes, however it is clear that most commercially available media,
while containing many of the basic requirements for cell survival, are inadequate to fully
support the complex requirements of hepatocytes. Serum-free media are desirable, since
serum is undefined, contains factors that do not aid maintenance of differentiated function
(432), and promotes growth of non-parenchymal cells. High initial concentrations of amino
acids (5-10 fold greater than in serum) are required to offset rapid utilisation and
maintain protein synthesis (438,439); DNA synthesis also depends strongly on proline
content(440). Of carbohydrates, lactate and pyruvate are better substrates than glucose
unless it is at very high concentration (>20mM). Selenite, transferrin, and linoleic acid are
commonly added to hepatocyte culture media, in addition to other trace elements not
present in simple media, whose individual contribution to culture quality is uncertain.
Indeed such assessments are often difficult to make or even irrelevant in isolation, given
the complex interaction by which a hormone/factor with a positive effect on one function
may have no or a negative effect on others, and that interactions between hormones are
not predictable sums of their individual actions (441'442)
Glucocorticoids have the most marked effect of hormones on preservation of function
and of hepatocyte viability and are universally added to media. Two-dimensional gel
analyses have shown that synthesis of approximately 80 proteins changes in the first 20
hours of rat hepatocyte culture (44j) and that dexamethasone at 30-100nM is sufficient to
reverse or retard these changes (with induction or repression of a further group), and
preserve albumin synthesis and morphology (444). Insulin enhances cell attachment,
survival and anabolic functions— effects that are maximal at lOOnM (439>. Epidermal
growth factor may also preserve hepatocyte morphology and albumin synthesis in
addition to its mitogenic effects (441>. The beneficial effects on hepatocyte function of
other hormones such as glucagon and tri-iodothyronone, are less well documented
(442,445)
Non-physiological supplements have also been reported to benefit hepatocyte
preservation or function, although how exactly is not usually clear. DMSO (2%) is best
characterised and causes initial detachment of a proportion of cells but in the remainder
preserves several liver specific functions and hepatocyte morphology for several weeks, in
a glucocorticoid and insulin dependent manner(444). However these effects are largely due
to abnormal mRNA stability rather than restoration of gene expression levels.
Phenobarbital and nafenopin extend culture lifespans, and phenobarbital promotes long
term retention of albumin secretion (10-20% initial values) and cytochrome P-450b
activity (436>446). Nicotinamide may benefit cultures <447). Butyrate (5mM) prolongs
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hepatocyte survival and preserves phenotype and morphology, perhaps by modulating
histone acetylation (448-449).
In summary, there are few published systematic evaluations of the contributions of
individual medium components to maintenance of hepatocyte phenotype; those available
are performed on rat hepatocytes. However, defined complex media are now formulated
that extend survival and substantially preserve at least some hepatocyte-specific functions
and characteristics in simple monolayer culture.
4.2.b The MTT assay.
The MTT assay was chosen here as a convenient means to compare the effects of
different substrata and medium formulations on primary hepatocyte culture. For a given
medium formulation, formazan dye production by hepatocytes was proportional to
number plated (Pearson's linear correlation coefficient, r= 0.997; p<0.0001), although
falling off at higher plating densities as the culture surface became saturated and plating
efficiency dropped (Figure 15) . However it was not possible to use this method to
accurately track cell number over time because hepatocyte metabolic activity decreases
with time in culture, reducing the MTT-metabolising capacity of individual cells (87'450).
Thus the assay results are a product of both cell number and preservation of hepatocyte
metabolic capacity in culture. However, as it is desirable to maintain both of these factors
the assay was considered a useful if not completely specific index for culture
optimisation. One advantage of the assay was that direct observation ofmonolayers after
incubation with MTT, in which viable cells contained dark formazan crystals, permitted
validation of culture viability on a cell-by-cell basis, in addition to measurements of total
formazan production by the colorimetric assay.
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Figure 15Correlation ofhepatocyte plating density with MTT assay. Cells were plated on fibronectin-coated
petmanox wells (0.78cm2) for I hour before beginning the IvTTT assay.
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4.2.c Substratum composition.
Permanox has been reported to give better preservation of at least some hepatocyte
enzyme activities (cytochrome P450) (436 451)9 compared with other tissue culture plastic,
and was used in most of the experiments recorded here. Precoating culture surfaces with
fibronectin or collagen I considerably reduced hepatocyte detachment after 4-5 days of
culture. Fibronectin has also been reported to promote hepatocyte DNA synthesis(54) and
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Figure 16: Effects ofdifferent culture substrata and media on hepatocyte culture, as assessed by MTT assay.
Hepatocytes were plated (0.6x1 /cm2) as described in methods, then changed after 45 minutes to the indicated
medium.
(a) Freshly plated hepatocytes; (b) After 2 days culture.
Key: black, uncoatedpermanox, ; red, collagen coated (20pg/cm2); blue, fibronectin coated (2Qpg/cm2).
All media were supplemented with insulin (300nM) and dexamethasone (lOOnM). Fbs indicates 1% serum
supplement, EGF indicates 25ng/ml EGF supplement. Triplicate observations.
Fibronectin or collagen I coating ofpermanox did not affect MTT assay values for freshly
plated hepatocytes (Figure 16a), however by 48 hours of culture there was a tendency for
fibronectin-coated surfaces to give superior MTT results compared with either collagen I
or uncoated permanox, irrespective of the culture medium formulation (Figure 16b).
Rates ofapoptosis were also slightly lower for cultures maintained on fibronectin-coated
permanox, compared with uncoated tissue culture plastic, suggesting a direct action of











Figure 17: Effect ofculture substratum on hepatocyte apoptosis after 4 days culture in DMEM/F12, with
dexamethasone (lOOnM), insulin (300nM) and EGF (25ng/ml). Collagen andfibronectin were coated at
20pg/cm2.Cells were plated at 0.3x105/cm2. At least 1000 cells counted per observation; n=2 (permanox), 3
(collagen), 5 (fibronectin). Values expressed as mean + standard error ofthe mean.
4.2.d Culture medium formulation
Three media were evaluated on mouse hepatocyte cultures, a 1:1 mixture ofHam's F12
with Dulbecco-modified Eagle's minimal essential medium (DMEM/F12), Hepatozyme
SFM (Gibco) and a custom modification ofChee's medium (Appendix). DMEM/F12 is a
readily available culture medium that has been reported to be more effective than other
commonly available formulations for murine hepatocyte culture and growth<4;,2).
Hepatozyme SFM is a recently marketed complex medium designed for serum-free
culture of hepatocytes with increased preservation of liver-specific functions. Chee's
medium is a substantially modified form ofEagle's Minimal Essential Medium, with a
particularly high amino acid content and which contains a novel combination of glucose
with other carbohydrates. It has been shown to allow prolonged hepatocyte survival with
excellent preservation of several differentiated functions(436 444 453 >
The medium formulation had an immediate effect upon MTT-metabolising activity of
freshly plated hepatocytes, with Chee's medium giving values over 35% greater than
those with DMEM/F12, independent of supplementation with serum or epidermal growth
factor (Figure 16a). At this stage there was no difference in the viable cell numbers, as
assessed by trypan blue exclusion and counts ofMTT-metabolising cells. Therefore this






















Figure 18: Effect ofmedium formulation on primary hepatocyte culture, assessed by MTT assay.
Cells were plated (0.3x105/cm2) on fibronectin-coatedplastic and changed to test media after 1 hour. MTT assays
were performed at the indicated times after plating. All media were supplemented with dexamethasone (lOOnM) and
insulin (1.5pM).
Key to media: Black bars, Chee's + 2% serum; red bars, Chee's; Blue bars, Hepatozyme SFM; Purple bars,
DMEM/F12. Six replicates per observation (values expressed as mean + standard error).
Comparison of all 3 media over the first 6 days of primary culture (Figure 18) showed
that the two complex media, Hepatozyme SFM and modified Chee's, were superior to
DMEM/F12, however modified Chee's medium preserved MTT values best. Direct
observation of cultures confirmed that the differences were due at least in part to greater
final cell numbers in Chee's medium (Figure 19).
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Figure 19 Phase contrast micrography of4-day-old hepatocyte cultures afterMTT exposure. The viable cells are replete
with dark crystals in the cytoplasm. Hepatocytes had been cultured in different media, as follows: a, DMEM/F12 b,
Hepatozyme SFM; c, Chee's; d, Chee's + 2% serum.
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4.2.(1.1 Apoptosis in different culture media.
The observations just described suggested the possibility that rates of hepatocyte cell
death differed in the different culture media. Therefore comparative rates of apoptosis in
the different media were evaluated. The results in Figure 20 show lower apoptotic indices
in Chee's compared with F12/DMEM medium, most evident at the latest timepoint.
Moreover, although serum-free Chee's medium initially provoked a prolonged increase in
apoptotic indices compared with serum-supplemented medium, these reduced to levels
comparable with serum-supplemented Chee's. Inspection at the 6 day timepoint showed a
greater degree of confluence in Chee's (both serum and serum-free) compared with the
F12/DMEM-cultured wells. Thus, the culture medium formulation is relevant to
achieving low levels ofhepatocyte apoptosis under serum-free conditions, and different
rates ofapoptosis between media are responsible at least in part for the differences





Figure 20: apoptotic indices in different media. After plating and attachment (lhr), primary hepatocytes were
cultured in either Chee's medium or DMEM/F12 for up to six days, before fixing andfeulgen-stainingfor
assessment ofapoptosis, as described in methods. Both media were similarly supplemented with ITS, lOOnM dex
and 1% serum, and comparison was also made with serum-free Chee's medium.
Key: red bars, Chee's medium (serum free), black bars, Chee's medium (1% serum), purple bars, DMEM/F12 (1%
serum).
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4.2.e Culture medium osmolality
Normal rat plasma osmolality is approximately 290mOsol/kg, and most mammalian cell
culture media are within the range 280-310mOsmol/kg. However, when formulating a
new culture medium (SMI) for primary rat hepatocytes, containing high concentrations
of amino acids, Schwarze found that the best preservation of cultures occurred when the
medium osmolality was increased to 405mOsmol/kg (438). This unusually high osmolality
requirement was thought to be because facilitated transport of amino acids across the
hepatocyte plasma membrane made the large amino acid component of the medium
osmotically "transparent", necessitating an increased concentration ofNaCl in the
medium to compensate.
Murine serum osmolality is normally about 3 lOmosmol/kg, significantly greater than that
of humans or rats, and like medium SMI, Chee's medium contains very high
concentrations of amino acids. Therefore the effect of increasing the osmolality of
modified Chee's medium was tested by adding NaCl to medium of known osmolality and
incubating hepatocytes for 48 hours (Figure 21). Allowing that NaCl does not ionise
completely so the contribution of extra NaCl to osmolality is slightly less than the
combined molar concentrations ofNaf and Cf (as assumed in the figure), and that
evaporation over the 48 hours increases osmolality, the results indicate that optimal value
for hepatocyte culture is about 400mOsmol/kg, with a sharp fall in culture viablility at
greater osmolalities. Thus the findings of Schwarze for defined medium SMI, also apply
to mouse hepatocytes cultured in Chee's medium; moreover the mouse hepatocytes are
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Figure 21: Effect ofmedium osmolality on hepatocyte culture, assessed byMTT assay.
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4.2.f Elimination of non-parenchymal cells
Although the cell isolates were highly purified hepatocytes, contaminant growth of non-
hepatocyte populations was initially a concern for the p53-deficient animals, given the
spontaneous immortalisation of p53-null mouse embryo fibroblasts in vitro (454>.
Therefore, Chee's medium was made hepatocyte-selective by substituting 0.4mM
ornithine for arginine. Hepatocytes contain ornithine decarboxylase, which allows them to
synthesize arginine de novo from ornithine, whereas arginine is an essential amino acid
for the other liver cell populations (438). Dexamethasone (25nM) was included in the
medium for its beneficial effects maintaining hepatocyte phenotype, but it also suppresses
fibroblastic growth. Under serum-free conditions no survival or outgrowth of fibroblastic
cells was seen, whereas with even 1-2% serum rare clones ofmorphologically distinct,
small, fibroblastic cells could be detected after 7-8 days culture of p53-null cells.
4.3 Summary
A method of primary murine hepatocyte isolation and serum-free culture has been
established, with attention to factors that promote culture purity and viability. Chee's
medium has been reported to promote maintenance of differentiated function in cultured
rat hepatocytes and for mouse hepatocytes the present modification— with increased
osmolality, increased buffering capacity and ornithine substituted for arginine — is also
shown to give superior culture preservation, compared with the other media formulations
tested that have been recommended for hepatocyte culture. The use of serum-free
conditions allows fully defined conditions of supplementation with cytokines to be tested,




5.1.a p53-deficient hepatocytes are more likely than wild type to
proliferate in culture
Before isolation for culture from quiescent adult liver, virtually all hepatocytes are in the
Go phase (43). They are thus effectively synchronised before receiving the proliferative
stimulus of isolation and primary culture. In culture, both wild type and p53-null
hepatocytes showed a rise in BrdU positivity from near zero at plating to a peak at 72-96
hours in culture, but the BrdU positive fraction was consistently greater in the null cells
(Figure 22) (p<0.0001). Thus more null hepatocytes were cycling, but with a similar
kinetics ofentry from Go to S phase as wild type. This finding was independent of the
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Figure 22. Effect ofp53 genotype on hepatocyte DNA synthesis in primary culture.
BrdU incorporation into hepatocytes was measured at the indicated times after isolation andplating. Cells were
cultured in Chee's medium with 30nM dexamethasone. Four degrees ofcontinuous mitogen supplementation were
evaluated: (a) no mitogen; (b) 300nM Insulin; (c) 300nM Insulin + 25ng/ml EGF, (d) 300nM Insulin + 1% FBS.
Results expressed as mean ± standard error of the mean for duplicate cultures from 3 mice ofeach genotype (i.e.
n=6)
Key: wild type O; p53 homozygous null □.
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Treatment Wild type p53-deficient
No mitogen 16(100%) 127(100%)
Insulin (300nM) 20 (125%) 145(115%)
Insulin + 25ng/ml EGF 55 (346%) 199(157%)
Insulin + 1% FBS 53 (336%) 161 (127%)
Table 12. Area under curve, caluculatedfor the proliferation curves in Figure 22 (arbitrary
units).
5.1.b p53-deficient hepatocytes are less sensitive to cytokine
growth regulation
Mitogens (EGF, serum) in culture medium much increased the BrdU labelling indices of
wild type hepatocytes (Table 12). By contrast, the already high BrdU indices ofp53-null
hepatocytes were less influenced by these factors (Table 12). This suggests that p53-null
cells were more likely than wild type to proliferate but were relatively unresponsive to
further stimulation by cytokines.
0 24 48 72 96 120 144 0 24 48 72 96 120 144
Hours in culture
Figure 23. Inhibition ofhepatocyte DNA synthesis by TGFpj
BrdU incorporation into cultured hepatocytes was measured at the indicated times after isolation andplating. Cells
were cultured in Chee's medium with lOOnM dexamethasone, 1.5juM insulin, 25ng/ml EGF\ to which 160pM TGF/3]
was addedfrom 20 hours. Negative controls omitted TGFf3i. Results expressed as mean ±standard error of the
mean.
(a) wild type (b) p53 homozygous null Key: open symbols, TGFpi-treated; closed symbols, negative controls.
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Treatment Wild type p53-null
Control 52 (100%) 179 (100%)
TGFP! (160pM) 6 (12%) 68 (38%)
Table 13. Area under curve, calculatedfor the proliferation curves in Figure 23 (arbitrary units).
Responsiveness to cytokine inhibition ofproliferation was also decreased in the p53-null
hepatocytes. When incubated in high concentrations of TGF(3i— sufficient to abrogate
wild type hepatocyte proliferation— p53-null hepatocyte proliferation was only reduced
to the level of untreated wild type controls (Figure 23, Table 13).
In addition to inhibition ofproliferation, TGFPi produces apoptosis of rat and human
hepatocytes; therefore the effects on apoptosis ofmouse hepatocytes were tested.
However, when primary wild type murine hepatocytes were cultured with TGFPi for up
to 48 hours, there was no induction of apoptosis over 3 logs ofTGFPi concentration
(10-lOOOpM) (Figure 24). Therefore TGFPi does not readily induce mouse hepatocyte
apoptosis in vitro— an observation also made by others<I5I)— and this cannot account
for the differences between genotypes in the ability of TGFPi to inhibit proliferation.
Hours incubated with TGF p
Figure 24: Apoptosis after treatment ofwild type hepatocytes with TGFfij.
TGFPi at the indicated concentrations was added to culture medium from 24 hours after hepatocyte isolation.
Apoptosis was counted on feulgen-stained cultures at the indicated time points. Cells were cultured in serum-free
Chee's medium supplemented with 30nM dexamethasone, lOOnM insulin. Results are the mean ofduplicate
observations for each point.
Key: Black, negative control; Green, lOpM TGFp; Blue, lOOpM TGFp; Red, lOOOpM TGFp.
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5.1.c p53-deficient livers have an enhanced proliferative response
to hyperplastic and regenerative stimuli
To test whether the p53-dependent differences in proliferative activity also occur vivo,
liver regeneration was induced by administering a necrogenic dose of carbon
tetrachloride. Necrosis was fully developed by 24 hours after drug administration and
affected 35—40 % of the hepatocyte parenchyma, as determined by image morphometry.
Necrosis was followed by a sharply defined wave ofDNA synthesis in residual
hepatocytes, as assessed by pulse labeling with BrdU, peaking 60 hours after
administration ofCCI4. As shown in Figure 25 and Figure 26, regenerating p53-null livers
had a synchronous but significantly greater peak ofDNA synthetic activity when
compared with wild type (p<0.05), in agreement with the findings in culture. Liver:body
weight ratios after CCfi did not show differences between genotypes (Figure 27),
however the usefulness of this measurement to assess changes in liver mass was reduced
by inflammatory infiltration, oedema and the continued presence and contribution to
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Figure 25. Liver regeneration by wild type andp53-deficient mice after administration ofCCI4.
(a) BrdU incorporation into hepatocytes was evaluated at the indicated times after CCU injury. Results are
expressed as mean ± standard error ofthe mean (3—6 miceper observation).
Key: p53 wild type O; p53 homozygous null □.
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c
Figure 26: Pulse BrdU labelling of livers, 60 hours after CCI4 injury, showing increased BrdU immunopositivity
(darkly stained nuclei) in p53 null liver (a), compared with wild type (b). Original magnification xlOO.
(c) shows the pattern ofhepatocyte necrosis 24 hours after administration ofCCI4— affecting acinar zone 3
hepatocytes (indicated to the right ofpicture, around the central vein)(haematoxvlin & eosin stained tissue
section). This is a wild type animal; p53-null mice showed no differences in the character, timing or extent ofnecrosis
produced after CCI4.
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Figure 27 Changes in liver and body weights ofwild type andp53-deficient mice following CCI4 treatment at time
zero. Results expressed as mean ±standard error of the mean ofobservations on 2-9 mice per point.
Key: blue, wild type; red, p53 null.
Next the hyperplastic responses of livers to a xenobiotic mitogen were compared between
wild type and p53-deficient mice. Such agents are well described as tumour promoters in
experimental hepatocarcinogenesis. A single dose of a non-genotoxic mitogen, 1,4 bis 2-
(3,5 dichloropyridyloxybenzene) (TCPOBOP), 3mg/kg i.p.(400), induced a surge ofDNA
synthesis and mitotic activity within hepatocytes by 3 days which appeared to be
randomly distributed within the hepatic acini. This was accompanied by an increase in
relative liver mass (liver:body weight index) which was maintained at 23 days despite the
return ofBrdU incorporation and mitotic indices to baseline levels (Table 14). Both the
mitogen-induced surge in DNA synthesis and the ultimate increase in liver:body weight
ratio were greater in p53 null livers compared with wild type, showing an amplified
response ofp53-deficient hepatocytes to the TCPOBOP (Table 14). No dysplasia or foci
ofpersistent proliferation were apparent in any treated livers.
3 days after treatment 23 days after treatment
Corn oil TCPOBOP Corn oil TCPOBOP
BrdU (% +ve of 700 cells) wild type 0.32 (0.13) 8.25 (0.13) 0.23 (0.19) 0.07 (0.04)
p53 null 0.57(0.24) 14.70(2,91)* 0.13 (0.06) 0.04(0.04)
Liver/body weight (%) wild type 5.51 (0.18) 8.82(0.51) 5.52(0.12) 9.80(0.43)
p53 null 5,41 (0.40) 8,61 (0,49) 5.65(0.37) 11.17(0.70)
* significantly greater than wild type (p=0.04, Mann Whitney test)
n=3-5 mice per observation.
Values expressed as mean (standard error ofmean)
Table 14. Effect ofp53 genotype on hepatic responses to an exogenous mitogen (TCPOBOP).
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Flow cytometric analyses of nuclear ploidy showed that the proportion of diploid nuclei
increased after TCPOBOP treatment, but this did not differ significantly between p53
genotypes (Figure 28). There was no aneuploidy.
3 23 3 23
days after treatment
Figure 28. Hepatocyte nuclear ploidy after single dose TCPOBOP treatment ofwild type andp53 deficient mice.
Results are the mean ±standard error ofthe mean ofobservations on 3-5 miceper time-point.
Key: red, TCPOBOP-treated; blue, negative controls. The symbol numbers indicate theploidypopulation
represented (i.e. 2n, 4n, 8n,16n).
5.1.d Polyploidisation in the aging liver is p53-independent
Since the results showed differences between wild type and p53-null mice in proliferative
characteristics, it was of interest to examine the effect ofp53-deficiency on hepatocyte
nuclear ploidy. Hepatocyte nuclear DNA content was evaluated by flow cytometry in
livers from one hundred and thirty mice aged between 2-137 days (42 wild type, 50
p53-heterozygous and 38 p53-null). At necropsy all livers appeared grossly normal.
Twenty six mice were female. The results for males and females have been combined
(Figure 29) as preliminary analysis showed no significant differences in ploidy according
to gender. In neonatal mice, hepatocytes are diploid, having a 2n Go DNA content. At
this stage, any 4n cells are G2 proliferating hepatocytes or cycling residual extramedullary
haemopoietic cells. Shortly after weaning and continuing through adult life, there is a
progressive increase in the relative proportion ofpolyploid hepatocytes and,
concomitantly, increasing degrees ofpolyploidisation. However, it is evident from Figure
29 that p53 genotype does not influence the timing, trend or degree of hepatocyte
polyploidisation under these basal conditions. Aneuploidy was not detected in any
sample.
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Figure 29. Effects ofp53 genotype on postnatal hepatocyte polyploidisation.
The relative proportions ofdiploid (2n%), tetraploid (4n%), octaploid (8n%) and hexadecaploid (16n) nuclei at
different ages (range 2-137 days) are depicted as scatterplots (left column) and as Lowess plots (right column).
Key: , A wild type; , □ p53-heterozygous; ,0 p53-homozygous-null.
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5.2 Hepatocyte apoptosis
5.2.a p53 regulates hepatocyte dependence on survival factors
24 48 72 96 120
Hours in culture
Figure 30: Hepatocyte apoptosis in culture, assessed at the indicated times after plating. Cells were cultured in
Chee fs medium with 30nM dexamethasone. Four degrees ofsupplementation were evaluated: (a) none; (b) 300nM
Insulin; (c) 300nM Insulin + 25ng/ml EGF, (d) 300nM Insulin + 1% FBS. Results are the mean ±standard error of
the mean for duplicate cultures from 3 mice ofeach genotype (i.e. n=6).
Key: p53 wild type O; p53 homozygous null □.
Treatment Wild type p53-null
Dex 195 (100%) 64 (100%)
Dex + insulin 129 (66%) 49 (77%)
Dex + insulin + EGF 69 (35%) 25 (39%)
Dex + insulin + FBS 49 (25%) 24 (38%)
Table 15. Area under curve, calculatedfor the apoptosis curves in Figure 30 (arbitrary units).
Insulin, or insulin with EGF or serum, reduced apoptosis ofwild type hepatocytes in
culture (p<0.01). These factors are therefore survival factors for mouse hepatocytes.
When apoptosis ofwild type and p53-deficient hepatocytes in culture was compared,
p53-deficient hepatocytes had lower apoptotic indices than wild type, under a variety of
culture conditions (Figure 30a-d). The lower apoptotic indices were apparent before
BrdU uptake began, so were not directly related to either DNA synthesis or cell
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proliferation. The survival benefit conferred by p53 deficiency was greatest when trophic
support in the culture medium was least (compare Figure 30a,b with c,d). p53 deficiency
therefore reduces dependency on survival factors, but confers little survival advantage
when these factors are not limiting and wild type apoptotic rates are low anyway.
5.3 Hepatocyte responses to damage
p53 function is important in many other cell types for normal responses to DNA damage.
To evaluate the role ofp53 in hepatocyte responses to DNA damage, two genotoxic
stimuli were used: y-irradiation (which causes DNA strand breaks and base damage) and
uv-c irradiation (254nm; which predominantly produces photodimers)(455>.
5.3.a p53 in DNA-damaged hepatocytes
p53 protein responses to the genotoxic injuries were evaluated in 2 ways. First, by
immunocytochemistry for p53 protein; second, by a transfected p53 reporter plasmid in
cultured hepatocytes— to assess transcription activation by p53.
5.3.a. 1 uv-cinjury (10J/m2) produces p53 protein and transactivation
responses
uv-c irradiation (10J/m2) ofhepatocyte cultures produced nuclear p53 protein
accumulation in most hepatocytes, as assessed by immunocytochemistry, and the
response peaked at around 24 hours after irradiation (Figure 31, Figure 32).
p53 immunopositivity of unirradiated, control cultures slowly increased with time in
culture. This may reflect a "stress response" to the culture environment and the





Figure 31: (a) immunocytochemistry for p53 protein, performed on hepatocyte monolayers fixed 24 hours ajter
10J/m2 uv irradiation. There is strong nuclear immunopositivity (brown staining) in most ofthe irradiated
hepatocytes. The primary antibody used was pAB421 (see methods section 3.2.f.l). (b) is the negative control. Cells
were cultured in Chee's medium with dexamethasone 30nMinsulin 3Q0nM.
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hours after uv
Figure 32.p53 immunopositivity(pAb 421) ofhepatocyte cultures after uv-c injury (10J/m2). Cells were culturedfor
24 hours before irradiation. Results are the mean ± standarderror of the mean for duplicate cultures from 2 mice.
Key: O open symbols unirradiated, • solid symbols irradiated.
Transfection experiments. Plasmids were introduced into primary hepatocytes by
lipofection using cationic liposomes. Optimum transfection efficiency was determined by
standard means of varying the mass ofDNA transfected, the lipid:DNA ratio, and the
duration of transfection. There was no evidence of toxicity with the protocol used and
transfection efficiency was consistently between 15 and 20% of cells— as determined on
cultures transfected with the constitutive /acZ-expression plasmid pCMVp, by estimating
the proportion of stained, i.e. ZacZ-expressing, hepatocytes after incubation with Img/ml
X-Gal, ImM MgCl2, lOmM Fe3(CN)6, lOmM Fe4(CN)6 in phosphate buffered saline
(Figure 12). The Xgal assay is relatively insensitive and therefore the transfection
efficiency indicated by this method is a minimum figure. The assay did serve however to
demonstrate the repeatability of the transfection method.
The optimised lipofection protocol differed somewhat from those suggested for primary
rat hepatocytes by previous authors <406-407-456( although overall transfection efficiencies
(15-20%) were a little better (eg 5-10% for Ponder et al, 10% for Jarnegin). In particular,
whilst optimum lipid:DNA ratios (6:1) and transfection times (6 hours) were comparable,
the optimal amount ofDNA (lpg/1.9cm2 plate) utilised in each transfection was
considerably greater, and the reason for this is not clear. Watanabe has reported that with
mouse primary hepatocytes very high (circa 15:1) Lipofectin:DNA ratios and extended
lipid/DNA preincubation times yielded greater transfection efficiencies (upto 45%)(405),
however this was not the case in the present system.
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Figure 33. (3-galactosidase activity in primary hepatocytes transfected with pCMVpplasmid that constitutively
expresses LacZ. n=4
Firstly, the kinetics ofplasmid expression after transfection were examined in hepatocyte
cultures transfected with the constitutively-expressing pCMVp plasmid. In these cultures
pgalactosidase activity was detectable by the ONPG colorimetric assay within 12 hours,
and showed relatively stable levels from 24^48 hours, slightly decreasing by 72 hours
(Figure 33). Therefore, subsequent experiments on transfected cells were performed
between 24 and 48 hours after transfection.
Wild type hepatocytes transfected with the p53-reporter plasm id (pRGCAFosLacZ) or
its control plasmid (pAFosLacZ) showed no significant P-galactosidase activity,
equivalent to untransfected controls (Figure 34). However after treatment with 10J/m2
uv-c there was specific induction of p-galactosidase expression from the p53 reporter
plasmid, peaking at about 14 hours after irradiation and subsequently decreasing to
control levels by 24 hours (Figure 34a). Activity of the negative control plasmid remained
at baseline (Figure 34b). Parallel experiments on pCMV-transfected hepatocytes showed
that the same dose ofuv-c irradiation produced a 37% decrease in the (constitutively
expressed) p-galactosidase activity (Figure 34b). This decrease was probably due to non¬
specific transcriptional suppression by uv, a well documented effect(457) that makes the
observation of increased p53-reporter gene expression after uv injury even more
significant.
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Figure 34. p53 reporter plasmid /3-galactosidase expression following uv-c treatment of transfectedprimary
hepatocytes.
(a) p53 reporter activity in hepatocytes following 10J/m2 uv-c. /3-galactosidase activity is expressed relative to
untreated transfected hepatocytes. The activity at 14 hours is significantly greater than control values (p 0.04).
(b) Effect ofuv-c treatment on (3-galactosidase expression from thep53 reporterplasmid (RGCAFosLacZ), the
negative control plasmid (AFosLacZ) and the constitutive pCMV/3plasmid. Results are shown 14 hours after uv-c
(indicated by +), untreated controls are indicated by -. Activity ofthe treated RGCAFosLacZ reporter is
significantly greater than the control (p=0.04); the treatedpCMV(3plasmid is significantly lower than control
(p=0.02)
(a) and (b) are result of independent experiments, each involving duplicate observations at each time point.
5.3. a.2 No p53 response to y-irradiationinjury (15Gy)
By contrast to uv injury, y-irradiation produced no significant change in expression from
any plasmid, with the p53-reporter and its control remaining at basal levels from 2 to 24
hours after irradiation (Figure 35a), and constitutive pCMVp expression equivalent to
unirradiated control transfectants (Figure 35b). Furthermore, p53 protein did not
accumulate to levels detectable by CM5 or pAb421 immunocytochemistry in wild type
hepatocytes irradiated either in vivo, in accord with previous in vivo observations by
Midgely et al on 5Gy-irradiated normal mouse livers(297), or in proliferating primary
cultures (Figure 36). Thus there is no evidence for a change in p53 protein level or
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Figure 35. p-galactosidaseactivity fter 15Gy y-irradiation.
(a) constitutive controlplasmid (pCMVp),(b) O® p53 reporterplasmid (RGCAFosLacZ), AA negative control
plasmid (AFosLacZ).Open symbols unirradiated, solid symbols irradiated.
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Figure 36. p53 immunopositivity (pAb 421) ofcultured hepatocytes after y-irradiation (15Gy). Cells were cultured
for 71 hours before irradiation, (n=4)
Key: O open symbols unirradiated, • solid symbols irradiated.
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5.3.b
5.3.c Apoptosis in DNA-damaged hepatocytes
5.3. c.1 uv-cproduces p53-independent apoptosis
uv-c irradiation ofboth wild type and p53-deficient hepatocyte cultures produced
delayed, dose-dependent apoptosis, appearing from about 48 hours after irradiation
(Figure 37). However there was no significant difference between genotypes in the
apoptotic responses to uv-c.
Figure 37.Apoptosis in primary hepatocyte cultures after uv-c irradiation.
(a) Time course ofapoptosis after 50J/m2 uv-c.
(b) Dose response ofapoptosis at 72 hours after irradiation.
Cells were cultured in Chee's medium with lOOnM dexamethasone, 1.5pM insulin, 2% serum. Results are the mean
with standard errorfor duplicate culturesfrom 3 mice ofeach genotype (i.e. n 6).
Key: p53 wild type unirradiated O; irradiated •/ p53 homozygous null unirradiated □; irradiated ■.
5.3.C.2 Survivalfactors in culture medium confer resistance to uv-induced
apoptosis
The apoptosis induced by uv-irradiation could be inhibited by supplementation ofmedium
with survival factors (dexamethasone, insulin, serum). With high levels of
supplementation hepatocytes became moderately resistant to uv cytotoxicity, requiring uv
fluxes above 15-20 J/m2 to show significant induction of apoptosis (Figure 38). The
effects of survival factors on uv-induced apoptosis were next compared between p53
genotypes. A dose-response experiment comparison 48 hours after uv injury suggested
that p53-deficient cells were less sensitive than wild type to removal of survival factors
from culture medium (Figure 39). However subsequent time course experiments showed
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no significant difference between genotypes in the sensitivities to uv irradiation under
different levels ofmedium supplementation (Figure 40).
120
Hours after uv irradiation
Figure 38. Apoptosis after uv-cirradiation under high levels ofmedium supplementation. Wild type hepatocytes
were cultured in Chee's medium, supplemented with lpM dexamethasone, 1.5pM insulin, 25ng/ml EGFand 2%
serum. Results are themean with standard errorofduplicate observations.
Key:0 unirradiated; Jk uv-irradiated (15J/m2); H uv-irradiated (50J/m2).
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Figure 39. Effect ofp53 genotype on the reduction by survivalfactors ofuv-c-induced apoptosis: dose-response of
apoptosis at 48 hours after irradiation. Cultures were either unsupplemented □; supplemented with 30nM
dexamethasone and lOOnM insulin O; or with 500nM dexamethasone, 1.5pM insulin and 2% serum A. Results
shown as mean (± standard error) ofduplicate to quadruplicate cultures from each of3 wild type (n=7), 1 p53
heterozygous (n 4), and 2 p53-deficientmice (n=5).
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Figure 40. Effect ofp53 genotype on the reduction ofuv-c-induced apoptosis by survival factors: time-course of
apoptosis after 10 or 50J/m2 uv-c. Cultures were either unsupplemented □; or supplemented with 500nM
dexamethasone, 1.5juM insulin; 2% serum O. Results are mean (± standard error) for duplicate cultures from each
of2 wild type and 2 p53-dejicientmice (i.e. n=4).
5.3.C.3 y-irradiation does not trigger hepatocyte apoptosis
Gamma irradiation (5Gy) readily induces p53-dependent apoptosis in cells such as
thymocytes and intestinal crypt epithelium <291'458), but doses up to 15Gy did not induce
hepatocyte apoptosis in vivo— in neither quiescent nor regenerating liver (Figure
41c,e,g,h), nor in proliferating primary cultures (Figure 41a). By contrast, apoptosis
appeared in irradiated hepatic sinusoid lining cells (endothehal/Kupffer cells),
demonstrating adequate dose delivery (Figure 41e).
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Figure 41. Effect of y-irradiation on hepatocyte apoptosis.
(a,b) Cultured hepatocytes after 0 , 5 or 15 Gy y-irradiation.
(c,d) Hepatocyte apoptosis in vivo after whole body y-irradiation (15Gy)
(e) Hepatocyte and (f) Hepatic sinusoid lining cell apoptosis in vivo, in regenerating wild type mouse liver. Mice
were given CCI4 at time zero, as described in Methods, and y-irradiated or mock-irradiated 48 hours later
(timepoint indicated by vertical dashed line).
Each point represents the mean (± standard error) ofobservations on 3-6 mice.
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F/g 4/ continued. Failure of15Gy y-irradiation to produce accumulation of immunoreactive p53 in wild type
mouse hepatocytes.
Mice were y-irradiated as described in Materials and Methods, (g) shows immunohistochemistry for p53 on y-
irradiated liver, 6 hours after irradiation; (h) shows unirradiated control liver at the same timepoint.
H"7^
5.3.d Cell cycle activity of hepatocytes after DNA-damage
5.3.d.l uv-cinjury produces p53-dependent growth arrest
Proliferating hepatocyte cultures were uv-c irradiated 60 hours after plating (shortly
before the normal peak ofentry to replicative DNA synthesis (see Figure 22)), and the
effects ofuv treatment on replicative DNA synthesis were evaluated by BrdU
immunocytochemistry following serial 6 hour incubations in BrdU-containing medium.
The results showed a significant decrease in BrdU uptake in wild type hepatocytes after
uv-treatment that did not occur in uv-treated p53-deficient cultures (Figure 42).
Figure 42. Effect ofuv-c treatment (10J/m2) on BrdU incorporation by cultured hepatocytes.
Cells were uv-irradiated 60 hours after plating, and the proportion ofcells incorporating BrdU (6 hour pulse) at
serial intervals was assessed using immunocytochemistry.
Results are the mean with standard errorfor duplicate cultures.
Key: wild type unirradiated O; irradiated •; p53-null unirradiated □; irradiated H
Thus, hepatocytes show a uv-induced, p53-dependent Gi/S phase cell cycle arrest,
confirming a previous report on rat hepatocytes using antisense p53 <30l), and further
demonstrating that p53 in hepatocytes mediates growth arrest but not apoptosis after
DNA damage.
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5.3.d.2 y-irradiation in vivo produces p53-dependent growth arrest, and
aberrant mitoses in p53-deficient livers
Since y-irradiation induces a p53-dependent growth arrest in other cell types (459-460); and
is described to inhibit liver regeneration<46l), the effects of irradiation on regenerating
wild type and p53-deficient livers were compared. Livers were y-irradiated (15Gy) 48
hours after administration ofCCI4, when most hepatocytes were in late Gi, just before
entry to S phase (Figure 43a,b). It is evident from Figure 43a and c that y-irradiation of
wild type mice suppressed both hepatocyte entry to S phase (Figure 43a) and the
subsequent passage through mitosis at 72 hours after CCI4 (Figure 43c). These results are
in keeping with an efficient Gi/S cycle arrest, from which release is not seen in the course
of this experiment. By contrast, y-irradiation of p53-null livers reduced by less and did
not delay the subsequent S phase peak ofBrdU positivity, indicating a much reduced
Gi/S arrest (Figure 43b). The reduced peak and prolonged fall in BrdU positivity shown
by the irradiated p53-null livers may be due to slowed progression through S phase—
well described after y-irradiation(462). This was followed by a striking rise in the mitotic
index 24 hours after irradiation (mitotic counts of 103, 77 and 205, compared with 15, 13
and 8 in unirradiated mice; Figure 43d). Clearly, as well as defective Gi/S arrest, there
was no significant G2 arrest. Many of the mitotic figures at this time were abnormal, with
aberrant forms, isolated chromosomes and chromosomal bridges (Figure 44).
It is therefore likely that this mitotic peak was due to a population of extensively
damaged hepatocytes proceeding to and arresting within mitosis. Even a slight increase in
the normally brief duration ofmitosis (30-45 minutes) would cause the observed mitotic
index to rise considerably, as cells accumulated in this phase. The excess in mitotic
figures was not evident at later timepoints, suggesting that the cells had undergone either
catastrophe and elimination, or delayed and possibly aberrant completion ofmitosis. G2
arrest by wild type irradiated livers could not be demonstrated in the present study
because release from the Gi/S arrest was not observed. However, G2 arrest by
regenerating rat liver after y-irradiation has been reported (463-464). Therefore, these
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Figure 43. Effects of l5Gy y-irradiation on DNA synthesis (a,b) andmitotic activity (c,d) by regenerating wild type
andp53 null livers. Mice given CCU at time zero as described in Methods, were y-irradiated or mock-irradiated 48
hours later (arrowheads). Mitotic activity and BrdU incorporation into hepatocytes was measured at the indicated
times after CCI4 injury. Results are expressed as mean ± standard error of the mean (3-5 mice per observation). The
large error bar for the mitotic count ofunirradiated null mice at 48 hours is due to a single exceptional animal that
is unexplained. Two other animals at this timepoint hadmitotic counts of10 or below.
Key: wild type unirradiated O; irradiated #; p53 null unirradiated □; irradiated ■.
Figure 44. y-irradiated regenerating p53-deficient mouse livers, 72 hours after CCI4 (24 hours after 15Gy y-
irradiation). Note the abnormal mitotic figures. Haematoxylin counterstain. Original magnification lOOx.
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5.4 Effects ofp53-deficiency on responses to a liver
carcinogen, diethylnitrosamine
The data presented so far suggested that hepatocytes without functional p53 were
defective in normal responses to DNA damage, and this increased the susceptibility to
develop genetic abnormality after exposure to a DNA damaging agent. Therefore it was
decided to test whether p53-deficiency might affect the consequences ofexposure to a
single dose of a genotoxic liver carcinogen (diethylnitrosamine) vivo.
The results ofhistological analyses of livers taken from mice 10 weeks after exposure to a
dose ofdiethylnitrosamine (10 or 50mg/kg) are shown in Table 16 and summarised
graphically in Figure 46. No mouse developed hepatocellular carcinoma by 10 weeks
after carcinogen treatment, however, both morphologically-altered foci and diffuse
cytological atypia were observed (Figure 45). Untreated mice did not develop altered
foci, and rarely had diffuse atypia. By contrast, after DEN treatment, p53-null livers were
more likely than wild type to develop diffuse atypia; p53-heterozygous mice had an
intermediate likelihood of showing diffuse atypia, suggesting gene-dose-dependent
susceptibility. This trend was demonstrated at both doses ofDEN (significant difference
between genotypes at lOmg/kg DEN, p<0.001, Chi Square). Moreover, after lOmg/kg
DEN, p53-null mice were also more likely to have altered foci than heterozygous or wild
type mice — although the numbers are too small for meaningful statistical analysis.
Figure 45: Liver ofa p53 null mouse exposed to DEN (50mg/kg) 10 weeks previously. A morphologically altered
focus is present just under the liver capsule, which is elevated. (H & E, original magnification xlOO). The foci
consist ofsmall, predominantly mononuclear hepatocytes with increased cytoplasmic basophilia. Smaller foci were
often centrally placed in the liver lobules, adjacent to the central vein (acinar zone 3), with slight distortion of
adjacent hepatic plates.
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Table 16. Liver abnormalities in mice 10 or 16 weeks after intraperitoneal DEN on day 12.










wild type affected/total [%]
females: affected /total
























Red indicates that thefoci occurred in a liver with diffuse cytological atypia.
a) diffuse cytological atypia.
DEN dose: No DEN lOmg/kg 50mg/kg
p53 status Weeks after DEN: 10 10 10
wild type affected/total [%] — 5/32 [16%] 3/6 [50%]
females: affected /total 0/7
heterozygous affected/total [%] 1/10 [10%] 15/37 [41%] —
females: affected /total (1/5) 4/14
null affected/total [%] 0/17 23/29 [79%] 12/12 [100%]




het hom wt het hom wt horn
control DEN 1X DEN 5X
Figure 46. Prevalences ofdiffuse cytological atypia and morphologically-atypicalfoci in DEN experiments,
key: red bars, cytological atypia; blue bars, altered foci. Proportions given are number affected/total,
wt, het, hom indicate resultsfor wild type, p53-heterozygous andp53-null mice, respectively.
DEN lx, lOmg/kg DEN; 5x, 50mg/kg DEN
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6. Discussion of results
6.1.a p53 sensitises hepatocytes to cytokine regulators of
proliferation and apoptosis
There were no apparent consequences ofp53 deficiency for unstimulated livers, which
were quiescent and had similar histology, ploidy distributions and liver:body weight ratios
to wild type. Differences in both proliferation and cell death only became apparent after
hepatocytes were released from quiescence (Go) by culture, xenobiotic (TCPOBOP) or
CCfi-induced fiver necrosis. In cells thus stimulated p53 deficiency increased the
proportion ofhepatocytes that proceeded through S phase. Moreover the increase in
cycling fraction was shown in culture to be relatively independent ofand unaffected by
mitogens. In parallel, loss ofp53 reduced dependence on cytokine support for survival.
Thus cells with no p53 were able to survive and proliferate under conditions that caused
wild type cells to undergo growth arrest and apoptosis. Therefore there is no evidence
that p53 is necessary for repficative quiescence, indeed it does not appear to have a role
in normal fiver, however p53 becomes important once hepatocytes are released from G0,
sensitising them to mitogen and cytokine regulators of cell cycle progression and
apoptosis.
This model is consistent with data that normal rat hepatocytes, stimulated by isolation and
primary culture (or by partial hepatectomy), progress apparently autonomously from Go
to mid-Gi, but are critically dependent upon mitogens for further progression through the
cell cycle (51'. The passage from Go to Gi has been defined in hepatocytes by the
sequential expression of certain oncogenes, ending with p53 expression in mid-late Gi (37).
Although no significance has been previously ascribed to this physiological elevation of
p53 during fiver regeneration, the present results suggest that p53 is a critical effector of
the mitogen restriction point. Absence ofp53 disables the restriction, allowing
appropriately stimulated hepatocytes to cycle independently ofmitogens.
The reduced ratio between peak labelling and mitotic indices in p53-null mice, compared
with wild type, suggests a prolonged S phase and/or G2 phase in the regenerating p53-
deficient hepatocytes. Although this is not a well recognised feature ofp53 deficiency, I
have also observed a prolongation of S phase in p53-deficient embryonic stem cells
compared with wild type (S. Prost et al., submitted). Whether the increased cycling
fraction is restricted to particular ploidy subsets ofhepatocytes, which differ in relative
sensitivity to mitogens (70), remains to be determined.
After fiver regeneration, cytokines are believed to be important to stop hepatocyte
proliferation, and TGFpi is perhaps the most potent(44). However, although loss ofp53
made cultured hepatocytes less responsive to TGFPi mitoinhibition, regenerating p53-
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deficient livers did not show abnormally persistent proliferation. Therefore mechanisms
other than TGF(3i are important to terminate proliferation in vivo. p53 probably sensitises
hepatocytes to cell cycle inhibition by TGFPi through co-operative activation of p21WAH
(l41). The potential for p21VVAF1 to inhibit liver growth has been shown in mice with a liver-
specific p21WAF1 transgene (,49). The mice had small livers with hypoplastic lobules and did
not show the normal compensatory hyperplasia of remaining lobes after partial
hepatectomy.
There is no comparable published data on the proliferative characteristics of hepatocytes
from p53-null mice. Tsukada has stated that p53-null hepatocytes had no enhanced
proliferative potential in culture, compared with wild type, but provided no data <294).
Albrecht recently reported that tritiated thymidine uptake by the liver remnant 36 hours
after partial hepatectomy (the peak ofDNA synthesis in wild type mice) did not differ
between wild type and p53-deficient mice <7). The methodology and data were not
presented, and so it is difficult to make a comparison with the present results, however
the discrepancy is interesting. The stress stimulus of CC14 may provide a greater
oppurtunity for p53 deficiency to manifest; indeed Columbano has described unpublished
data that CC14 induces very high levels of p53 mRNA expression in mouse liver <295) The
present results can also usefully be compared with a report of the effects of introducing
mutant p53 into a well-differentiated hepatocyte cell line. Dumenco found that
transfection into a TGFa-transgenic hepatocyte cell line of a transactivation-deficient
mutant p53 (ser246), reduced the serum-dependence for growth, in keeping with the
present results (,5S). By contrast, the mutant transfectants retained sensitivity to TGF|3
mito-inhibition and did not have a growth advantage in serum-enriched media. These
differences to p53-deficient primary hepatocytes may be due to the TGFa-transgene in
the cell line, or other unidentified genetic changes arising during immortalisation.
Alternatively there may be differences between the phenotype due to p53 deletion and
that of the p53 mutant (see Introduction)( ,56)
There is no other published data on the apoptotic characteristics of hepatocytes from
p53-null mice. The present results show for the first time that insulin, EGF or serum
decrease apoptosis in mouse hepatocytes and so are survival factors for these cells. The
reduced need of p53-deficient hepatocytes for these survival factors is concordant with
data that stable transfection of a mutant p53 into hepatocyte cell lines increased colony
formation and enhanced survival, although these studies did not assess apoptosis (-,5r>-,58)
It is possible that p53 does not directly trigger apoptosis ofwild-type hepatocytes in the
absence of survival factors, but is acting only as a modulator of sensitivity to undergo
apoptosis through other, cytokine-regulated pathways.
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6.1.b Hepatocyte responses to DNA injury
6.1.b.l p53
p53 protein levels, although characteristically altered during the course of various p53-
dependent responses, are not specific to a particular response, and in other cell types do
not necessarily correlate with changes in functional activity. Therefore, when it became
evident that in hepatocytes, p53-dependent responses could be observed without
immunocytochemical evidence of increased p53 concentration (i.e. y-irradiation-induced
growth arrest), a functional assessment of p53 was made (of transactivation activity),
using a transiently-transfected p53-reporter plasmid.
Transient reporter plasmid assay for p53
The results show that transient transfection is a suitable method to evaluate p53 function
in normal cells after DNA damage, and that the method is sufficiently stable and reliable
to be used to provide a time course of the p53 response. Previous studies have used
stably transfected carcinoma cell lines and found increased p53 reporter expressiort after a
variety of genotoxic treatments, including uv and y-irradiation (465-466) ancj etoposide (4r>7)
Zhan reported a single time point at 24 hours whilst Lutzker used pooled clones carrying
3 different reporter constructs and found expression to steadily increase over a time
course of 2-12 hours after treatment. However stable transfection is clearly not feasible
for primary culture work. Zhan et al did attempt transient transfection of a PGb-CAT
p53 reporter plasmid but could not demonstrate significant induction of expression after
the same genotoxic injuries that produced responses in stable transfectants. This could be
due to low transfection efficiencies or to an attenuated p53 response by the carcinoma
cells to DNA injury compared with hepatocytes, although the latter seems unlikely given
the efficient induction in stable transfectants. Stabilisation of p53 after calcium phosphate
transfection has been reported and might have masked p53 responses to genotoxic
treatment in their study (46X' No such effect was apparent for lipofection in the present
study, since (3-galactosidase activity was similar (baseline) in untreated p53 reporter and
control plasmid transfectants. The relative levels of p53 reporter induction are
comparable with those observed using a transiently transfected PG^-CAT reporter to
evaluate changes in p53 function during primary keratinocyte differentiation (469).
In conclusion, although potentially less sensitive than study of clones with a stably
transfected reporter, this transient reporter assay is adequate to evaluate authentic p53
responses to levels of DNA injury commonly applied in studies of p53, and moreover can
be applied to primary and non-clonogenic cell populations, giving the power of greater
relevance to in vivo responses, combined with a defined cellular environment.
p53 after DNA injury
p53 protein accumulation after UV irradiation has been reported in a variety of cell
types in vivo or primary culture, including human skin keratinocytes, dermal fibroblasts
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and mouse primary prostatic fibroblasts (470_475) Indeed there is no report of failure to
produce p53 changes by UV treatment. The present results for p53 immunopositivity in
uv-treated hepatocytes are comparable with recently published time courses of p53
immunopositivity in UV-b treated mouse and rat hepatocytes (232'301'476> it is of interest,
and not previously reported, that occasionally only one nucleus of a binucleate hepatocyte
showed p53 immunopositivity; however, the significance of this observation is unknown.
After uv-c treatment, p53 transactivation activity (reporter plasmid) had already peaked
and returned to baseline when p53 protein levels were at peak. Therefore increased p53
transactivational activity after uv-c was not simply a reflection of increased protein levels,
and so may be independently regulable in hepatocytes, as suggested for some other cell
types (467"469'477'478). If so, the relative importance of these two changes for initiation of a
p53-dependent response has yet to be determined. By contrast to the present results, Lu
reported that p53 transactivation activity in a mouse prostate fibroblast cell line was
decreased after uv-c irradiation (16 hours after 10 and 50J/m2), whilst protein levels
increased (479). That study used the same reporter plasmid construct (RGCAFosLacZ) as
used here. However, whilst the data may reflect a tissue-specific difference in p53
regulation, it is difficult to exclude an artefact of transcriptional suppression by uv and the
relatively insensitive immunofluorescence method used to detect reporter plasmid
expression.
Assessment of p53 immunopositivity in liver after whole body y-irradiation of normal
mice gave similar negative results to Midgely (297) and Ogawa (283), here using a higher
dose (15Gy) and extending the observation to proliferating hepatocytes in culture
(showing that cell cycle status did not influence the findings) (fig 41, p97 and p97a).
y-irradiation also failed to alter reporter gene activity, at a dose adequate to arrest liver
regeneration in vivo and that induces hepatic O6 alkyl transferase expression, both by
p53-dependent mechanisms. The data are supported by MacCallum, who recently
reported no increased p53 transactivation activity in y-irradiated liver, as assessed by
activity at a RGC reporter transgene (the same construct as used here) (298). Therefore, by
contrast with uv-injury, p53-dependent responses to y-irradiation were accomplished
without detectable increase in p53 concentration or evidence of p53-dependent
transactivation.
This suggests that the basal state of p53 in hepatocytes is sufficient to permit the
responses, or that a different property of p53 is stimulated by y-induced DNA injury (480).
It is possible that the lack of reporter response merely reflects a lower sensitivity than
given by endogenous biological activities such as growth arrest(481), but a third intriguing
possibility remains — that p53 is transcriptionally activating genes through only a subset
of its response elements which does not include the RGC motif. p53 binds to its response
elements with different affinities that can be changed selectively and in opposite ways by
altering its phosphorylation state (482). It would therefore be necessary to use several
reporter constructs to accurately assess changes in p53 transactivation activity.
Nevertheless, these results suggest that a common p53-dependent response (i.e. growth
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arrest) to two different types ofDNA injury can proceed through different activities of
p53. Since p53 mutants vary in their ability to activate specific response elements (483_486);
different p53 mutations in carcinogenesis might have consequences for susceptibility to
different types ofDNA damage and to assessments of specific transcriptional
transactivation.
In conclusion, p53 responses to genotoxic injury varied with agent. The observation of
distinct p53 transactivational and immunopositivity responses in hepatocytes to the two
different types ofDNA injury is of particular interest since both agents caused p53
dependent growth arrest. Thus qualitatively different genotoxic stimuli acted differently
through p53 yet had a common consequence in growth arrest.
6. l.b. 2 p53 couples DNA damage to growth arrest but not apoptosis
Hepatocyte p53-dependent growth arrest after uv was also observed by Tsuji, using an
antisense strategy (301), whilst no comparable in vivo data to that presented here is
available. The suggestion that p53 regulates both Gi and G2 checkpoints of proliferating
hepatocytes has been made for some non-epithelial cell lines, but not demonstrated in
vivo, and implies a critical importance for p53 in preventing the passage to mitosis of
DNA-damaged hepatocytes.
p53 coupled genotoxic injury to growth arrest, but there was no direct relationship
between p53 status and hepatocyte apoptosis after DNA damage, y-irradiation did not
produce hepatocyte apoptosis at doses effective on other cell types, often in a p53-
dependent manner, including intestinal crypt epithelium (458), thymocytes (291), peripheral T
lymphocytes, mitogen activated T lymphocytes {487-488)? cardiac and pulmonary
endothelium and mesothelium <489), splenocytes <297) and spermatocytes (490). Midgley has
also observed that 5 Gy y-irradiation in vivo did not induce hepatocyte apoptosis(297), and
the present results extend that finding to proliferating hepatocytes in culture, regenerating
liver and a higher dose (15Gy). Moreover, Bax, a downstream promoter of p53-
dependent apoptosis, was not induced in liver by y-irradiation (491). By contrast, uv
treatment did produce apoptosis, as also recently observed on primary rat hepatocytes by
Worner(232), but this was not p53-dependent despite stabilisation and activation of p53.
There was no early peak of apoptosis within the first 48 hours after uv, as is characteristic
of p53-dependent apoptosis in other cell types (291>458<492-493> This suggests that p53-
dependent apoptosis due to DNA damage is not enabled in normal hepatocytes and
therefore other genes may be more critical to such pathways in liver. Indeed, the time
course of hepatocyte apoptosis after uv treatment was similar to that for the IRF-1-
dependent apoptosis of mitogen-activated T lymphocytes after y-irradiation (488), although
recent experiments using the present culture system have shown that IRF-1 does not
regulate the hepatocyte apoptosis induced by uv-irradiation (S. Prost, C.O.C. Bellamy,
D.J. Harrison et al., in preparation). Nevertheless, other genes may be more critical to
such pathways in liver, and represent better targets for novel cancer chemotherapeutic
strategies. In particular, the observation that cytokines reduced apoptosis ofDNA-
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damaged hepatocytes has implications for genotoxic drug therapy of liver neoplasms,
suggesting a utility for cytokines to either manipulate tumour cell chemosensitivity, or to
promote normal cell survival, as has also been noted for other cell types exposed to
different genotoxins and cytokines (494-495) The pathways of protective cytokine action on
DNA-damaged hepatocytes are unclear but there was no evidence for p53 involvement.
This contrasts with the effect of cytokines to reduce hepatocyte apoptosis in unirradiated
cultures, where p53 status regulated cytokine dependence. Since the same cytokines were
used to prevent apoptosis in both circumstances, this implies that different pathways are
involved. Taken together, the data illustrate the tissue specificity of different p53-
dependent responses and provide further evidence that apoptosis and cycle arrest
mediated by p53 are independent pathways.
In conclusion, hepatocyte responses to genotoxic injury varied with agent, but the role of
p53 was limited to cell cycle arrest whilst other factors (including the type of injury, the
cytokine environment and perhaps other genes), determined cell survival.
6.1.c Ploidy regulation is p53-independent in unstimulated livers
Polyploidisation occurs in a variety of non-neoplastic cell types, either constitutively or in
response to defined pathophysiological stresses, and is a feature of normal postnatal liver
development (2-49f,). It is a tightly regulated process in which only integral multiples of
diploid karyotype are permitted, but neither the purpose nor the regulation of this
irreversible process are well understood (73-75-497) [ndeed the mechanisms underlying the
normal couplings of S phase to M phase and ofM phase to cytokinesis are rather poorly
defined in eukaryotic cells other than yeast ( ' v7?-497) Murine hepatocyte polyploidisation
occurs to a relatively high degree, reportedly predominantly through acytokinetic mitosis
to produce binucleate cells, followed by nuclear fusion (thus doubling cell ploidy) in
subsequent cell cycles <2). Other unusual patterns of mitosis also occur, particularly for
high ploidy cells, and indeed, during the analyses of BrdU immunocytochemistry, bizarre
labelling patterns were seen, including labelling of only one of a pair of nuclei and
labelling of only a half or a quarter segment of a mitotic spindle. It seemed reasonable to
hypothesize that p53 could influence liver polyploidy, given observations linking loss of
p53 function to centrosome amplification, loss of G2/mitotic checkpoints and abnormal
tetraploidisation in other cell types (454-498"505) p53 a)so transcriptionally activates p21, a
broad spectrum inhibitor of cdk-cyclin complexes, certain of which probably regulate
polyploidisation <-')'°"71 Dysregulation of p21 (both under- and over-activation) has been
linked to abnormal ploidy control and dysfunctional cytokinesis in carcinoma cell lines
l74■7l)fi, and to formation of giant polyploid hepatocytes in transgenic mice (149). Moreover,
expression in mouse liver of an SV40 T transgene (known to inhibit function of p53 and
the pRb family) produced hyperpolyploidy prior to carcinoma development(509>. However
the present results show that p53 genotype did not influence the onset, rate or degree of
normal hepatocyte polyploidisation. This suggests that the excessive polyploidisation of
SV40 T transgenic hepatocytes was due to interference by the transgene with the pRb
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family, rather than p53. Indeed hepatocytes of adult chimaeric Rb-deficient mice had
abnormal nuclear pleomorphism, suggestive of hyperpolyploidy (510).
p53 did not regulate liver ploidy under basal conditions, but these findings in unstimulated
livers do not exclude a role for a p53-dependent pathway in determining altered
polyploidisation following DNA damage (511). Indeed, hepatocyte polyploidisation has
been reported to increase in the months following y-irradiation <463'512)5 and ERCC1-
deficient mice that are defective in DNA repair show persistent p53 accumulation in
hepatocytes and develop abnormal liver polyploidy (296). The relationship of polyploidy to
aneuploidy is not well defined, and whether polyploidy represents an adaptive
phenomenon to genotoxic stress is unclear, but the present findings that p53 deficiency
might allow generation of abnormal hepatocyte ploidy after DNA injury suggest it will be
of interest to compare polyploidisation responses to DNA damage ofwild type and p53-
deficient livers. In this way, as for regulation of proliferation and cell death, p53 may be
important for ploidy regulation only when the hepatocyte is stressed.
6.2 Final discussion
6.2.a What does p53 do in the liver?
p53 does not appear to have a role in normal liver growth and function. However,
hepatocytes are competent to induce p53 protein and function, and the present results
have shown differences between p53-deficient and wild type hepatocyte responses to
trophic and genotoxic stimuli. It seems that p53 has an important modulatory role on
both proliferation and cell death, but only when the hepatocyte is stressed: hepatocytes
with no p53 survive and proliferate in culture under conditions ofminimal trophic
support, whereas wild type cells will growth arrest and undergo apoptosis. Thus, p53
appears to sensitise and so link stimulated hepatocytes to their environment — by
inflicting a requirement for suitable cytokine stimuli in order that cell proliferation can
proceed and cells continue to survive. In this way, p53 imposes "social control" upon
stimulated hepatocytes.
In DNA-damaged hepatocytes, by contrast with several other cell types, p53 promotes
recovery rather than deletion (apoptosis). This is achieved through growth arrest if
hepatocytes are proliferating— p53-deficiency allowed y-irradiated proliferating
hepatocytes to proceed unchecked from G1 to mitosis, and the observation of abnormal
mitotic figures directly demonstrates the increased potential for chromosomal disruption.
p53 may also directly enhance hepatocyte DNA repair activity: the data ofRafferty et al
show that induction of at least one type of hepatic DNA repair activity (06-alkyl guanyl
transferase) after y-irradiation is p53-regulable (300). However the significance of those
data is uncertain because that enzyme does not directly repair y-irradiation-DNA damage,
and so is a rather non-specific response. Nevertheless, the role of p53 in regulation of
hepatic DNA repair is of great interest. Recent studies in our laboratory in these primary
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hepatocytes have provided some evidence that p53 could regulate hepatocyte DNA
nucleotide-excision repair.
Thus, the phenotype of p53-deficiency in liver is latent, but under conditions of excessive
tissue damage and repeated induction of compensatory proliferation p53 is likely to
become a major player. The implications for carcinogenesis will now be discussed.
6.2.b Implications for hepatocarcinogenesis
The liver carcinogens Hepatitis B x protein and aflatoxin interact directly with p53
protein and gene respectively, suggesting a role for p53 dysfunction in early human
hepatocarcinogenesis which the present study has sought to understand. The results
define a latent phenotype for p53 deficiency in hepatocytes that is likely to be revealed
under pathological conditions involving sustained tissue damage and regeneration, such
as are found in chronic active hepatitis or cirrhosis, and that allows sustained survival,
increased proliferation and impaired damage responses that could accelerate
carcinogenesis. These observations are of particular relevance to human
hepatocarcinogenesis, which almost always occurs on a background of chronic liver
damage and regeneration, and could explain a selection for p53 dysfunction in clones of
hepatocytes in an unfavorable environment within inflamed liver. This concept accords
with the observations ofGraeber et al that in an unfavourable environment (hypoxia),
p53 deficiency conferred a survival advantage to transformed fibroblasts through
decreased apoptosis <5I;,). By downregulating dependence upon local cytokines for
survival and proliferation, p53 deficiency could have similar consequences for
chronically-stressed hepatocytes.
It is perhaps not surprising therefore that others report no increased frequency of
hepatocellular carcinoma in untreated or single dose chemical carcinogen-treated p53
* * (292 29"^ 36^4)
heterozygous and homozygous deficient mice ' ' . Such models do not produce the
chronically disturbed hepatic environment that precedes virtually all human hepatocellular
carcinomas and that is probably necessary to fully manifest the latent phenotype of p53
dysfunction described here. A more appropriate model might be to evaluate the effects of
a cross between p53-deficient and Hepatitis B surface antigen transgenic mice. The latter
develop a chronic necroinflammatory hepatitis, with regenerative hyperplasia in high
producer lineages that leads eventually to development of hepatocellular carcinoma '''
Nevertheless, results in the present study suggest that p53-deficiency does change the
response of hepatocytes to DEN treatment, although no conclusions can be made about
carcinoma development. Cytological atypia in p53-deficient liver has not been described,
and has no known significance. However the changes observed are characteristic in
humans of epithelial dysplasia, and together with the abnormal appearence of y-irradiated
regenerating livers, are strongly suggestive of a predisposition to pre-neoplastic change in
p53-deficient hepatocytes, after DNA damage. The increased prevalence of
morphologically atypical foci with reduction in p53 gene doseage supports this idea.
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7. Appendices
Hepatocyte isolation and culture
Perfusion medium
Hepatocyte perfusion medium (Life Technologies), or
Ca ' and Mg^-free Hank's buffered saline (Sigma)
EGTA 0.5mM
EDTA ImM






Gentamicin (Life Technologies) 50mg/ml
HEPES (Sigma) 40mM
Insulin (Bovine pancreatic. Life Technologies) lOOnM
pH 7.5
Immediately before use, add:
Collagenase 0.06-0.065%, final concentration (filter-sterilised)
DNAse I (Boerhinger) 40pg/ml, final concentration
Plating medium

















phenol red, Na 10mg/l
HEPES 30mM
osmolality 330 mOsm/kg, by adjusting NaCl concentration
pH 7.45
Supplementedprior to use with:
L-glutamine 4mM
Gentamicin (Life Technologies) 50mg/ml
Sodium selenite (Sigma) 30nM
Transferrin (Sigma) 6.25pg/inl
Hormone supplements, ifnot stated specifically:
Dexamethasone (Sigma) lOOnM
Epidermal growth factor (mouse submaxillary gland. Sigma) 25ng/ml
Insulin (Life Technologies) 300nM
Coating of culture surfaces
Fibronectin
Fibronectin (Sigma) was allowed to adsorb overnight at 4°C from a lOpg/ml sterile solution in PBS,
calculated to give l-2pg fibronectin /cm:. The solution was aspirated just prior to plating of hepatocvtes.
Collagen type 1
A 0.01% solution of type I collagen (Sigma, rat tail) in 0.1M acetic acid, sterilised over chloroform, was
allowed to air dry onto culture surfaces at 37°C to give 10-20pg/cm2. Dishes were stored at 4°C and if
necessary washed to neutral pH by PBS prior to plating of hepatocytes.
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Fixation and staining







5% v/v glacial acetic acid
85% v/v methanol
10% v/v pure formalin solution (40% formaldehyde in water)
Schiff's solution
Dissolve 2.5g Fuchsin Basic (99% pure grade) in 500ml water, just boiled
Cool to 50°C. Add 50ml 1M HC1
Cool to room temperature. Add 5g potassium metabisulphite and leave in the dark for 24hours
Add 5g activated charcoal and agitate for 2 minutes
Filter (Whatman No 1) to a clear colourless solution
Store at 4°C in the dark
5-bromo-4-chloro-3-indolyl (3-D-galactopyranoside (X-gal) solution
In PBS (pH 7.1):
lOmM K3Fe(CN)6 (potassium ferricyanide)
lOmM K3Fe(CN)6.3H20 (potassium forrocyanide)
ImM MgCl2
lmg/ml 5-bromo-4-chloro-3-indolyl p-D-galactopyranoside (Sigma, from lOOmg/inl stock solution in











filter sterilised and stored at 4°C




DDW to 1 litre
pH 7
Autoclaved
LB agar (Luria-Bertani agar)
500ml LB medium
7.5g agar
autoclaved. cooled to 50°C
antibiotics added as appropriate:
lOOmg/ml ampicillin or 50mg/ml Kanamycin Sulphate (Sigma)
Poured onto a microbiological 10cm petri dish
gel loading buffer
0.25% bromophenol blue (w/v)
1% Ficoll
50% glycerol
0.1% sodium dodecyl sulphate
25mM EDTA
pH8










p53 genotyping by polymerase chain reaction.
The reaction mix contained three primers, one wild type p53-specific (binding within
exon 6), one targeting construct-specific (binding within neo) and one common to both
wild type p53 and targeting construct (binding within intron 7).
Primers (5'—> 3'):
Intron 7 (3') CAAAGAGCGTTGGGCATGTG (5')
Exon 6 (5') GTGGTGGTACCTTATGAGCC (3')
Neo (5') CATCGCCTTCTATCGCCTTC (3')
Reaction mix
lx Taq polymerase buffer (Life Technologies)
2mM MgCl2 (Life Technologies)




1.25 units Taq polymerase (Life Technologies)
2pi genomic DNA
Polymerase chain reaction conditions
94°C for 2 minutes, then 30 cycles of 94°C for 1 minute, 62°C for 1 minute and 72°C for
1 minute. Finally 72°C for 10 minutes.
Reaction products
p53 wild type: 642 bp
p53 target construct: 510 bp
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Running means.
Running meansfor the rate ofhepatocyte apoptosis in monolayer cultures.
Running means were established on three independent replicate cultures of hepatocytes
(chambers 1-3), fixed and stained by the Feulgen method. Each running mean was
recounted on each culture, one or two times, as shown.
Running means for apoptosis in vitro (chamber 1)
0 '—
0 1000
Number of cells counted









Number of cells counted
1500








Number of cells counted
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Running meansfor the proportion ofBrdU immunopositive hepatocytes in monolayer
cultures.
Running means for BrdU immunopositivity were established on 2 independent replicate
hepatocyte cultures, fixed and stained as described in Methods. Each running mean was




Running means for BrdU in vitro (chamber 1)
500 1000 1500
Number of cells counted
Running means for BrdU in vitro (chamber 2)
500 1000 1500
Number of cells counted
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Running meansfor the proportion ofBrdU immunopositive hepatocytes in tissue
sections from TCPOBOP-treated mice.
A running mean was established and recounted once, as shown.
Running mean of BrdU positivity
0 500 1000 1500 2000
Cells counted
Running mean for the proportion ofBrdU immunopositive hepatocytes in tissue




BrdU running mean for CCI4-treated mice
°
0 5 10 15
high power (x40 objective) fields counted
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Cell death in health and disease: the biology and regulation
of apoptosis
Christopher O. C. Bellamy, Roger D. G. Malcomson, David J. Harrison and Andrew H.
Wyllie
Apoptosis is a morphologically stereotyped form of cell death,
prevalent in multicellular organisms, by which single cells are
deleted from the midst of living tissues. Recognition of the
cellular corpses and their removal by phagocytosis occurs
without disturbance to tissue architecture or function and
without initiating inflammation. Apoptosis is regulable and
is of fundamental importance to tissue development and
homeostasis. Cellular susceptibility to apoptosis is determined
by a variety of signals, of both extracellular and internal
origin, includingproliferative status. Dysregulated apoptosis
is important in the pathogenesis ofseveral important human
diseases including neoplasia, and recognition of the defects
involved is prompting development of new therapeutic
strategies.
Key words: apoptosis / genetic regulations / homeostasis
Physiological cell death is an inconspicuous yet
prevalent phenomenon in complex multicellular
organisms. It is characterized by the deletion of
scattered, single cells from the midst of a living tissue
without disturbance to the continuity of tissue archi¬
tecture or function. With few exceptions cellular
death is accomplished by a process with a structural
stereotype, termed apoptosis, that strongly suggests a
common underlying effector mechanism.1 Apoptosis
is observed in circumstances as diverse as embryoge-
nesis, normal adult tissue turnover and organ atrophy;
it is also fundamental to the regulation and operation
of pathophysiological processes such as the immune
response, inflammation and the elimination of cells
after genotoxic injury (Figure 1). The realisations that
apoptosis represents an innate cellular defence
against carcinogenesis, that the regulatory pathways to
apoptosis (but not the effector mechanisms) are
frequently disabled in malignant neoplasms and that
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many cancer chemotherapeutic agents may act by
induction of apoptosis have stimulated intense inves¬
tigation into the underlying molecular controls.
The structural changes of apoptosis
In apoptosis coordinated changes occur in the
nucleus, the cytoplasm and at the cell surface (Figure
2).2 The time to onset of apoptosis after a lethal
stimulus is variable but the changes are rapid (a few
minutes duration): cells lose contact with their neigh¬
bours and round up. The endoplasmic reticulum
dilates and superficial cisternae fuse with the plasma
membrane. Other cytoplasmic organelles remain
largely unaffected. At the same time there is a striking
loss of cell volume, apparently due to voiding ofwater
and ions with consequent compaction of the organ¬
elles and an increase in cell density. The nucleus
condenses and chromatin marginates to form dense
granular caps under the intact nuclear membrane.
The nucleolar fibrillar centre dissociates from its
transcriptional complexes. The cell surface starts to
bleb violently and time lapse phase contrast studies
show an extraordinary bubbling appearance.3 Around
this time the nucleus breaks up into several mem¬
brane-bound fragments. The cell itself then splits into
multiple membrane-bound 'apoptotic bodies', some
of which contain nuclear fragments. The apoptotic
bodies are phagocytosed almost immediately by
neighbouring cells or by macrophages without elicit¬
ing an inflammatory reaction, in contrast to necrosis
as described below. Apoptotic bodies in phagosomes
remain recognizable by light microscopy for up to a
few hours and are consequently the predominant
form of apoptosis recognized in tissue sections. In
epithelia or cultured monolayers apoptotic bodies can
instead be shed into lumina or the culture medium
where they degenerate within a couple of hours: they
gradually lose membrane integrity (becoming perme¬
able to vital dyes) and metabolic activity ceases.
Apoptosis is not the only possible mode of cell
death. Necrosis is a non-specific term for a variety of
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Figure 1. Prevalence of apoptosis in physiological and disease contexts (modified and reproduced
with permission ofJohn Wiley and Sons, Chichester, UK).
other modes of death in which, in contrast to
apoptosis, the cell plays only a passive role while it is
destroyed. Cell lysis during necrosis releases intra¬
cellular contents into the extracellular space, result¬
ing in inflammation and further secondary tissue
damage. Necrosis typically involves contiguous cells
and is associated with tissue architectural disruption
whilst apoptosis generally affects scattered single cells
and preserves the tissue architecture (except in
special circumstances such as embryonic remodel¬
ling).1 Necrosis is always pathological whereas apopto¬
sis is a physiological process that may also be triggered
in pathological situations.
Kinetic considerations
The 'gold standard' for identification of apoptosis is
Figure 2. (A) Transmission electron micrograph showing late stage apoptotic fibroblast with
fragmentation of the cell into membrane-bound apoptotic bodies. (B) Early apoptosis showing
distinct peripheral chromosome condensation against the intact nuclear membrane. (C)
Phagocytosed apoptotic body within a phagosome. (D) Cell surface changes in apoptosis: scanning
electron micrograph of an apoptotic thymocyte, showing loss of microvilli and gaping cisternal
pits, formed by fusion of dilated endoplasmic reticulum with the surface. (Reproduced with
permission of Kluwer Academic Publishers, Dordtrecht).
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morphological assessment. A comment on methods of
evaluation of apoptosis has been given elsewhere1 but
the importance of quantitation is worth stressing. The
speed of apoptosis and the rapidity of clearance of
apoptotic bodies in vivo (a few hours at most)3 mean
that the identification of only a few apoptotic bodies
in a tissue section can represent a considerable degree
of cumulative cell loss. Numerically small differences
in 'apoptotic indices' (i.e. the percentage of cells that
are apoptotic) can therefore be of great biological
import. For example, an intravenous bolus of anti-
CD4 antibody increases the apoptotic index in murine
lymph nodes from 0-06% to 1-33%, and this is
sufficient to halve the total cell count of the lymph
nodes within 48 h.6 Unfortunately studies of this
nature require that large numbers of cells be counted
in order to achieve running means for apoptotic
indices and allow statistical evaluation of differences.
Furthermore, to be able to ascribe changes in tissue or
tumour size to altered rates of apoptosis, parallel
quantitative evaluation of cell proliferation is neces¬
sary. Other factors such as the rate of disposal of
apoptotic bodies will also affect the perceived apopto¬
tic index.
Underlying cell biology of the effector
processes
Cytoplasmic events
The abrupt increase in cell density is due to voiding of
water and ions, possibly channelled to the cell surface
through the endoplasmic reticulum.2 As yet no
mechanism has been identified to account for this
profound and sudden fluid shift. The cell size and
shape changes during apoptosis require major cytos-
keletal reorganization that is still largely uncharac-
terized, although actin polymerization (in part stimu¬
lated by protein kinase C) is essential for the budding
that generates apoptotic bodies.' Some apoptotic
cells, e.g. hepatocytes, also activate tissue trans¬
glutaminase to produce an insoluble shell of cross-
linked protein.8 Although increased transcription of
specific mRNAs frequently precedes apoptosis (see
below), a site-specific endogenous RNAse activity late
in apoptosis is suggested by the rapid degradation of
ribosomal and messenger RNA in apoptotic cells.910
The role of proteolysis (e.g. of terminin proteins)11 is
unclear but specific regulatory proteases are consider
later.
Nuclear events
As mentioned above, the nuclear membrane is not
lost during apoptosis, unlike mitosis. However the
subjacent nuclear lamina (which anchors chromatin)
is disassembled by depolymerization of constituent
lamin filaments.1213 Larnin phosphorylation and
depolymerization also occurs during mitosis, catalysed
by cdc2 kinase, and it is possible the same mechanism
operates during apoptosis.14 That elements are com¬
mon to mitosis and apoptosis is as likely to reflect a
general role in regulation of nuclear structure as to
indicate any deeper similarity between these distinct
processes. In contrast to mitosis the depolymerized
lamins subsequently undergo proteolysis in apoptosis,
perhaps making lamina disassembly irreversible.13
Ubiquitin conjugation of nuclear proteins appears to
be important in some (but not all) examples of
apoptosis, and has been suggested to regulate some of
the chromatin structural changes.13 A specific feature
of apoptosis is rapid DNA cleavage. Initially large
transient 50 kbp and 300 kbp fragments are detect¬
able that probably represent chromatin loops and
rosettes detached from the anchoring nuclear
matrix.16 In many cell types there is further rapid and
extensive double strand cleavage of internucleosomal
DNA to yield a series of oligonucleosome chains of
180-200 bp multiples (180 bp is the length of DNA in
a single nucleosome). These are visualised as the
characteristic 'DNA ladder' on agarose gel electro¬
phoresis.2 The DNA cleavage is not sequence specific
and the precise identity of the nuclease (s) responsible
is still unknown (see ref 17, A. Eastman this issue,
pp45-52, for a detailed discussion). It is sufficient to
say here that nuclease is constitutively present in some
cell types but is induced in others prior to apoptosis.
The nuclear changes of apoptosis can occur without
oligonucleosome generation (e.g. TGF |3l-induced rat
hepatocyte apoptosis), which when present may be a
very late event, after chromatin margination.1618,19 Of
note is that mitochondrial DNA is not fragmented in
apoptosis, indicating that DNA fragmentation is a
specific nuclear event.20'21
Surface changes
A key property of apoptotic bodies is their rapid
recognition and phagocytosis by adjacent cells or
professional phagocytes. Cell surface changes during
apoptosis that promote recognition are best charac¬
terized for apoptotic'inflammatory cells, and include
loss of sialic acid (thereby exposing glycoprotein side-
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chain sugars) and exposure of membrane phosphati-
dylserine.22 A third mechanism involves thrombo-
spondin secreted by macrophages to form a
molecular bridge between apoptotic cell and macro¬
phage surface CD36 or a3|33 integrin.22 Importantly
phagocytosis of apoptotic cells does not activate
macrophages to produce an inflammatory
response.1
Organization of effector events
An ordered set of molecular events underlies the
phenomena of apoptosis. To what extent these events
are organized as a linear cascade or as parallel
independent processes at multiple subcellular sites is
unclear. It is of interest however that the nucleus is
not essential for the cytoplasmic changes of apopto¬
sis. 2,1 The degree of redundancy built into effector
mechanisms is also unknown, although no obligate
gene (i.e. without which apoptosis cannot occur at all)
has yet been identified. Expression of effector mole¬
cules in non-apoptotic cells is variable: thymocytes
must synthesize protein and RNA in order to undergo
apoptosis in response to some stimuli,24 but other cell
types constitutively possess the effector molecules, as
demonstrated by apoptosis in the presence of protein
or RNA synthesis inhibitors. For other cells inhibition
of protein synthesis itself triggers apoptosis, suggest¬
ing the presence of a short-lived protein inhibitor of
cell death. These observations have led to the concept
of states of readiness ('priming') for apoptosis,
determined by the dynamic activity of regulatory
pathways to induce or deplete effector molecules.2
The idea has implications for chemotherapy in that
cells in a highly primed state (with all the apoptotic
machinery in place) might be more susceptible than
unprimed companions to the triggering of apoptosis
by cytotoxic stimuli. The increased sensitivity to
cytotoxic agents of cells in 'proliferative' compart¬
ments of tissues when compared with non-prolifer-
ative compartments has been cited as an example of
priming, although whether this difference is due
simply to accumulation of effector molecules is
unproven. In fact current models suggest that cell
cycle activation is actually lethal itself, unless specific
rescue factors prevail (see next section).
The regulation of apoptosis
Broadly speaking, physiological apoptosis can be
externally triggered or a cell-autonomous event (Fig¬
ure 3). Cell-autonomous apoptosis is a hard-wired
phenomenon, often termed 'programmed cell death'.
It is exemplified in morphogenesis by the coordinated
death of web space cells that sculpts digits from the
coarsely-shaped limb bud,1 and by the chronologically
and spatially invariant death of 131 cells (12% of total,
excluding germ cells) that occurs during develop¬
ment of the nematode Caenorhabditis elegans.2o The
nature of the internal clock or switch that activates
death is not known, although study of mutant C
eleganswith abnormal cell death phenotypes has led to
characterisation of some of the genes involved, as
Drugs, toxins,
radiation.
Matrix attachment, e.g. integrin receptors.
Figure 3. Cartoon illustrating the diverse sources of signals that regulate susceptibility to
apoptosis.
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discussed below. The rationale for this sort of inevita¬
ble cell death is easy to appreciate in limb morphoge¬
nesis but is less clear for C elegans, where mutant
animals that lack programmed cell deaths survive and
appear grossly normal. Observed minor behavioural
changes and slower maturation have been hypothe¬
sized to put the cell death-deficient animals at a
selective disadvantage compared with wild-type.
External signals
Specific ligand-receptor binding can transduce both
death and survival signals. It is of relevance that a
'survival factor' need not be a mitogen and also that
mitogens are not necessarily survival factors; indeed
there appears to be benefit in separating the two
functions. The TNF receptor superfamily includes
several members that participate in positive and
negative regulation of cell death, for example TNFRI,
Cl)4f)„ NGFR, CD30 and the fas antigen.26"28 Receptor
activation is not necessarily determinate of outcome
and signal context is critical. For example, TNFa-
induced apoptosis is blocked by expression of the zinc
finger peptide A2(f , and fas stimulation kills chron¬
ically but not recently activated T cells, (a distinction
postulated as a mechanism for limiting the extent of
normal immune responses).30 The importance of
context is well illustrated by the dual signal model of
B cell responses to crosslinking of surface immunoglo¬
bulin by antigen.2' Crosslinking induces apoptosis,
but not if a second signal is provided by costimulation
of surface CD40. The ligand for CD40 is present on
activated (but not resting) T helper cells, so apoptosis
is only blocked during an antigen-specific immune
response. Therefore, according to the model, self-
reactive B cells will normally be deleted on encounter¬
ing antigen, as a result of the absence of activated self-
reactive T cells that could provide a rescuing signal.
Thus the humoral signal of antigen binding is read in
the context of a cellular signal (CD40 binding). Some
agents have dual effects on the same cell population,
for example TGFfj 1 is a cytokine that both inhibits
DNA synthesis and stimulates apoptosis of hepatocytes
and endometrial stromal cells.31,32 It is not clear what
determines the particular response at individual cell
level.
Competitive selection
When apoptosis is the default fate of newly generated
cells, competitive selection for survival factors is a
powerful strategy to ensure that only those cells
survive that are best suited to perform a particular
function. Evidence from central nervous and haemo-
poietic systems suggests there are specific factors for
different cell types and 'windows of susceptibility'
during which cells are dependent upon particular
factors.33"35 This type of scenario is in contrast to the
fixed, programmed cell death of C. elegans. For
example, in neuromuscular development lower motor
neurones are generated in excess and deleted by
apoptosis if their axons fail to contact muscle end
plates, the source of neurotrophic survival or rescue
factors.34 Likewise, during nephrogenesis, metaneph-
ric mesenchyme converts to epithelium under the
influence of an inductive signal from the ureteric
bud.36 This signal rescues from the apoptosis that is
the fate of uninduced cells. A similar principle brings
about the increase in affinity of specific antibody
produced during a humoral immune response (affin¬
ity maturation). This is achieved by selection for long
term survival of only a small subpopulation of
centroblasts, based upon the relative affinity of their
surface immunoglobulin for the antigen, presented
on follicular dendritic cells.37 The remainder die by
apoptosis in the light zone of the lymph node
germinal centre, being seen as 'tingible bodies' within
adjacent macrophages. Accessory survival signals are
provided by cell adhesion molecules on the follicular
dendritic cells, ICAM-1 and VCAM-1, which bind
centroblast LFA-1 and CD49d respectively.38
Dependence on survival factors is also a key method
of cell population size regulation. In kinetic terms a
continuously renewing tissue (e.g. gut epithelium,
bone marrow) consists of stem cells, progeny transit
cells (which may or may not divide a few times) and
post-mitotic, differentiated cells. There is normally
overproduction of transit cells of which only a
proportion survive to maturity, through the action of
specific rescue factors, e.g. IL-la, IL-6 for myeloid
progenitor cells. The concentration of transit cell
rescue factors is thus limiting and a determinant of
final population size. Paracrine survival factors also
maintain tissue localisation, e.g. within bone marrow.
A requirement for survival factors by mature cells,
which may differ qualitatively from that of immature
cells, is illustrated by the atrophy of thyroid or adrenal
glands after hypophysectomy, prostatic regression
after castration and involution of post-lactational
breast parenchyma that are all characterised by
increased apoptosis.1 2 The social control hypothesis
provocatively takes the concept of survival factors to
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its limit by suggesting that all cells (except blas-
tomeres) are continuously dependent on survival sig¬
nals from other cells to avert an intrinsic death
35
program/
This section has so far described how soluble factors
and cell-cell interactions can control cell death, but
cell-matrix interactions also regulate apoptosis. Spe¬
cific contact of surface integrin receptors with extrac¬
ellular matrix molecules is an important survival
signal for differentiated endothelial and epithelial
cells.39,40 Without integrin-matrix binding these cells
undergo apoptosis, a phenomenon that has been
termed anoikis ('homelessness').40 Such cells cannot
therefore survive out of position if the appropriate
matrix requirements are not fulfilled. Thus matrix
composition localizes seed to soil in an unforgiving
manner, a concept of critical importance to under¬
standing mechanisms of neoplastic progression. In
contrast, fibroblasts do not show integrin depend¬
ence,40 in keeping with the need to rove across tissue
boundaries during repair of injury.
Signal transduction
The signal generated by a stimulus must be trans¬
mitted to effector molecules that often lie in different
subcellular compartments. Transduction pathways
vary according to the trigger stimulus but two major
areas of focus are cytosolic calcium and protein
kinases. Apoptosis is usually preceeded by a rise in
cytosolic calcium concentration and possible down¬
stream targets include calmodulin and calpain.41,12
Calmodulin and calpain are themselves pleiotropic
molecules whose precise roles in apoptosis need to be
clarified. Protein kinase C (PKC) has been identified
as both a positive and negative regulator of apopto¬
sis,42 while a protein kinase A pathway is active in
thymocyte apoptosis.43 It is possible, though without
proof, that the conflicting roles of the PKC family may
reflect the selective involvement of PKC isotypes44 or
interaction with other signalling pathways such as
sphingomyelin-ceramide.43 The ras pathway has long
been known to transduce growth signals from plasma
membrane to nucleus but is also a negative regulator
of apoptosis when overexpressed in fibroblast cell
lines.46'4' Overexpression of activated raf kinase, a
downstream element in the ras pathway, was also
found to prevent apoptosis induced by IL-3 with¬
drawal.48 New evidence for crosstalk between these
different pathways is revealing a complex network of
vertical and horizontal interactions that integrates
different signals to determine the outcome of a
stimulus.49 The machinery for context-dependent
responses is thus coming to light. A major unanswered
question is how these pathways converge on the
common effector processes of apoptosis.
Genetic regulation of apoptosis: strategies for
investigation
Simple observational studies on tissues can be very
informative, providing physiological paradigms for
cell death. These studies indicate the tissue compart¬
ments most susceptible to apoptosis under basal
conditions, and can also provide prima facie evidence
for a role for apoptosis in specific disease.2,50 In C.
elegans and Drosophila, observation of abnormal cell
death phenotypes in mutant animals has allowed
genetic analysis to identify novel genes controlling cell
death.25,51,52 The characterization of mammalian
homologues of such genes and the use of double
mutant animals to order the genes in a 'death
pathway' show the power of the model.25,53,54 Con¬
versely, specific genetic manipulation of animals or
cells offers clues to the functions of known genes of
interest. Antisense aligonucleotides are a potentially
powerful tool to abrogate a particular gene's function,
although in practice a number of confounding factors
present themselves. In fact each strategy inevitably has
significant advantages and disadvantages: for exam¬
ple, drugs are powerful tools for the study of
apoptosis; many are cancer chemotherapeutic drugs
and as they reveal more about the regulation of cell
death so that information in turn will suggest novel
strategies of chemotherapy (see ref 55, this issue).
However, interpretation of the effects of pharmaco¬
logical agents must discriminate action at specific
points on physiological death pathways from non¬
specific activation of a suicide program. Likewise,
genetic experiments that use the unregulated over-
expression of genes in (genetically abnormal) cell
lines are susceptible to criticisms of physiological
relevance. Animals with germline targeted knockout
of selected genes are a more physiological model, yet
unique gene functions will still be much more readily
apparent than those less critical or redundant, but
which have relevance. Transgenic animals carrying
extra genes in the germline that are constitutively
overexpressed are also powerful models but still
difficult to interpret in terms of normal function.
Together these different approaches have provided
information that forms a surprisingly concordant
picture of the internal regulation of apoptosis. They
have delineated genes of three broad classes in a
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common mechanism— those suppressing apoptosis,
those defining the final common activation elements
and those 'upstream' of the suppressors, but 'down¬
stream' of the signal transduction described earlier,
which we call here intermediate genes.
Genes suppressing apoptosis
Induction of the bcl-2 gene is often critical in the
action of survival factors. Bcl-2 is a mammalian
homologue of the C. elegans ced-9 gene, whose
function it can partially replace,53 and it can prevent
apoptosis caused by a variety of physiological, patho¬
logical and pharmacological stimuli."'6 How bcl-2
works is uncertain, although presumably it acts close
to the final irreversible steps of apoptosis on which
afferent pathways converge. There is evidence that bcl-
2 affects calcium partitioning and cellular redox
status, although this is still controversial (see ref 57,
RW Craig, this issue, pp35-43, also 58,59). However
Bcl-2 is not a universal antidote to cell death. For
example, ectopic bcl-2 expression by cortical thymo¬
cytes can prevent the induction of apoptosis by
irradiation, glucocorticoids and antibodies to CD3,
but does not affect negative selection.60 This may be
partly due to the presence of bcl-2 antagonists such as
bclxs which is expressed at high levels in immature
(CD4+CD8+) thymocytes.61 Bclxs has not been shown
to interact directly with bcl-2 but another antagonist,
bax, seems to exist in dynamic equilibrium between
bax-bax homodimers that are permissive for apoptosis,
and bax-bcl-2 heterodimers which may be a biologically
active form of bcl-2 that suppresses apoptosis.62'63 It is
not yet clear whether the bcl-2 antagonists simply
quench survival functions of bcl-2 or whether they
have intrinsic lethal properties that bcl-2 must hold in
check. In either case the relative amounts of such
molecules in a cell could predetermine its response to
a lethal stimulus. In tissues where bcl-2 is not essential
for survival such as the CNS (which develops normally
in mice lacking bcl-2),64 functional analogues exist,
such as bclxL which is expressed at high level in
brain.61 The antiapoptotic actions of the ras pathway
were discussed earlier and it will be of interest to
determine whether the bcl-2 family interacts with ras/
raftransduction pathways. Abl is another antiapoptotic
gene that in contrast to bcl-2 is biochemically well
defined. The abl product is a tyrosine protein kinase
and a constitutively activated form, retroviral v-abl, can
suppress the apoptosis that follows growth factor
withdrawal in vitro.6o Protein kinase C and phospho¬
lipid hydrolysis may be mediators of this effect.61' An
abl fusion product (bcr-abl) in Philadelphia chromo¬
some-positive human leukaemic cells is also con¬
stitutively activated and probably suppresses apoptosis
in the malignant cells.6' In addition to v-abl viruses
have evolved a number of strategies to suppress
apoptosis and these are discussed separately below.
Distal activating genes
The ced3 and ced4 genes of C. elegans are strong
candidates for distal activating genes if not ultimate
effectors of apoptosis.25 One vertebrate structural
homologue of ced3 is ICE (interleukin-1 (3 converting
enzyme), a cysteine protease that when overexpressed
in fibroblasts induces apoptosis and inhibitors of
which prevent the neuronal apoptosis that follows
NGF withdrawal.34 The universality of ICE's ability to
induce death and its actual relevance to physiological
apoptosis of normal cells are yet to be tested and it is
likely that a family of ICE-related proteases will be
identified. In some systems bcl-2 is able to inhibit ICE-
induced cell death, placing it downstream of ICE-like
proteases in regulation of apoptosis.34 Analogous
attempts to order the ced3/ced4 and ced9 genes in a C.
elegans putative death pathway are more speculative.
Animals with ced9 gain of function do not show ced3/
c«W-dependent cell deaths, whilst animals lacking ced9
function show excessive and abnormal ced3/ced4-
dependent cell deaths. '2 If the three genes lie along
one linear pathway then these observations place ced9
proximal to ced3/ced4,52 However, if ced9 activation is a
separate pathway to a ced3/ced4 death cascade then
ced9 action could be either proximal or distal to ced3/
ced4 and still be consistent with the data above. Given
the many similarities of ced9 to bcl-2 and of ced3 to ICE
it would seem reasonable at present to expect ced9 to
act downstream of ced3. The reaper peptide of
Drosophila also seems to be a distal activator for
apoptosis.31 Reaper expression precedes apoptosis by
1-2 hours and is detectable in apoptotic bodies.
Deficiency of reaper blocks developmental and radia¬
tion-induced apoptosis, although not completely,
showing that reaper is not obligate for apoptosis to
occur. Reaper has no homology to known peptides
and the effect of expression in vertebrate cells is not
yet reported.
Intermediate genes
Many genes that regulate apoptosis were first identi¬
fied as oncogenes or oncosuppressor genes. The c-myc
oncogene is classically associated with promotion of
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cell division and one might expect that constitutive
activation of myc would be sufficient to induce
autonomous cell proliferation. However, this is not so;
in culture, activation of myc induces apoptosis unless
specific rescue factors are also present, for example
IGF-1 for fibroblasts or IL-3 for myeloid cells.3'68 Thus
myc activation simultaneously generates two possible
outcomes in these cells: death (by default) or pro¬
liferation (if rescued) (Figure 4). Deregulated
expression of the myb oncogene, at least in myeloid
cells, may have a similar effect.69 Such coupling of
oncogene activation to survival factor dependence
may serve two purposes. It opens a window of
susceptibility to apoptosis (a 'high turnover' state),
allowing competitive selection of susceptible cells to
regulate population size as described above. It also
forms an inbuilt safety mechanism to delete cells in
the event of incongruous oncogene activity. A corol¬
lary of the 'high turnover' state model is that because
proliferating cells in general are poised for apoptosis
they will be susceptible to a variety of triggering
agents, including cancer chemotherapeutic agents. In
support of this idea epithelial cells in the proliferative
zone of gastrointestinal crypts are more sensitive to
irradiation and cytotoxic agents than adjacent non-
proliferating crypt cells.'" Tissue compartments in a
high turnover state are therefore in a precarious
balance between population expansion (excess pro¬
liferation) and regression (excess apoptosis), deter¬
mined by the availability of mitogens, survival factors,
cytotoxic stimuli and recruitment into or out of the
high turnover state, e.g. differentiation. At a molec¬
ular level it is unclear whether the coupling of cell
cycle activation to apoptosis is specifically mediated by
myc or by a downstream component of an active cell
cycle.
The p53 oncosuppressor gene is the most fre¬
quently mutated gene in human malignancy (see ref
71, C.E. Canman, M.B. Kastan, this issue, ppl7-25). It
is critical for a DNA damage response to DNA strand
breaks, produced either directly or during the exci¬
sion-repair of other DNA lesions. In different cell
types, such breaks result in G1 arrest or apoptosis.72'73
What determines the differences in response is
unclear, although of interest is the observation that
overexpression in a cell line of transcription factor
E2F-1 (a positive regulator of myc expression74,
involved in cell cycle regulation), switched a p53-de¬
pendent G1 arrest to a high turnover state with excess
apoptosis.75 E2F is shut off by hypophosphorylated
pRb (the active retinoblastoma gene product), a
negative regulator of cell cycle progression that is
inactivated by cyclin-dependent kinases (cdk) in Gl,
themselves a target in p53-induced Gl arrest (via
WAF1).'6"'8 An interesting pathway is thus sketched
out, in which p53/WAF1 growth arrest is achieved
through cdk inhibition to activate pRb, which then
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Figure 4. Schematic diagram to illustrate the differential susceptibility to apoptosis of proliferation-
competent cells: cell cycle activation invokes a committment to apoptosis (a 'high turnover state')
that is modulated by the dynamic action of 'survival genes' and their antagonists to determine net
tissue growth or contraction. Note that apoptosis can occur in all the states of activation depicted.
This scheme is not concerned with apoptosis following cellular injury (e.g. p53-dependent death),
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function would prevent shut-down of E2F-1, which
could then induce a high turnover state, as described
above. This model is supported by the example of
mice deficient in the retinoblastoma gene product.
They die in utero with CNS and haemopoietic abnor¬
malities, characterized by excessive proliferation and
apoptosis.79 The direct mechanisms ofp53-dependent
apoptosis are also becoming clearer. p53 down-
regulates bcl-2 expression and also upregulates its
antagonist ftax80'81 This suppresses a major anti-
apoptotic pathway and places p53 proximal to bcl-
2/bax in the regulation of apoptosis.8"
The purpose of the decision to enter G1 arrest after
DNA damage is unclear but one attractive hypothesis
suggests that it provides an opportunity to repair DNA
lesions before DNA replication occurs.8 5 If the dam¬
age is in some way recognized as irreparable, the
hypothesis suggests that jb53-dependent apoptosis
would be triggered, to prevent the replication of
damaged DNA and a gradual accumulation of genetic
defects that might result in carcinogenesis. In support
of this hypothesis thymocytes and gastrointestinal
crypt cells of p53-deficient mice lack the normal
apoptotic response to DNA damaging agents, intrigu-
ingly in a gene-dose dependent fashion.818" In
addition p53 has been shown to be critical for the
maintenance of genomic integrity in serially passaged
cells, and mice without functional p53 genes die
prematurely from malignancies.86'8' Thus p53 is
involved in the policing, the ministration and the
execution of cells with DNA damage. It is hardly
surprising therefore that p53 mutations are common
in malignancy, given the advantages for neoplastic
progression that disabling of p53 confers.
p53 is not critical for all apoptotic pathways (for
example murine thymocytes from p53-deficient ani¬
mals retain a normal apoptotic response to gluco¬
corticoid),84 but it is implicated in apoptosis effected
in vitro by mechanisms apparently unrelated to DNA
damage. Thus p53 is required for normal sensitivity in
vitro of haemopoietic cells to survival factors and loss
of even a single allele reduces (but does not remove)
the requirement for survival factors.88 Introduction of
wild-type p53 into a leukaemic cell line has also been
reported to generate dependence on IL-6 for survival,
and p53 was necessary for the apoptotic response to
serum withdrawal in a cell line cotransfected with
adenovirus E1A and ras oncogenes.89"91 Therefore,
although mice deficient in p53 develop normally84
and p53 is clearly not essential for developmental cell
death, altered survival factor thresholds may influence
population selection during development and pro¬
vide a more favourable environment for
carcinogenesis.
A number of other gene products are implicated in
the control of apoptosis (e.g. clusterin, c-rel, fos, cyclin
Di92-95) ^ kut jn most instances it still remains to sort
primary regulators from secondary perturbations.96'97
Recent evidence from a myeloid leukaemia cell line
has implicated the Mydll8 gene as a downstream
mediator of TGF|3-induced apoptosis and has sug¬
gested that bcl-2 inhibits apoptosis of these cells via
downregulation of Myd.118 expression.69
Disease connotations: apoptosis in disease and
the responses to disease
It is evident that apoptosis provides a powerful
regulatory mechanism for many aspects of normal
tissue growth and function. This section extends the
discussion to describe how apoptosis regulates the
responses to disease and how defective regulation of
apoptosis may be central to the pathogenesis of many
important disorders.
Inflammation
The response to injury or infection has itself consider¬
able potential to damage tissue and it is therefore
tightly regulated. Neutrophils, eosinophils and mono¬
cytes die by apoptosis within a relatively short period
(e.g. 3-4 days for eosinophils in culture), however
death can be significantly delayed by proinflammatory
cytokines such as C5a (neutrophils), IL-1|3, TNF-a,
IFN-y (monocytes) and IL-5 (eosinophils).98'99 In
contrast TGF|3 and TNFa accelerate eosinophil and
neutrophil apoptosis respectively.100'101 This suggests
a potential mechanism in vivo for control of the
survival and ultimately the removal of these poten¬
tially dangerous cells from sites of inflammation when
the inflammatory stimulus subsides. Defects in these
mechanisms or in the clearance of apoptotic cells may
underlie some chronic inflammatory diseases (e.g.
hypereosinophilic syndromes) due to inappropriate
persistence of inflammatory cells with continued
release of toxic cellular contents perpetuating tissue
injury and inflammation. Of interest in this regard
is the multifocal inflammatory disease and tissue
necrosis that occurs in mice without functional
TGF|3l.102
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Autoimmunity
Apoptosis is critical for the development, function
and regulation of the immune system (see ref 103,
B.A. Osborne, this issue, pp27-33). One instructive
example is thymocyte maturation. A competent
immune system must recognise a wide variety of
foreign antigens but provision must be made to delete
self-reactive effector cells that would otherwise cause
autoimmune disease. In the thymus, 97% of thymo¬
cytes are deleted in their first few days of life.104 This
occurs as a result of a complex weeding-out process in
which immature thymocytes die by apoptosis unless
able to recognise and bind antigen presented in
association with self MHC molecules (positive selection
for MHC restriction) and yet die also if the receptor
occupancy is too great (negative selection)}03 The
principle is that high receptor occupancy is likely to
reflect reactivity to self-antigen since most antigen
presented in the thymus is self-derived. However,
negative selection is certainly more complex than
that, and further contributory mechanisms involving
other surface signals are likely.103"108 In concert with
thymic selection, peripheral deletion ofmature T cells
is also important to prevent autoimmune tissue
damage. One mechanism involves apoptosis induced
by activation of surface fas molecules. Fas (CD95, Apo-
1 receptor) is a member of the TNF receptor
superfamily and like some other members can trans¬
duce a signal for either apoptosis or proliferation.
Mice without functional fas or fas ligand accumulate
abnormal CD4CD8T cells and develop autoimmune
disease resembling human systemic lupus erythemato¬
sus (SLE).94 These mice have lost the antigen-driven
fas-dependent apoptosis of mature T cells that main¬
tains tolerance to self.110 Further compelling evidence
for a direct pathogenetic role of fas-mediated cell
death is provided by the recent observations in SLE
patients of elevated serum levels of a soluble form of
fas at concentrations that blocked induction of fas-
mediated apoptosis in vitro, and that in mice caused
altered lymphocyte development and proliferation
responses to self antigen.111
Cytotoxic lymphocyte (CTL) killing
Cell-mediated cytotoxicity is an integral component of
specific host defences, for example against virally
infected cells, and apoptosis is believed to be the
mode of death in a proportion of CTL-induced target
cell killing.26 Evidence suggests that activation of
target cell fas by the CTL is an important mechanism
for this cell-mediated apoptosis, although engage¬
ment of target cell TNF receptors may also act to
trigger apoptosis in some instances.112'113 The finding
that activation of surface fas on hepatocytes triggers
apoptosis114 suggests a potential pathogenetic mecha¬
nism for viral or perhaps autoimmune hepatitis that
may have implications for new strategies of therapy. It
is of relevance to note that CTL can kill by a
mechanism that involves perforin insertion into target
cell membranes and granule exocytosis.26 The relative
importance and interactions of these different modes
of killing is not established.
AIDS
The gradual depletion of CD4+T cells during HIV
infection that leads to clinical AIDS is thought to be
due to excessive apoptosis.114 HIV-infected cells
express a viral envelope transmembrane gpl20-gp41
complex which binds the CD4 D1 domain of unin¬
fected T cells and triggers apoptosis directly.113
Furthermore HIV particles shed gpl20 which,
although unable to trigger apoptosis itself, can bind
CD4 and program uninfected T cells for apoptosis
(instead of proliferation) in response to subsequent T
cell receptor stimulation by antigen.116 The deletion
of naive and memory T cell clones on encountering
their specific antigen abolishes the individual's ability
to mount a specific immune response to
infections.6'116
Neoplasia
Escape by cells from normal activation of apoptosis
allows survival of 'forbidden clones' that would
otherwise have been deleted. This might allow the
propagation of, for example, new genetic defects that
would have been eliminated through p53-dependent
apoptosis. In addition, reduced dependence on sur¬
vival factors may be important in the early stages of
carcinogenesis to allow expansion of subpopulations
of cells capable of subsequent progression to malig¬
nancy. An example is experimental liver tumour
promotors such as nafenopin and phenobarbital that
reversibly inhibit apoptosis with consequent hyper¬
plasia and development of preneoplastic foci.117
Constitutive bcl-2 expression by follicular lymphomas
is an example of a death suppression strategy in
human neoplasia.118 The qualities that allow survival
ofmalignant cells in foreign tissues have received little
attention but are a sine qua non for invasion and
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metastasis. It is likely that escape from integrin
dependence is one such necessary event.
Oncogenic viruses
Oncogenic viruses have developed strategies to pre¬
vent host cell apoptosis that have shed light on control
pathways. The Epstein Barr virus BHRFI protein is a
bcl-2 homologue, whilst the LMP-1 protein upregu-
lates bcl-2 expression and induces the A20 zinc finger
protein that confers resistance to TNFa cytotox¬
icity.119121 The adenovirus E1B gene encodes a
functional homologue of bcl-2 and a protein that
inactivates the p53 oncosuppressor.122121 In fact
several viruses inhibit p53 function in different ways,
including SV40 (large T antigen), Epstein Barr virus
(EBNA5), human papillomavirus types 16 and 18 (E6
protein) and hepatitis B virus (HBx protein) (see ref
124 for references). This is a testament to the
importance of that molecule in countering abnormal
cell proliferation. Interestingly, many oncogenic
viruses contain genes that activate cells from the
growth arrested state (SV40 T antigen, adenovirus
ElA, HPVE7) probably via inactivation of Rb protein,
release of transcription factor E2F and activation of
c-myc. At least some of these changes also imply
increased susceptibility to apoptosis, as discussed
earlier. The combination therefore of pro-apoptotic
oncogenes with others having anti-apoptotic activity
appears to be an essential part of the viral strategy to
induce cell proliferation without also activating cell
death.
Cancer therapy implications
The ability to modify sensitivity to apoptosis through
the regulatory pathways has clear implications for the
treatment of malignancy.122' Potential strategies fall
into three categories— direct triggering of apoptosis
by cytotoxic agents, enhancing susceptibility to apop¬
tosis to increase the efficacy of other therapies, and
boosting the resistance of normal cells to apoptosis
(with survival factors). Restoration of function of
interrupted apoptotic pathways, e.g. /;53-dependent
apoptosis, with consequent self-deletion by tumour
cells would be a most attractive strategy. Bcl-2 antago¬
nists might likewise be expected to cause regression of
follicular lymphomas or at least to increase their
radio- or chemosensitivity. Induction of a high turno¬
ver state (with survival factor dependence) or antago¬
nism of tumour survival factors (e.g. antiandrogens
for prostate carcinoma, tamoxifen for oestrogen
receptor-expressing breast carcinomas) are other
approaches to therapy. Boosting normal cell resis¬
tance to apoptosis with exogenous survival factors can
be used after ablative therapy to improve restoration
of the normal cell population,121' reducing treatment
morbidity and allowing greater frequency of cytotoxic
treatments.
Conclusion
Apoptosis has an importance in physiology and
pathology that has only recently become fully appre¬
ciated. Its purpose is to rapidly delete single cells from
living tissue without interrupting tissue function or
structural integrity. Diverse fields of developmental,
cell and molecular biology are linking to contribute to
a deeper understanding of apoptosis that has a direct
relevance to a variety of human diseases and in some
instances suggests new therapeutic strategies. Much of
the basic biology of the regulation and effector events
of apoptosis remains obscure but the field is now
subject to such an intense level of investigation that it
is not unrealistic to expect great advances within a
very short time.
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Loss of function of the p53 tumour suppressor gene is a frequent and important
event in the genesis or progression of many human malignancies. Loss of p53
dependent apoptosis is believed to be critical to carcinogenesis in many of these
cases, suggesting the possibility to therapeutically restore this pathway and directly
eliminate malignant cells or increase or restore their sensitivity to chemotherapeutic
agents.
The regulation of p53-dependent responses is complex and variable between
cell types, and whether a cell undergoes apoptosis after activation of p53 is highly
sensitive to signal context, including environmental and cell intrinsic influences.This
article focuses upon p53-dependent apoptosis, considering current understanding
of the biochemical steps involved, the factors determining selection of apoptosis
over other p53 -dependent responses, the significance of p53 -dependent
apoptosis for the genesis, progression and drug resistance of human cancers, and
finally the prospects for clinical manipulation of this pathway in cancer therapy.
The new interest in apoptosis has touched many fields, but none more so
than cancer biology. Apoptosis is envisaged as eliminating cells with
DNA damage or growth dysregulation that could become precursors of
malignant clones. In this way it complements growth arrest and DNA
repair as mechanisms to preserve the genetic integrity of tissues. Until
recently these mechanisms represented distinct fields of research.
However, exciting new evidence suggests that a small set of common
regulatory molecules are involved, and the integration of previously
complimentary fields is bringing a new depth of understanding to cancer
biology. The p53 tumour suppressor gene product is central to this new
focus. Roles for p53 have been identified in aspects of DNA damage
recognition, DNA repair, cell cycle regulation and most particularly in
triggering apoptosis after genetic injury (see Ko and Prives1, for
overview
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p53 is the most commonly mutated gene in human malignancy,
prevalent in cancers of a wide variety of histogeneses and primary sites.
This wide occurrence of defective p53 derives from 3 properties. First,
wild type p53 is highly vulnerable to dysfunction caused by even a single
base change in the coding sequence. Second, in contrast with classical
tumour suppressor gene theory a single abnormal p53 allele or allele loss
can alter phenotype. Depending on the gene lesion, this manifests by a
©The British Council 1997 British Medical Bulletin 1996;53 (No. 3):522—538
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gene-dose dependent reduction in certain p53 functions, a dominant
negative inhibition of the remaining wild type allele's function, or gain of
a novel function(s) not associated with wild type. Third, the participa¬
tion of p53 in multiple pathways of fundamental importance to
carcinogenesis makes it an Achilles' heel of cancer suppression, a defect
in which can radically diminish cellular defences against carcinogenesis.
This article focuses upon p53-dependent apoptosis, highlighting
differences between cell types and reviewing current understanding of
the biochemical steps involved, the factors determining selection of
apoptosis over other p53-dependent responses, the significance of p53-
dependent apoptosis for the genesis, progression and drug resistance of
human cancers, and finally the prospects for clinical manipulation of this
pathway in cancer therapy.
The p53 protein
The biochemistry and molecular genetics of p53 have been reviewed in
detail elsewhere2. p53 is a nuclear DNA-binding phosphoprotein that
normally exists as a homotetramer or complex of tetramers. It is a
transcriptional activator of a specific set of target genes, and can exert
transcriptional repression, probably by interaction with transcription
factors or the general transcription machinery. p53 also interacts directly
with cellular proteins and is itself a target of several viral proteins. It is
present in vivo in a biochemically latent form and is normally rapidly
degraded (t1/2 -30 min), probably by ubiquitin-dependent proteolysis.
p53 activity and stability are regulated post-transcriptionally and post-
translationally by still incompletely understood mechanisms that include
alternative splicing, conformational change, phosphorylation, protein-
protein associations and regulation of nuclear localisation. p53 also
negatively regulates its own transcriptional activity through induction of
the mdm2 oncogene, forming a negative feedback loop. The activity and
stability of p53 protein vary in a cell cycle dependent manner, although
p53 is not required for normal mitotic or meiotic cycles.
p53-dependent apoptosis
Upstream events
Triggers for p53-dependent apoptosis include DNA damage, inappropri¬
ate oncogene activation, certain cytokines3 or cytokine deprivation4,
hypoxia5 and heat shock5. The biochemical pathways converging onto
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p53 are not clearly defined, although there is stimulus specificity, for
example thymocyte apoptosis triggered by DNA damage is p53-
dependent but that triggered by dexamethasone is not6.
DNA damage is the best defined stimulus of p53-dependent responses
and in several cell types is coupled to stabilisation and accumulation of
p53 protein. Indeed, analysis of cells and tissues of mice homozygous-
deficient for p53 has definitively shown that p53 is required for DNA
damage-induced apoptosis of cortical thymocytes6, myeloid progenitor
cells7, marrow pre-B cells8, quiescent peripheral B and T lymphocytes8,
cerebellar granule neurones9, keratinocytes10 and proliferating crypt
epithelial cells of small and large intestine11. In these situations p53 itself
may be the sensor of DNA damage. The full range of DNA lesions that
provoke a p53 response is not known, but primary lesions to which p53
binds directly in vitro include insertion/deletion mismatches and DNA
strand breaks. p53 binds avidly to strand breaks and this stabilises and
activates the otherwise short-lived protein. Whereas y-irradiation and
some chemical agents produce strand breaks directly, for many
genotoxins the strand breaks are only generated indirectly, during
DNA repair, when short patches of DNA bearing the damaged
nucleotides are excised. In this way, p53 is made sensitive to a broad
range of different DNA lesions. As yet poorly defined response-enabling
pathways are probably important for a normal p53 response to DNA
damage, since cells from patients with the inherited radiosensitivity
syndrome ataxia telangiectasia or Fanconi anaemia show an attenuated
and delayed p53 response to y-irradiation12'13.
Aside from DNA strand breaks, little is known about how the other
triggers of p53-dependent apoptosis couple to p53, but there is evidence
for distinct pathways5. One novel stimulus for p53 induction is depletion
of ribonucleotide triphosphates (rNTP), necessary for RNA synthesis14.
So far, this pathway has been linked only to p53-dependent growth
arrest rather than apoptosis, but the possibility that p53 could be
responsive to alterations in RNA as well as DNA is intriguing.
Signal transduction through p53
Within 3 h of y-irradiation in vivo, murine splenocytes, thymocytes and
osteocytes show dramatic accumulation of immunoreactive p53, lasting
for over 48 his. UV irradiation of human skin sufficient to produce mild
sunburn generates similar kinetics of p53 protein accumulation in
keratinocytes and dermal fibroblasts16. But although p53 accumulation
in normal cells is characteristic of p53-dependent responses, it is not
specific for any particular response, and indeed may not be the critical
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event that precipitates engagement of downstream pathways. In vitro,
large changes in transcriptional transactivation by p53 are achievable
independently of protein levels17'18 and p53 responses can be triggered
without changes in protein concentration, suggesting that accumulation
is not always sufficient or perhaps even necessary for engagement of p53
downstream responses. Instead 'activation' of p53, for example by
phosphorylation, could determine initiation of downstream events. p53
activates transcription of its target genes by interactions with specific
p53-response motifs and these interactions are selectively regulable
through changes in p53 phosphorylation19. Simultaneous up- and down-
regulation of p53 interactions with different response elements is
possible, and hence to better understand p53 function, experiments
using panels of reporter constructs for p53 response elements may be
necessary to dissect out qualitative changes in patterns of p53
transcriptional transactivation.
The binding of p53 by endogenous regulatory proteins can also
regulate function; for example the Wilms tumour suppressor gene
product, WT1, inhibits p53-dependent apoptosis without affecting p53-
dependent growth arrest20. Moreover, a significant proportion of p53
protein in at least some cell types is alternatively spliced, and almost
certainly functionally different to the whole protein21. However, the role
of alternative splicing in regulating p53 is not understood at present.
In summary, p53 is more than a simple link in a chain of signalling,
and there is a tremendous complexity of signal transduction possibilities
through p53. But whilst in vitro work is informative, still little is known
about how signals are processed through p53 in vivo.
Downstream events
Cells with only one functioning copy of the p53 gene have intermediate
rates of apoptosis between null and wild type cells (a gene dose effect),
suggesting an induction threshold for apoptosis that lies within the upper
range of physiological p53 activity, and a subtlety to regulation in vivo
that constitutive expression systems do not interrogate. The particular
p53 activity most critical for apoptosis is still a matter for debate.
Interpretation of various apparently contradictory findings is compli¬
cated by the use of expression systems generating supraphysiological
amounts of protein, or in which endogenous p53 or viral proteins that
target p53 are present. Nevertheless, in vitro there appear to be distinct
mechanisms by which p53 can be made to engage apoptosis22'23. One
mechanism requires specific transcriptional transactivation by p53,
perhaps of bax, a member of the bcl-2 family that in relative excess to
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bcl-2 permits apoptosis. However, bax is dispensable for p53-dependent
apoptosis in y-irradiated thymocytes24, suggesting that other factors are
more important. Transcriptional repression by p53, for example of bcl-
2, may also contribute to apoptosis25 and modifying influences by other
members of the bcl-2 family are probably relevant, for example bcl-xL
can inhibit p53-mediated apoptosis in vitro16.
Additional to effects on gene expression, p53 interacts directly with
proteins and there is evidence that binding of the TFIIH protein complex
is critical for a pathway of p53-dependent apoptosis that does not
involve specific transcriptional transactivation23. p53 inhibits the heli-
case activity of this complex by binding to the XPB (ERCC3) and XPD
(ERCC2) subunits, both of which are required in this apoptotic
pathway23'27. Thus, a single protein defect can compromise both repair
and apoptosis responses to DNA damage. The data are particularly
provocative since TFIIH participates in basal transcription, nucleotide
excision repair, and probably also in cell cycle control. Thus, a core
element is identified, through which dynamic regulation and coupling of
these critical cellular processes can be achieved and the balance shifted
according to circumstance. Moreover there is a basis for understanding
how defects in one pathway can have effects on the others and the
balance between them.
Once p53-dependent apoptosis is triggered, there is no evidence that it
differs in any way from apoptosis induced by other means, and it is not
doubted that downstream events feed into a common effector pathway
of apoptosis. In summary, the biochemical steps by which p53 triggers
apoptosis are still incompletely defined, but there is evidence for distinct
mechanisms that predominate according to cell type and may be
interactive22'23'28.
What determines the outcome?
When normal proliferating cells sustain DNA damage they respond in
one of two ways: cell cycle arrest or apoptosis, and p53 is implicated in
both. For example after 5 Gy y-irradiation, proliferating fibroblasts
growth arrest29, whereas proliferating intestinal crypt epithelium
undergoes apoptosis11, both by p53-dependent mechanisms. These and
other experiments show that cell type is an important determinant of the
outcome of p53 activation. However, in culture, it is possible to switch
one response to another (see below), suggesting a potential flexibility of
outcome and the existence of cellular decision mechanism(s) that
determine the predominant p53 response pathway. Greater under¬
standing of these issues would better define the contributions of p53 to
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tumour suppression in different tissues, and the data available will now
be discussed.
Growth arrest and apoptosis: p53 can cause cells to growth arrest at
certain stages in the cell cycle ('checkpoints'), of which the best
understood is late Gj phase arrest. p53 triggers G, arrest through specific
transcriptional activation of the cyclin-dependent kinase inhibitor, p21.
Embryo fibroblasts from p21-null mice are correspondingly severely
deficient in p53-dependent Gx arrest30'31 (although not completely so,
suggesting that other minor p53-responsive pathways to Gj arrest exist,
perhaps involving the p53 target gene GADD4532). By contrast, p21-
deficient mice retain p53-dependent apoptosis in tissues such as thymus
and small intestinal epithelium30'31. These and other experiments
indicate that the p21 growth arrest pathway is distinct from pathways
to p53-dependent apoptosis22'23.
It is possible that, in some circumstances, p53 simultaneously signals
growth arrest and apoptosis, and downstream suppression of apoptosis
is necessary to prevent that outcome. For example, use of a bcl-2
transgene to delay p53-dependent apoptosis in a myeloid leukaemia cell
line revealed a p53-dependent growth arrest34. Moreover, the suppres¬
sion of apoptosis may derive from the growth arrest pathway, as
suggested by experiments in which removal of p21 from colorectal
carcinoma cell lines that normally engaged p53-dependent growth
arrest, caused them instead to undergo apoptosis35. Intriguingly,
carcinoma cells heterozygous for p21 showed a split response between
growth arrest and apoptosis, suggesting that the switch of response
occurred within a narrow physiological range of p21 expression.
Therefore, although mechanistically distinct, the pathways of p53-
dependent growth arrest and apoptosis may communicate.
Commitment to p53-dependent apoptosis is also regulated by
extrinsic influences from the local environment; for example cytokine
survival factors can inhibit p53-dependent apoptosis4'7'36. Indeed, signal
context is a critical determinant of the response to p53 activation.
Experiments on cultured fibroblasts have shown that growth arrest
switches to apoptosis if the growth arrest signals (e.g. serum depletion or
activated p53) are challenged with forced growth activation signals (e.g.
from deregulated c-myc or E2F oncogenes)33'37'38. This link between
deregulated proliferation signals and apoptosis has also been observed in
vivo, in embryos null for the retinoblastoma (Rb) tumour suppressor
gene product, pl05Rb, that inhibits cell cycle progression. The embryos
die in mid-gestation with excessive, uncontrolled proliferation but also
apoptosis of cells in the developing nervous and haemopoietic systems.
Study of lens epithelium has shown that the apoptosis is p53-
dependent39. The coupling of contextually inappropriate proliferation
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signals to apoptosis probably represents a defence against autonomous
oncogene-driven proliferation, deleting the offending cell by apoptosis
unless other permissive factors are present. Such models are clearly
relevant to understanding tumour suppression (see below), although it is
still not certain how closely they reproduce mechanisms of choice within
normal cells.
DNA repair and apoptosis: p53 was originally suggested to facilitate
DNA repair simply through establishing growth arrest and so providing
extra time for completion of repair before DNA replication or mitosis.
However, a more active contribution is now evident. A detailed
consideration of this aspect of p53 function is beyond the scope of this
article, but it is clearly of great importance to clarify whether p53-
dependent apoptosis is coupled to its repair activities, as hinted by the
interaction with XPB and XPD described earlier. For example, do repair
and apoptosis after DNA damage share damage sensing mechanisms? Is
apoptosis triggered by repair rather than damage? One influential
hypothesis to explain responses to DNA damage suggests that cells have
the capacity to recognise when DNA damage is too profound to be
repaired completely or sufficiently rapidly, whereupon p53-dependent
apoptosis is triggered, preventing replication of a damaged genome40.
This remains unproven, but the observation of proteins common to
repair and p53-dependent apoptosis demonstrate potential for such a
decision mechanism.
p53-independent apoptosis
p53-independent pathways can determine apoptosis and growth arrest
responses to DNA damaging agents. Even cell types such as intestinal
crypt epithelium which show p53-dependent apoptosis (usually mani¬
fested within 24 h of genotoxic insult), can have additional late phase
p53-independent apoptosis (Clarke AR, unpublished results). These
pathways to apoptosis may be triggered by the DNA damage itself or
alternatively, genotoxins can affect cellular components other than DNA
and trigger apoptosis through pathways quite unrelated to the genetic
injury. For example activation of membrane sphingolipase by y-
irradiation is not related to the DNA damage41, but triggers apoptosis
in some tissue types through a ceramide pathway. This pathway is
probably p53-independent and may be responsible for most of the
pulmonary endothelial apoptosis observed after y-radiation injury42.
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IRF-1 and p53
In some cell types, apoptosis or growth arrest following y-irradiation has
been shown to be dependent upon the transcription factor interferon
regulatory factor 1 (IRF-1). For example, apoptosis of activated
peripheral T lymphocytes after y-irradiation is IRF-1 dependent and
not p53-dependent43. By contrast, IRF-1 is not required for the p53-
dependent apoptosis of y-irradiated thymocytes and, together, these data
suggest that p53 and IRF-1 pathways to apoptosis are independent and
operate in distinct cell populations43. The situation for growth arrest is
more complex: p21 expression can be up-regulated by several p53-
independent pathways, and at least one, requiring IRF-1, is also
stimulated by DNA damaging agents44. Intriguingly, experiments using
p53-null and IRF-l-null mouse embryo fibroblasts have shown that each
pathway alone is insufficient to trigger growth arrest and that they must
act in concert44. This suggests that a threshold of p21 activation exists
that is not easily achievable by a single damage response pathway. In this
way, p53-dependent growth arrest is mutually dependent upon co-
activation of one or more p53-independent pathways. Thus, once again,
the context in which an individual signal acts is seen to be critical to the
outcome of p53 activation.
Contributions of defective p53-dependent apoptosis to
cancer development
It is difficult or impossible to understand the contribution to tumour
suppression of different p53 functions without the use of model systems,
of which transgenic and gene-targeted mice continue to provide critical
data. Even so, the overlapping contributions to genomic stability and
tumour suppression of growth arrest, DNA repair, apoptosis and other
functions are probably not completely separable, and it may be the
interaction and coupling between these activities which will prove
critical in cancer development. Nevertheless, there is considerable
evidence that defective p53-dependent apoptosis has pathogenic
significance for human cancer.
Oncogene-triggered apoptosis
As described earlier, p53 can limit the carcinogenic potential of aberrant
oncogene activation, by triggering apoptosis. This is an effective
protection against not only endogenous oncogene activation but also
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viral oncogene expression in host cells. Not surprisingly, however,
oncogenic viruses such as EBV, adenovirus and HPV have evolved
counterstrategies to evade or block the induction of apoptosis, ipso facto
evidence for its importance. For example, the adenovirus E1A oncogene
is unable alone to transform primary cells since the affected cells die by
p53-dependent apoptosis. Elowever, adenovirus produces a second
protein, E1B, that inhibits p53-dependent apoptosis, and this allows
sustained proliferation and transformation to occur45.
The significance of oncogene-activated, p53-dependent apoptosis for
suppression of carcinogenesis has been directly tested in vivo: In a
transgenic mouse model of experimental choroid plexus tumours, a
variant of the SV40 T antigen that functionally disrupts only the
retinoblastoma family of proteins (leading to aberrant E2F oncogene
activation) but not p53, produced atypical hyperplasia associated with
increased apoptosis46. The added effect of p53 inactivation was shown to
reduce the excess apoptosis, without affecting proliferation rates, leading
to the rapid development of highly malignant tumours. A similar
demonstration was provided by mice bearing an HPV16 E7 transgene
that was expressed in photoreceptor cells47. The transgene caused
functional Rb-1 inactivation, leading to abnormal activation of the E2F
oncogene. In these transgenic mice the photoreceptor cells failed to
terminally differentiate and instead underwent apoptosis. However,
when the analysis was repeated on a p53-deficient genetic background, a
similar pattern of apoptosis was not observed and the transgenic animals
developed neoplasms arising from the photoreceptor cell layer.
DNA damage-triggered apoptosis
The elegant experimental systems described above show that p53-
dependent apoptosis in response to inappropriately activated prolifera¬
tion signals inhibits carcinogenesis at an early stage by deleting the
potentially neoplastic cells. They do not, however, test the hypothesis
that DNA damage-induced p53-dependent apoptosis suppresses carci¬
nogenesis. Indeed, this is difficult to do because of difficulty in isolating
p53-dependent apoptosis from its repair or growth arrest functions. For
example, p53 deficient keratinocytes from gene targeted mice were
reported to show a gene dose dependent reduction in the normal
apoptotic response to UV-irradiation, the prime aetiological agent of
squamous carcinoma of the skin10. This leads to survival of clones
which, over successive exposures to UV, should predominate over wild
type in the epidermis and acquire further mutations. However, p53
dysfunction also renders keratinocytes deficient in repair of UV-induced
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DNA damage48. Moreover, keratinocytes from mice carrying a mutant
p53 transgene showed only decreased DNA repair but no alteration in
apoptosis following UV irradiation, despite increased susceptibility of
these mice to UV-induced squamous skin carcinomas48. Thus the role of
p53-dependent apoptosis in UV-induced skin carcinogenesis remains
uncertain.
The intestine provides an alternative tissue to explore this question
since p53-dependent apoptosis following genotoxic damage of crypt
stem cells has been independently documented by different groups11'49.
However, in y-irradiated murine small intestine at doses adequate to
trigger p53-dependent stem cell apoptosis, p53 deficiency was not
associated with increased numbers of mutated stem cells compared with
wild type (as assessed in an endogenous indicator gene), suggesting that
inappropriate survival of genetically damaged cells does not necessarily
equate to increased tissue mutability in vivo (Clarke AR et al, in
preparation).
The thymus presents another tissue model for DNA damage induced
apoptosis in tumour suppression. p53 null thymocytes are deficient in
apoptosis after DNA damage but not other physiological stimuli (e.g.
corticosteroid) and are at a greatly increased risk of lymphomagenesis
that is still further accelerated by y-irradiation6'50. By contrast, p21~
deficient mice (which have defective p53-dependent G[ growth arrest but
preserved p53-dependent apoptosis) do not show increased susceptibility
to spontaneous cancers, including thymic lymphomas31. However,
whilst retention of p53-dependent apoptosis in these mice may explain
the preservation of tumour suppression, p53-dependent repair and other
cell cycle checkpoints could also be intact. Susceptibility of p21-null
mice to DNA damage-induced carcinogenesis has not yet been reported.
Thus, whilst DNA damage-induced p53-dependent apoptosis is likely
to contribute to suppression of carcinogenesis, particularly in haemo-
poietic or lymphoid tissues50, and in the embryo is critical to suppress
radiation-induced teratogenesis51, it can be difficult to separate such a
contribution from other p53-dependent activities.
Sensitivity to local environment
p53 regulates dependence on cytokine survival factors, as demonstrated
for haemopoietic cells7, prostate52 and hepatocytes (Bellamy COC et al,
submitted). A potential contribution of p53 dysfunction to carcinogen¬
esis and tumour progression is, therefore, through increased survival
(decreased apoptosis) in competitive or unfavourable environments, for
example within solid neoplasms or during neoplastic spread to other
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tissues. Hypoxia and associated necrosis are prevalent in solid malignant
neoplasms, and the latter has often been correlated with a poor
prognosis. Although normal cells were relatively resistant to hypoxia,
transformation was found to make them sensitive to apoptosis under
conditions of extreme hypoxia53. However, p53 deficiency (or Bcl-2
overexpression) protected against hypoxia-induced cell death both in
vitro and in vivo, and over successive exposures to hypoxia resulted in
overgrowth of cultures by an initially small fraction of p53-deficient
cells53. Hypoxia was thus shown to exert a selective pressure for loss of
p53-dependent apoptosis from neoplastic cells.
Wilms' tumour provides an authentic human example in which p53-
dependent apoptosis may be relevant to tumour progression. p53
mutations are rare in this paediatric malignancy except in the poor
prognosis anaplastic variant, characterised by focal areas of anaplastic
morphology within the neoplasm. In these tumours the p53 mutations
are restricted to the histologically anaplastic tissue, which was also
shown to display much reduced apoptosis compared with surrounding
non-anaplastic tumour54. These studies, therefore, imply a pathogenetic
role for p53 inactivation in Wilms' tumour progression and suggest that
loss of p53-dependent apoptosis may be the critical event, analogous to
the mouse models described above.
p53 and responses to cancer therapy: sensitivity or
resistance?
Irradiation and many drugs used to treat cancers are primarily
genotoxic, either directly or by disrupting DNA metabolism and, at
therapeutic doses, trigger apoptosis in the target cells. If the apoptosis is
due to DNA damage then the p53 status of the neoplastic cells might be
expected to modify the drug effect. Two contrasting scenarios are
envisaged. Firstly, in cells that readily undergo p53-dependent apoptosis
as the preferred response to DNA damage, p53 dysfunction could allow
survival and, therefore, resistance to treatment. Indeed the surviving cells
may have acquired further mutations as a result of exposure to the
treatment agent and behave more aggressively than before. However, if
p53-dependent apoptosis is not a readily invoked consequence of DNA
damage, and instead growth arrest and repair activities are compromised
by loss of p53 pathways, then neoplastic cells are more likely to enter S
phase and mitosis bearing high levels of unrepaired damage and viability
could be decreased. Moreover, the cycling fraction of p53 deficient cell
populations is often high and, if the drug is one that preferentially acts
during S phase or mitosis, lethality would be increased, simply because a
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greater proportion of neoplastic cells pass into susceptible cell cycle
phases during exposure of the patient to the drug. The consequences of
altered p53 status for drug efficacy in cancer therapy are, therefore,
difficult to predict. Indeed, in vitro evidence exists for sensitisation,
resistance and no effect conferred by loss of wild type p53 on the efficacy
of chemo- or radiotherapy55-58. Given these caveats to broad general¬
isations, some of the experimental evidence that p53 is relevant to cancer
therapy will now be discussed.
As discussed earlier, transformation of normal cells by oncogenes
sensitises them to triggering of apoptosis that is often p53-dependent.
This lowers the threshold at which irradiation and many drugs used in
cancer chemotherapy induce apoptosis, as demonstrated in vitro for
fibroblasts transformed by ElA+ras oncogenes. In that system, the p53
genetic background of the transformed fibroblasts was a critical
determinant of drug-induced apoptosis; p53 null transformed cells were
resistant to doses of y-irradiation or adriamycin that efficiently killed
p53 wild type transformed fibroblasts by apoptosis56. Significantly,
identical results were found in vivo when tumours derived from the
transformed cells were grown in mice and y-irradiated or adriamycin-
treated59. In other systems, oncogenes such as c-myc60 and HPV E7+ras61
have been similarly shown to induce p53-dependent sensitivity to
irradiation or chemotherapeutic drugs.
The elegant model systems just outlined are informative, but the role
of p53 in the efficacy of human cancer therapy is likely to be less clear-
cut due to other gene products also affecting chemosensitivity. One
important prediction of these observations, however, is that where
cytotoxic agents commonly induce p53-dependent apoptosis in trans¬
formed cells, loss of p53 pathways can produce a multiresistant
phenotype. This concept has implications for both de novo resistance
to treatment and the development of acquired resistance in recurrent or
relapsing malignancy. Indeed, in the murine ElA/ras-transformed
fibroblast tumour model, described in the previous paragraph, Lowe et
al found that over 50% of the initially treatment-resistant or recurrent
tumours derived from transformed fibroblasts on a p53 wild type
background had acquired p53 gene mutations59. Thus the cytotoxic
treatment (y-irradiation) had selected for apoptosis resistance, and
consequently enriched the tumour population in cells with defective p53,
which would be predicted to show resistance to other cytotoxic agents. It
also follows that reintroduction of wild type p53 function to such
cancers should restore sensitivity to therapy, and the prospects for
achieving this will be discussed in the next section.
As well as determining responses to genotoxic therapies for
malignancy, p53 status may affect responses to hormone ablation
therapy, such as anti-androgen therapy of prostate carcinoma52. The
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principle of this type of treatment is that some element of hormone
responsiveness or dependence is retained by the neoplasm and is
therefore a target for slowing tumour growth or induction of regression
by shifting the balance between cell proliferation and apoptosis. Since
p53 can regulate dependence of some cell types on survival factors, loss
of wild type p53 may confer resistance to hormone ablation therapy.
Gene specific therapy
As can readily be appreciated from the discussion so far, the ability to
reactivate p53-dependent pathways in neoplasms is a potentially
powerful therapeutic tool, by either directly provoking apoptosis or by
returning sensitivity to cytotoxic cancer chemotherapeutic drugs. Indeed,
retention of p53-dependent apoptosis probably explains the sensitivity
to chemotherapy of testicular neoplasms18'65. In vivo testing of this
hypothesis is clearly a priority, but it is too early yet for substantial data
to have accumulated62'63. The availability of inducible p53 gene
constructs, cloned into tumorigenic cell lines or introduced into the
germline, will allow p53 expression to be suddenly switched on within
neoplasms by exposure of the cells or tissue to the pharmacological
inducing agent, and permit better experimental evaluation of the
mechanisms and potential benefits of p53 therapy.
If benefit is shown for p53-specific therapy, the options for clinical
intervention are manifold. They include gene delivery systems by use of
lipid vehicles or viral vectors, or alternatively peptides designed to mimic
or activate particular aspects of p53 function and tagged for target cell
specificity might be used. Finally, structural mutants of p53 that are
unable to maintain a stable wild type conformation might be stabilised
by specific pharmacological agents, or perhaps even vaccinated against,
using mutant specific epitopes as immunogens. The results of a recent
study of the effects of retrovirally introduced wild type p53 on non-small
cell lung cancer in 9 patients are encouraging preliminary evidence that
reintroduction of p53-dependent apoptosis is a viable option for human
cancer therapy64.
Conclusion
The position of p53 at the head of key cellular pathways, without
actually being essential for life, and its susceptibility to dysfunction
through loss or mutation of a single allele, make a powerful but fragile
instrument of tumour suppression. The downstream links to central
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molecular regulators like TFIIH provide mechanisms for the co-
regulation of apoptosis, cell cycle and DNA repair after DNA damage,
and also illustrate how defects in one pathway could impinge upon the
others. p53 is pleiotropic and there are important differences between
cell types in both the upstream induction of p53 and the downstream
responses evoked. Thus the consequences of p53 dysfunction for
carcinogenesis must be read in the context of the specific lesion, the
cell type, differentiation state, genetic background and cellular environ¬
ment.
p53-dependent apoptosis is important for tumour suppression in some
tissues, such as thymus, or in particular biochemical situations, such as
forced oncogene activation. However, apoptosis may not be the
important tumour suppressor function of p53 in other tissues and in
some cell types p53 may be partially or completely redundant to
pathways dependent on other genes such as IRF-1. Moreover, the
particular balance of p53 downstream pathways that operates in normal
cells may be distorted in neoplasia, perhaps for example giving the
potential to therapeutically trigger p53-dependent apoptosis in a cell
type that would not normally engage this response. Achieving better
understanding of these issues is essential to more fully comprehend the
contribution of p53 to tumour suppression in different tissues, and is a
major goal of cancer biology.
Despite these complexities, evidence for a clinical utility of gene-
specific therapy of human cancer in specific situations is accumulating,
and the practicalities of implementing such therapy are already being
addressed.
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UV BUT NOT y-IRRADIATION INDUCES SPECIFIC
TRANSCRIPTIONAL ACTIVITY OF p53 IN PRIMARY
HEPATOCYTES
christopher o. c. bellamy*!, sandrine prost+, andrew h. wyllie and david j. harrison
Sir Alastair Currie Cancer Research Campaign Laboratories, University Department of Pathology, Medical School, Teviot Place,
Edinburgh, EH8 9A G, Scotland, U. K.
SUMMARY
The mechanisms are poorly understood by which p53 can stimulate different downstream events, including growth arrest, DNA repair,
tnd apoptosis, after DNA damage. Changes in protein levels do not predict a particular p53 response, but it is possible that differences
n functional activities such as transactivation are important. The present report describes the successful use of a specific p53 reporter
dasmid transfected into primary murine hepatocytes to evaluate p53 transactivation activity over time after two different genotoxic
njuries (^-irradiation, 15 Gy and UV-c irradiation, 10 Jim2) known to produce p53-dependent growth arrest in this cell type. The results
show that UV injury to hepatocytes was followed by a transient increase in transcriptional activation of the reporter plasmid by p53 and
■hat this response preceded changes in p53 protein levels, as assessed by immunocytochemistry. By contrast, y-irradiation injury failed
o induce detectable changes in either transactivation activity or hepatocyte p53 protein levels. The data show that p53 responses to DNA
damage are dependent on both cell and injury type and suggest that in hepatocytes they can be independent of protein concentration and
specific transcriptional activity. The results have implications for how particular dysfunctional p53 mutations in carcinogenesis could
alter hepatocyte responses to different DNA injuries. © 1997 John Wiley & Sons, Ltd.
J. Pathol. 183: 177-181, 1997.
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INTRODUCTION
The tumour suppressor protein p53 is a critical
mediator of DNA damage response pathways that
:ouple to growth arrest, apoptosis, and DNA repair.1
Cell lineages differ in the particular p53 response path¬
way engaged after DNA injury, but whether the choice
s regulated through p53, and by what mechanism, is
joorly understood. Accumulation of p53 protein is
lot specific to any particular p53-dependent pathway,
jut phosphorylation or alternative splicing could deter¬
mine the downstream events initiated by p53 by selec-
;ively regulating transactivation and transrepression
ictivities.2~5. It is therefore essential to complement
irotein quantitation with functional assays. Greater
mderstanding of these issues would better define the
:ontribution of p53 to tumour suppression in different
issues.
Despite good evidence for p53 dysfunction in hepato-
;ellular carcinomas,6'7 rather little is known about
i53 in normal hepatocytes. Proliferating hepatocytes
■espond to both UV and y-irradiation-induced DNA
njuries by p53-dependent growth arrest.8-9 However,
ilthough hepatocytes become strongly immunoreactive
or p53 protein after UV irradiation,9-10 this is not seen
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after-y-irradiation.11 The observation suggests that
qualitative differences in the character of the p53
response underlie the common biological response to
these two injuries; hence it was of interest to extend the
comparison to assessment of p53 function. The present
report describes the use of a p53 reporter plasmid
transfected into primary murine hepatocytes to investi¬
gate p53 transactivation activity at the ribosomal gene
cluster (RGC) response element following y- and UV-c
irradiation. The transient reporter assay is shown to be
sufficiently sensitive and reliable to evaluate authentic
p53 responses to DNA damage in primary culture.
MATERIALS AND METHODS
Plasmids
pCMV/5 (Clontech) is a mammalian expression
vector designed for the constitutive expression of
/2-galactosidase from the Escherichia coli lacZ gene in
mammalian cells. pRGCAFosLacZ is a reporter plasmid
for transcriptionally active wild-type p53.12 It is based
on the pBSK plasmid into which have been cloned
oligonucleotides containing two copies of a p53 RGC
consensus binding site, a transcriptionally inactive
mutant murine fos promoter, the lacZ gene (open read¬
ing frame), and the small t intron with the polyadenyla-
tion signals of SV40. Wild-type p53 binds to the RGC
elements and stimulates expression of //-galactosidase.
pRGCAFosLacZ and a negative control plasmid
pAFosLacZ, which is identical except that it lacks the
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RGC fragments necessary for p53 binding, were the
kind gifts of Professor S. H. Friend.
Hepatocyte isolation, culture, cationic
liposome-mediated transfection, and irradiation
Primary hepatocytes from adult male mice 6-10 weeks
old were isolated by a retrograde two-step perfusion
procedure13 and purified by centrifugation through
Percoll.14 The hepatocytes were plated into fibronectin-
coated 24- or 12-well tissue culture dishes in serum-free
modified Chee's culture medium at a density of 0-2-
0-3 x 105 per cm2 and transfection was performed after
approximately 40 h culture. The monolayers were fed
with fresh, serum-free medium a few hours prior to
transfection. The quantities of reagents given here are
optimized for a single 1-90 cm2 culture well and were
scaled up appropriately for larger well sizes. Lipofectin
reagent (6 p\ of 1 mg/ml, Life Technologies) was diluted
into 100 p\ of serum-free, antibiotic-free culture medium
and incubated at room temperature for 45 min. This
suspension was then mixed gently with 100 //I of serum-
free, antibiotic-free medium containing purified plasmid
DNA (1 /<g), incubated for a further 45 min at room
temperature, and then made up to 300 p 1 with further
medium. Hepatocytes were incubated with the DNA-
lipid suspension for 6 h in a humid 5 per cent C02/95 per
cent air atmosphere at 37°C, after which the DNA-
containing medium was replaced with 500 p\ of standard
culture medium. Twenty-four hours after commencing
transfection, the cultures were treated with either
y-irradiation (15 Gy) or UV-c (10J/m2). Cultures were
y-irradiated by a Cs137 source at 0-33 Gy/min or UV-c-
irradiated (254 nm) after complete removal of culture
medium, using a Spectrolinker XL-1500 (Spectronics
Corporation). Unirradiated controls were otherwise
transported and handled identically.
Quantitation of P-galactosidase activity by colorimetric
assay
/J-Galactosidase activity in transfected hepatocytes
was quantified using the colorimetric Beta-
Galactosidase Enzyme Assay System with Reporter
Lysis Buffer (Promega), following the manufacturer's
instructions. The assay measures the amount of yellow
hydrolysis product (o-nitrophenol) generated from
ONPG substrate (o-nitrophyl-/?-D-galactopyranoside),
compared with a series of known standards incubated in
parallel. The negative control was untransfected hepato¬
cytes. The reaction was stopped by adding 1 m Na2C03
and the absorbance at 420 nm read by an ELISA plate
reader (MR 5000, Dynatech). To account for variability
in the number of cells recovered from each well for
estimation of //-galactosidase activity, the protein con¬
centration of each cell extract was estimated using the
Biorad Protein Assay kit. The negative control used lysis
buffer. A standard curve was constructed using a bovine
serum albumin standard solution (Biorad), diluted to
final concentrations of 1-8 /ig/ml and incubated in
parallel with the test samples. The sample absorbance
was read at 595 nm.
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Fig. 1—/J-Galactosidase activity in primary hepatocytes transfectec
with pCMV/? plasmid that constitutively expresses LacZ
p53 protein immunocytochemistry
Hepatocyte monolayers were fixed in ice cold acetone/
methanol (1:1, v/v) for 10 min and stored dry at — 80°C
Immunocytochemistry was performed using a routine
avidin-biotin complex labelling technique after blocking
of endogenous biotin using a kit (Vector Laboratories)
Cells were incubated in a humid chamber overnight al
4°C with the primary antibody [mouse monoclonal
pAb421 (Oncogene Science)] at 1/1000 dilution in 5 pei
cent serum, 0-5 per cent Tween 20, and phosphate-
buffered saline (PBS). Negative controls omitted the
primary antibody. The secondary antibody [biotinylateb
rabbit anti-mouse F(ab')2 (Dako)] was applied fo
30 min at 1/400 dilution and positive cells were visual
ized using DAB chromogen. For each observation, 30C
cells were counted and the results were expressed as the1
percentage of cells showing nuclear p53 positivity.
RESULTS
Plasmids were introduced into primary cultures oj
adult murine hepatocytes by lipofection, since this
method is efficient and there was no evidence of toxicity
with the protocol used. Transfection efficiency using
cationic liposomes was consistently between 15 and
20 per cent, as assessed on pCMV/Ltransfected cells by
estimating the proportion of stained, i.e. expressing
LacZ, cells after incubating in 1 mg/ml X-Gal, 1 mM
MgCl2, 10 mM Fe3(CN)6, 10 mM Fe4(CN)6 in PBS.
The kinetics of plasmid expression were assessed in
cells transfected with the constitutively expressing
pCMVyg plasmid. In these cells, //-galactosidase activity
was detectable by ONPG colorimetric assay within 12 h,
with relatively stable expression levels from 24 to 48 h,
slightly decreasing by 72 h (Fig. 1). Subsequent exper¬
iments on transfected cells were therefore performed
between 24 and 48 h after transfection. |
Cells transfected with the p53-reporter plasmic1
(pRGCAFosLacZ) or its control plasmid (pAFosLacZ]
showed no significant /i-galactosidase activity, equiva¬
lent to untransfected controls. However, after treatment
with 10J/m2 UV-c, there was specific induction ol
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Fig. 2—p53 reporter plasmid //-galactosidase expression following UV-c treatment of transfected primary hepatocytes. (a) p53 reporter activity
in hepatocytes following 10 J/m2 UV-c. /J-galactosidase activity is expressed relative to untreated transfected hepatocytes. (b) Effect of UV-c
treatment on //-galactosidase expression from the p53 reporter plasmid (RGCAFosLacZ), the negative control plasmid (AFosLacZ), and the
constitutive pCMV/J plasmid. Results are shown 14 h after UV-c (indicated by +); untreated controls are indicated by — . Note that a and b are
results of independent experiments
(6-galactosidase expression in cells transfected with
(the p53 reporter plasmid, peaking at about 14 h after
irradiation and subsequently decreasing to control levels
by 24 h (Fig. 2a). The activity of the negative control
plasmid remained at baseline (Fig. 2b). There was a
concomitant 37 per cent decrease in constitutive pCMVyS
/Tgalactosidase activity after UV-c irradiation (Fig. 2b).
This was due to non-specific transcriptional suppression
by UV, a well-documented effect15 that makes the
observation of increased p53-reporter gene expression
following UV injury even more significant.
Immunocytochemical analysis of the UV-treated
hepatocytes showed p53 protein accumulation in treated
cultures, peaking around 24 h after irradiation (Fig. 3).
It is noticeable that baseline p53 immunopositivity
increased slowly with time in culture. This is unex¬
plained but may reflect a 'stress response' to the culture
environment and the acquisition of undefined cellular
injuries.
By contrast to UV injury, y-irradiation produced no
significant change in expression from any plasmid, with
the p53-reporter and its control remaining at basal levels
from 2 to 24 h after irradiation (Fig. 4A), and pCMV/?
expression equivalent to unirradiation control transfect-
ants (Fig. 4B). Furthermore, there was no effect of
y-irradiation on p53 immunopositivity (data not shown),
in accord with previous in vivo findings of Midgley
et al.11
DISCUSSION
Hepatocytes and p53 after DNA injury
The present findings confirm reports that p53 protein
accumulates in hepatocytes after UV910 but not
y-irradiation11 and extend these differences to include
p53 transactivation activity. The data are supported by
100
Hours after UV (10J/m )
Fig. 3—Time course of p53 immunopositivity after treatment with
UV-c at 10 J/m2. Results are mean ± SE (n=2-4) for replicate cultures
in a typical experiment that was repeated three times with similar
findings. O, unirradiated; •. irradiated
© 1997 John Wiley & Sons, Ltd. JOURNAL OF PATHOLOGY, VOL. 183: 177-181 (1997)





































0 8 12 16 20 24
hours after y irradiation (15 Grays)
Fig. 4—/?-Galactosidase activity after 15 Gy y-irradiation. (A) □ Constitutive control plasmid (pCMV/?); (B) O,# p53 reporter
plasmid (RGCAFosLacZ); A. A negative control plasmid (AFosLacZ). Open symbols: unirradiated; solid symbols: irradiated.
MacCallum et a/.,16 who recently reported no increased
p53 transactivation activity through RGC in liver after
y-irradiation in vivo. This observation of distinct p53
transactivational and immunocytochemical responses to
two different types of DNA injury in hepatocytes is of
particular interest, since at the doses used here both
agents induce a p53-dependent growth arrest in prolif¬
erating hepatocytes, without significant apoptosis.8-9
Thus, qualitatively different stimuli act differently
through p53, yet have a common consequence.
After UV-c treatment, p53 transactivation activity
had already peaked and returned to baseline when p53
protein levels were at peak. Increased p53 transactiva¬
tional activity after UV-c is not therefore simply a
reflection of increased p53 protein levels and may be
independently regulable in hepatocytes, as suggested for
some other cell types.2-5'17-18
In contrast to UV-c, y-irradiation of hepatocytes
failed to alter reporter gene activity at a dose adequate
to arrest liver regeneration in vivo and that induces
hepatic 06-alkyl transferase expression, both by p53-
dependent mechanisms.8-19 These responses to
y-irradiation are therefore accomplished without a
detectable increase in p53 concentration or evidence of
p53-dependent transactivation. This suggests that the
basal state of p53 in hepatocytes is sufficient to permit
the responses, or that a different property of p53 is
stimulated by y-irradiation-induced DNA injury. It is, of
course, possible that the lack of reporter response merely
reflects a lower sensitivity than given by endogenous
biological activities such as growth arrest,20 but a third
intriguing possibility remains that p53 is transcription¬
ally activating genes through only a subset of its
response elements which does not include the RGC
motif. p53 binds to its response elements with different
affinities that can be changed selectively and in opposite
ways by altering its phosphorylation state.4 It would
therefore be necessary to use several reporter constructs
to assess accurately changes in p53 transactivation|
activity. Nevertheless, these results suggest that a com-j
mon p53-dependent response (i.e., growth arrest) to two
different types of DNA injury can proceed through
different activities of p53. Since p53 mutants vary in
their ability to activate specific elements,21-24 different
p53 mutations in carcinogenesis might have conse¬
quences for susceptibility to different types of DNA
damage.
Transient reporter plasmid assay for p53
The present results show for the first time that
transient transfection is a suitable method to evaluate
p53 function in normal cells after DNA damage and that
the method is sufficiently stable and reliable to be used
to provide a time course of the p53 response. Previous
studies have used stably transfected carcinoma cell lines
and have found increased p53 reporter expression after a
variety of genotoxic treatments, including UV and
y-irradiation25'26 and etoposide.18 Zhan reported a single
time point at 24 h, whilst Lutzker used pooled clones
carrying three different reporter constructs and found
expression to increase steadily over a time course of 2-12
hours after treatment. However, stable transfection is
clearly not feasible for primary culture work. Zhan el al.
did attempt transient transfection of a PGn-CAT p53
reporter plasmid, but could not demonstrate significant
1997 John Wiley & Sons, Ltd. journal of pathology, vol. 183: 177-181 (1997)
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induction of expression after the same genotoxic injuries
that produced responses in stable transfectants. This
could be due to low transfection efficiencies or to an
attenuated p53 response by the carcinoma cells to DNA
injury compared with hepatocytes, although the latter
seems unlikely given the efficient induction in stable
transfectants. Stabilization of p53 after calcium phos¬
phate transfection has been reported and might have
masked p53 responses to genotoxic treatment in their
study. No such elfect was apparent for lipofection in the
present study, with /Tgalactosidase activity at equivalent
levels in p53 reporter and control plasmid transfectants.
The relative levels of p53 reporter induction are compar¬
able to those observed using a transiently transfected
'PG13-CAT reporter to evaluate changes in p53 function
during primary keratinocyte differentiation.17 Therefore,
although potentially less sensitive than the study of
clones with a stably transfected reporter, this transient
reporter assay is adequate to evaluate authentic p53
responses to levels of DNA injury commonly applied in
studies of p53. Moreover, it can be applied to primary
and non-clonogenic cell populations, giving the power of
greater relevance to in vivo responses, combined with a
defined cellular environment.
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ABSTRACT Despite good evidence for p53 dys¬
function in human hepatocellular carcinomas, little is
known of the significance of p53 to normal hepato-
cytes and whether p53 dysfunction is relevant to early
hepatocarcinogenesis. We have therefore examined
the consequences of targeted p53 deficiency in he-
patocytes for regulation of apoptosis, proliferation,
and ploidy. p53 deficiency was silent in normal liver
and did not affect progression from diploidy to
polyploidy in the aging liver. However, in primary cul¬
ture the absence of p53 resulted in increased hepa-
tocyte proliferation indices and decreased sensitivity
to proliferation inhibition by TGF(3. Moreover, p53-
deficient cells continued to survive and proliferate
under conditions of minimal trophic support that led
to growth arrest and apoptosis of wild-type cells. In
vivo, p53-deficient mice had enhanced proliferative
responses to both xenobiotic hepatomitogen and
CCLt-induced liver necrosis, although lack of persis¬
tent proliferation showed that other control
mechanisms are important. There was no simple re¬
lationship between p53 and apoptosis after DNA
damage because UV irradiation led to p53-indepen-
dent apoptosis, even though p53 was stabilized. How¬
ever, p53 did couple DNA damage to growth arrest,
and abnormal mitoses after y-irradiation of regener¬
ating p53 null livers demonstrated circumstances
where loss of G! and G2 checkpoints may generate
abnormal ploidy. Thus p53 becomes important when
hepatocytes are released from G0 and stressed, sen¬
sitizing them to mitogen and cytokine regulators of
cell cycle progression and apoptosis. Hence p53 de¬
ficiency is likely to be significant in an environment
of persistent regenerative stimuli and unfavorable
trophic support or in the presence of other enabling
genetic lesions. This model is relevant to human
hepatocarcinogenesis, which almost always occurs
against a background of chronic hepatocellular
destruction in hepatitis and cirrhosis. In that con¬
text, by reducing the need for cytokine support and
disabling DNA damage-induced growth arrest, p53
deficiency should facilitate the expansion of preneo¬
plastic clones in chronic liver disease.—Bellamy, C.
O. C., Clarke, A. R.,Wyllie, A. H., Harrison, D.J. p53
deficiency in liver reduces local control of survival
and proliferation, but does not affect apoptosis after
DNA damage. FASEBJ. 11, 591-599 (1997)
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The p53 oncosuppressor gene product is a critical
mediator of G! cell cycle arrest and apoptosis after
DNA damage (1). These responses may protect
against replication of damaged DNA by permitting
DNA repair or deleting the affected cell. Accordingly,
loss of p53 function can result in loss of the G[ check¬
point arrest, abrogation of DNA damage-associated
apoptosis, karyotype instability, and accelerated car¬
cinogenesis. More recently, p53 has been reported to
affect G2 cycle arrest, centrosome replication, mitotic
spindle organization, and to regulate DNA repair
(see ref 1 for references). It has also become clear
that there is tissue variability in the induction of par¬
ticular p53-regulated responses. For example, after y-
irradiation, fibroblast cell lines undergo
p53-dependent Gi/S phase arrest, whereas prolifer¬
ating intestinal crypt epithelial cells undergo p53
gene dose-dependent apoptosis but growth arrest is
p53-independent (2, 3). Clearly, therefore, it is fun¬
damentally important to consider the tissue context
when evaluating the roles of p53 in suppression of
carcinogenesis. This report has investigated the roles
of p53 in the liver, specifically the hepatocyte.
Liver carcinoma is a major cause of cancer death
worldwide. Mutations in the p53 tumor suppressor
gene, usually with loss of the residual wild-type allele,
are frequent in human hepatocellular carcinomas
(HCC)2 and correlate positively with increasing his¬
tological grade of carcinoma and early recurrence,
' Correspondence: Department of Pathology, University
Medical School, Teviot Place, Edinburgh, EH8 9AG, Scotland,
UK.
2 Abbreviations: HCC, hepatocellular carcinoma; TCPO-
BOP, 1,4 bis 2-(3,5-dichloropyridyloxybenzene); TGF, trans¬
forming growth factor; EGF, epidermal growth factor; BrdU,
5-bromo-2'-deoxyuridine; FBS, fetal bovine serum.
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Figure 1. Effects of p53 genotype on hepatocyte
polyploidization assessed by flow cytometry of pro-
pidium-iodide-stained nuclei (40) from wild-type
and p53-deficient mice (18). The relative propor¬
tions of diploid (2n%), tetraploid (4 n%), and oc-
taploid (8 n%) nuclei at different ages (range 2-137
days) are depicted as Lowess plots. p53 null (—); p53
heterozygous (—); wild type ( ).
Age days
suggesting that defective p53 function is of patho¬
genic significance and confers increased clinical ag¬
gression (4, 5). Studies of intratumor heterogeneity
have suggested that p53 mutation and allele loss are
late events in human HCC, mediating tumor pro¬
gression but occurring after carcinogenesis (6). How¬
ever, several lines of evidence indicate that p53
dysfunction can precede hepatocarcinogenesis and
have a pathogenic role. First, abnormal accumulation
of p53 protein has been observed in hepatocytes of
patients with cirrhosis and liver cell dysplasia, high-
risk lesions for carcinoma development (7, 8). Sec¬
ond, exposure to aflatoxin B,, a dietary mutagen and
a cofactor in human hepatocarcinogenesis, is associ¬
ated with a characteristic point mutation in p53 (9).
This mutation has been demonstrated in nonneo¬
plastic hepatocytes, particularly in areas of high af¬
latoxin exposure where HCC is prevalent (10). Third,
dysfunctional p53 is probably more common in HCC
than is appreciated from standard genetic screens of
"hotspot" regions because of both mutation distri¬
bution (11) and functional inactivation without mu¬
tation, best characterized for chronic hepatitis B
infection. Hepatitis B virus is the major etiological
agent of human HCC: the hepatitis B X protein het-
erodimerizes with and inactivates p53 in vitro and in
vivo; in transgenic mice this is temporally and spa¬
tially associated with the development of HCC from
preneoplastic lesions, providing strong evidence that
p53 dysfunction is relevant to hepatocarcinogenesis
(12-14).
However, critical facts remain undetermined. The
normal functions of p53 in hepatocytes are unknown.
It is not known whether p53 dysfunction in nonneo¬
plastic hepatocytes can confer a selective advantage
relevant to early hepatocarcinogenesis nor how such
an advantage might be manifested—through dys-
regulation of cell cycle, apoptosis, DNA repair, or a
combination.
This study used a mouse model to examine the ef¬
fects of targeted disruption of the p53 gene in other¬
wise normal hepatocytes. In vivo observation and
primary hepatocyte culture were used to dissect out
the roles of p53 in the regulation of hepatocyte
polyploidization, proliferation, apoptosis, and the re¬
sponses to DNA damage.
RESULTS
Constitutive hepatocyte polyploidization is p53-
independent
Hepatocyte nuclear DNA content was evaluated by
flow cytometry in livers from 130 mice aged between
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2 and 137 days (42 wild-type, 50 heterozygous, and
38 p53 null) (Fig. 1). In neonatal mice, hepatocytes
were diploid. Shortly after weaning and continuing
through adult life there was a progressive increase in
the relative proportion of polyploid hepatocytes and,
concomitantly, increasing degrees of polyploidiza-
tion. However, it is evident from Fig. 1 that p53 ge¬
notype did not influence the timing, trend, or degree
of age-related hepatocyte polyploidization. Aneu-
ploidy was not detected in any sample.
p53-deficient hepatocytes are more likely to
proliferate
Before isolation for culture from quiescent adult
liver, virtually all hepatocytes are in the G0 phase
(15). The populations are thus effectively synchro¬
nized before receiving the proliferative stimulus of
isolation and primary culture. In culture, both wild-
type and p53 null hepatocytes showed a rise in BrdU
positivity from near zero at plating to a peak at 72-
96 h in culture, hut the BrdU positive fraction was
consistently greater in the null cells (Fig. 2). Thus
more null hepatocytes were cycling, but with a similar
kinetics of entry from G() to S phase as wild type. This
finding was independent of the presence ofmitogens
in the culture medium (insulin, epidermal growth
factor [EGF], fetal bovine serum [FBS]). After the
addition of mitogens, the BrdU indices of wild-type
hepatocytes were much increased (Fig. 2). By con¬
trast, the high BrdU indices of null hepatocytes were
little influenced by these factors. This suggests that
p53 null cells were more likely than wild type to pro¬
liferate but were relatively unresponsive to further
stimulation by cytokines. Responsiveness to cytokine-
induced mitosuppression was also decreased in the
p53 null hepatocytes. When incubated in high con¬
centrations of TGFp sufficient to abrogate wild-type
hepatocyte proliferation, p53 null hepatocyte prolif¬
eration was only reduced to the level of untreated
wild-type controls (Fig. 3).
To test whether these p53-dependent differences
in proliferative activity also occur in vivo, liver regen¬
eration was induced by administering a necrogenic
dose of carbon tetrachloride. This produced a
sharply defined wave of DNA synthesis in residual he¬
patocytes, as assessed by pulse labeling with BrdU,
peaking 60 h after administration of CGI,. As shown
in Fig. 4, p53 null livers had a synchronous but sig¬
nificantly greater peak ofDNA synthetic activity when
compared with wild type, concordant with in vitro
data above.
We next compared the hyperplastic responses of
wild-type and p53 null livers to a xenobiotic mito¬
gen. Such agents are well described as tumor pro¬
moters in experimental hepatocarcinogenesis. A
single dose of a nongenotoxic mitogen, 1,4 bis 2-
(3,5-dichloropyridyloxybenzene) (TCPOBOP)
(16), induced a surge of hepatocyte DNA synthesis
and mitotic activity at 3 days. This was accompanied
by an increased livenbody weight ratio that was
maintained at 23 days despite the return of BrdU
incorporation and mitotic indices to baseline levels
(Table 1). Both the mitogen-induced DNA synthe-
A B
Hours in culture
Figure 2. Effect of p53 genotype on hepatocyte DNA synthesis in primary culture. Hepatocytes were isolated from age-matched
male mice (18) by two-step retrograde perfusion (41) and Percoll purification (42), then plated onto chamber slides (Lab Tek).
Cultures were pulse-exposed to 40 pM BrdU (3 h) before ethanol fixation. BrdU incorporation (% positive of 500 cells) was
assessed by immunocytochemistry using monoclonal rat anti-BrdU IgG2a (Sera Lab). Cells were cultured in serum-free Chee's
medium with 30 nM dexamethasone (Sigma) plus no mitogen (A); 300 nM insulin (B) (Life Technologies); 300 nM insulin +
25 ng/ml epidermal growth factor (Q (EGF, Sigma, mouse submaxillary gland); 300 nM insulin + 1% fetal bovine serum (FBS)
(D). Wild type (O); p53 null (□). Mean ± sem for duplicate cultures from three mice of each genotype (n = 6).
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Figure 3. Inhibition of hepatocyte DNA synthesis by TGFJI,
assessed by BrdU immunocytochemistry (see Fig 2). Cells were
cultured in Chee's medium with 100 nM dexamethasone, 1.5
pM insulin, and 25 ng/ml EGF to which 160 pM TGFJ3 was
added after 20 h. Negative controls omitted TGFp. ,4) Wild
type; B) p53 null. Open symbols, TGFp-treated; filled symbols,
controls. Mean ± sem.
sis and the ultimate increase in liver:body weight
ratio were greater in p53 null livers compared with
wild type, showing an amplified response of the
p53-deficient hepatocytes to the TCPOBOP (Table
1). No dysplasia or foci of persistent proliferation
were apparent in any treated livers.
p53 regulates hepatocyte dependence on survival
factors in primary culture
p53-deficient hepatocytes had lower apoptotic in¬
dices in culture than wild type (Fig. 5). The lower
apoptotic indices were apparent before BrdU uptake
began and thus were not directly related to either
DNA synthesis or cell proliferation. The survival ben¬
efit conferred by p53 deficiency was greatest when
trophic support in the culture medium was least. p53
deficiency therefore reduces dependency on survival
factors, but confers little survival advantage when
these factors are not limiting and wild-type apoptotic
rates are very low anyway.
Hepatocyte responses to DNA damage
Two well-characterized genotoxic stimuli were tested:
y-irradiation and UV-c (254 nm) (17).
Gamma irradiation readily induces p53-depen-
dent apoptosis in some cell types (2, 18), but doses
of up to 15 Gy did not induce hepatocyte apoptosis
or accumulation of immunoreactive p53, either in
vivo or in proliferating primary cultures (data not
shown), confirming previous observations (19).
Since y-irradiation induces a p53-dependent
growth arrest in other cell types (1) and inhibits
liver regeneration (20), the effects of irradiation on
regenerating wild-type and p53-deficient livers
were compared. Livers were y-irradiated (15 Gy) 48
h after CC14 administration, when most hepatocytes
were in Gi, just before entry to S phase (Fig. 6A, B).
It is evident from Fig. 6A and C that irradiation of
wild-type mice suppressed both entry to S phase
(Gi/S arrest) and the subsequent passage through
mitosis at 72 h after CC14. By contrast, irradiation
of p53 null livers reduced by less and did not delay
the subsequent S phase peak of BrdU positivity
(Fig. 6B), indicating a much reduced Gi/S arrest.
The reduced peak and prolonged fall in BrdU pos¬
itivity may be due to slowed progression through
the S phase, well described after y-irradiation (21).
This was followed by a striking rise in the mitotic
index 24 h after irradiation (mitotic counts of 103,
77, and 205 compared with 15, 13, and 8 in unir¬
radiated mice) (Fig. 6D). Clearly, as well as defec¬
tive Gi/S arrest, there was no significant G2 arrest.
Many of the mitotic figures were abnormal, with
aberrant forms, isolated chromosomes, and chro¬
mosomal bridges (Fig. 7). It is therefore likely that
this mitotic peak is due to damaged hepatocytes
proceeding to and arresting within mitosis. The ex¬
cess in mitotic figures was not evident at later time
points, suggesting that the cells had undergone ei¬
ther catastrophe and elimination or delayed and
possibly aberrant completion of mitosis. Even a
slight increase in the normally brief duration ofmi¬
tosis (30-45 min) would cause the observed mitotic
index to rise considerably, as cells accumulated in
this phase. G2 arrest by wild-type livers cannot be
demonstrated in the present study because release
from the G] arrest was not observed. However, G2
arrest by regenerating rat liver after y-irradiation
has been reported (22, 23). Therefore, these ex¬
periments show for the first time that in liver, Gi
and G2 checkpoint arrests after y-irradiation are
p53-dependent.
UV irradiation of wild-type hepatocyte cultures
produced both p53 protein accumulation and dose-
dependent apoptosis (Fig. 8). However, unlike other
cell types (1, 2, 18), apoptosis was p53-independent
(Fig. 8). UV-induced apoptosis was reduced by sur¬
vival factors (insulin, serum, dexamethasone) inde¬
pendently of p53 genotype (data not shown). Like
y-irradiation in vivo, UV blocked entry of cultured
hepatocytes to S phase in a p53-dependent manner
(data not shown), confirming a previous report using
antisense p53 (24) and together demonstrating that
p53 in hepatocytes mediates growth arrest but not
apoptosis after DNA damage.
DISCUSSION
p53 sensitizes hepatocytes to cytokine regulators of
proliferation and apoptosis
There was no phenotype for p53 deficiency in un¬
stimulated livers. Differences in both proliferation































Figure 4. Liver regeneration by wild-type and p53 null mice after ad¬
ministration of carbon tetrachloride (0.5 ml CCl4/kg i.p. 5% v/v in
corn oil). Two h before killing, mice received an i.p. bolus of BrdU
labeling agent (Amersham). A) Hepatocyte BrdU incorporation as¬
sessed by immunohistochemistry (see Fig. 2) (positive cells per 20
high-power fields) at the indicated times after CC14 injury. Mean ±
SEM (three to six mice per observation). Wild type (O); p53 null (□).
B, Q Liver BrdU immunopositivity (dark-stained nuclei) 60 h after
CC14 injury to p53 null (B) and wild-type (C) mice. Hematoxylin coun¬
ters tain.
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and cell death became apparent only after hepato-
cytes were released from quiescence (G0) by culture,
xenobiotic (TCPOBOP), or CCl4-induced liver ne¬
crosis. In cells thus stimulated, p53 deficiency
increased the proportion of hepatocytes that pro¬
ceeded through S phase. Moreover, the increase in
cycling fraction was shown in culture to be relatively
independent of and unaffected by mitogens. In par¬
allel, loss of p53 reduced dependence on cytokine
support for survival. Thus, cells with no p53 were able
to survive and proliferate under conditions that
caused wild-type cells to undergo growth arrest and
apoptosis. Therefore, there is no evidence that p53
is necessary for replicative quiescence; indeed, it does
not appear to have a role in normal liver. However,
p53 DEFICIENCY IN THE LIVER
p53 becomes important once hepatocytes are re¬
leased from G0, sensitizing them to mitogen and cy¬
tokine regulators of cell cycle progression and
apoptosis.
This model is consistent with data that normal rat
hepatocytes stimulated by isolation and primary cul¬
ture (or by partial hepatectomy) progress apparently
autonomously from Gn to mid-G], but are critically
dependent on mitogens for further progression
through the cell cycle (25). The passage from G0 to
G, has been defined in hepatocytes by the sequential
expression of certain oncogenes, ending with p53
expression in mid-late Gi (26). Although no signifi¬
cance has been previously ascribed to this physiolog¬
ical elevation of p53 during liver regeneration, the
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TABLE 1. Effect ofp53 genotype on hepatic responses to a xenobiotic mitogen (TCPOBOPf
3 days after treatment 23 days afte r treatment
Corn oil TCPOBOP Corn oil TCPOBOP
BrdU index (% of 700 cells counted) Wild type 0.32 (0.13) 8.25 (0.13) 0.23 (0.19) 0.07 (0.04)
p53 null 0.57 (0.24) 14.7 (2.91)* 0.13 (0.06) 0.04 (0.04)
Liver/body wt (%) Wild type 5.51 (0.18) 8.82 (0.51) 5.52 (0.12) 9.80 (0.43)
p53 null 5.41 (0.40) 8.61 (0.49) 5.65 (0.37) 11.17 (0.70)
"Adult male mice were given an i.p. bolus of 3 mg/kg 1,4 bis 2-(3,5 dichloropyridyloxybenzene) (TCPOBOP) in corn oil. BrdU labeling
agent (Amersham) was administered i.p. 18 h before mice were killed. BrdU immunopositivity (% of 700 hepatocytes) was assessed on methanol-
fixed tissue sections (see Fig 2. legend). Mean (sem), for 3-5 mice per observation. * Significantly greater than wild type (P = 0.04, Mann
Whitney test).
present results suggest that p53 is a critical effector
of the mitogen restriction point. Absence of p53 dis¬
ables the restriction, allowing appropriately stimu¬
lated hepatocytes to cycle independently ofmitogens.
The reduced ratio between peak labeling and mi¬
totic indices in p53 null mice compared with wild
type suggests a prolonged S phase and/or G2 phase
in the regenerating p53-deficient hepatocytes. Al¬
though this is not a well-recognized feature of p53
deficiency, we have also observed a prolongation of
S phase in p53-deficient embryonic stem cells com¬
pared with wild type (S. Prost et al., unpublished re¬
sults).
After liver regeneration, cytokines are believed to
be important in order to stop hepatocyte prolifera¬
tion, and TGFp is perhaps the most potent (27).
However, although loss of p53 made cultured he¬
patocytes less responsive to TGF(3 mitoinhibition,
regenerating p53-deficient livers in vivo did not
show abnormally persistent proliferation. There¬
fore, mechanisms other than TGFp are important to
terminate proliferation in vivo. p53 probably sensi¬
tizes hepatocytes to cell cycle inhibition by TGFp
through cooperative activation of p21 (28). The po¬
tential for p21 to inhibit liver growth has been
shown in mice with a liver-specific p21 trans-
gene (29).
In hepatocytes, p53 couples DNA damage to growth
arrest but not apoptosis
p53-coupled genotoxic injury of hepatocytes to
growth arrest and the finding of abnormal mitoses
after y-irradiation of regenerating p53 null livers
demonstrated circumstances where the loss of cell cy¬
cle checkpoints may generate abnormal ploidy. By
contrast, there was no simple relationship between
p53 and apoptosis after DNA damage, since UV ir¬
radiation led to p53-independent apoptosis even
though p53 was stabilized. The induction in hepa¬
tocytes of the DNA repair enzyme Oe-alkyl guanyl

























Figure 5. Hepatocyte apoptosis in culture (% of 500 cells), assessed on Feulgen-stained hepatocyte monolayers. Cells were
cultured in Chee's medium with 30 nM dexamethasone plus unsupplemented (A); 300 nM insulin (B); 300 nM insulin + 25
ng/ml EGF (C); 300 nM insulin + 1% FBS (Z>). Mean + SEM for duplicate cultures from three mice of each genotype (n = 6).
Key: wild type (O); p53 null (□).
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Figure 6. Effects of 15 Gy y-irradiation on DNA synthesis (A,
B) and mitotic activity (C, D) by regenerating wild-type and
p53 null livers. Mice given CC14 at time zero (see Fig. 4) were
y-irradiated or mock-irradiated 48 h later. Mitotic activity (per
20 high-power fields) and BrdU incorporation (see Fig. 4)
were assessed on hematoxylin-stained tissue sections; mean ±
SEM (three to five) mice per observation). The large error bar
for the mitotic count of unirradiated null mice at 48 h is due
to a single exceptional animal and is unexplained. Other an¬
imals at this time point had mitotic counts of 10 or below.
Wild-type unirradiated (O); irradiated (•); p53 null
unirradiated (□); irradiated (■).
dependent (30); taken together, these data suggest
that in hepatocytes p53 facilitates cellular rehabilita¬
tion rather than deletion after DNA injury, in con¬
trastwith cell types such as intestinal crypt epithelium
(2), thymocytes (18), and splenocytes (19). These ob¬
servations provide further evidence that apoptosis
and cycle arrest mediated by p53 are independent
pathways, and illustrate the tissue specificity of differ¬
ent p53-dependent responses. Moreover, the finding
that hepatocyte apoptosis after DNA damage is not
regulated by p53 suggests the existence of apoptotic
pathways under different genetic control, but may
also have relevance to tumor suppression and rep¬
resent better targets for novel cancer chemothera-
peutic strategies. The observation that cytokines
reduced apoptosis induced by DNA damage also has
implications for genotoxic drug therapy of liver neo¬
plasms, suggesting a utility for cytokines to either ma¬
nipulate tumor cell chemosensitivity or promote
normal cell survival. Similar observations have been
made in other systems (31, 32).
Thus, p53 assists hepatocytes sustaining DNA dam¬
age to recover from the genotoxic injury through
growth arrest if they are proliferating, and perhaps
by enhancing repair activity, but other factors (in¬
cluding the type of injury, the cytokine environment,
and perhaps other genes) regulate cell death.
Control of liver ploidy
Polyploidization is a feature of normal postnatal liver
development (33), but neither the purpose nor the
regulation of this irreversible process is well under¬
stood (34). The finding that p53 genotype did not
affect the progression from diploid to polyploid in
the aging liver is in keeping with the model presented
that p53 has no role in unstimulated hepatocytes, but
does not exclude a role for a p53-dependent pathway
in determining altered polyploidization after DNA
damage. Indeed, hepatocyte polyploidization in¬
creases after y-irradiation (35), and ERCCl-deficient
mice that are defective in DNA repair show persistent
p53 accumulation in hepatocytes and develop abnor¬
mal liver polyploidy (36). The relationship of poly¬
ploidy to aneuploidy is not well defined, but present
findings that p53 deficiency might allow generation
of abnormal hepatocyte ploidy after DNA injur)' sug¬
gest it will be of interest to compare polyploidization
responses to DNA damage of wild-type and p53-defi-
cient livers.
Implications for hepatocarcinogenesis
In a permissive environment p53-deficiency allows
sustained survival, increased proliferation, and im¬
paired damage responses that could accelerate car¬
cinogenesis. Hepatitis B X protein and aflatoxin
interact directly with the p53 protein and gene, re¬






















Figure 7. Mitotic activity of regenerating p53 null liver after y-
irradiation at 72 h after CC14 (24 h after 15 Gy y-irradiation).
Note the large number of mitotic figures, many of which are
abnormal. Dark staining nuclei are BrdU-immunopositive. In¬
set: abnormal mitotic figure, with chromosomal bridges visi¬
ble. Hematoxylin counterstain.
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Figure 8. UV irradiation of primary hepatocyte cultures. A) p53 immunopositivity after 10J/m2 UV-c. Immunocytochemistry was
performed on acetone/methanol-fixed cultures using pAb421 (Oncogene Science). B) Dose response of apoptosis evaluated 72
h after UV irradiation. Q Time course of apoptosis after 50J/m2 UV-c. Cells were cultured in Chee's medium with 100 nM
dexamethasone, 1.5 |UM insulin, 2% FBS. Wild-type unirradiated open circle; irradiated (O); p53 null unirradiated (□); irradiated
(■).
early human hepatocarcinogenesis that this study
has sought to identify. The results show that p53
has an important modulatory role on both prolif¬
eration and cell death, but only when the hepato¬
cyte is released from G0 or stressed (for example,
by reduction of trophic support). Hence, p53 is
likely to become important under disease condi¬
tions of chronic stimulation to proliferate and re¬
duced trophic support wherein p53-deficient
hepatocytes are likely to survive and outgrow p53-
competent neighbors. These observations are of
particular relevance to human hepatocarcinogen¬
esis, which almost always occurs on a background
of chronic liver damage and compensator)' regen¬
eration, and could explain selection for p53 dys¬
function in clones of hepatocytes in an unfavorable
environment within inflamed liver.
Perhaps it is not surprising therefore that there is
no increased frequency of hepatocellular carcinoma
in untreated or single dose chemical carcinogen-
treated p53 heterozygous and homozygous deficient
mice (37, 38). Such models do not produce the
chronically disturbed hepatic environment that pre¬
cedes by decades virtually all human hepatocellular
carcinomas and that is probably necessary to manifest
the otherwise latent phenotype of p53 dysfunction
described here. A more appropriate model might be
to evaluate the effects of a cross between p53-defi-
cient and hepatitis B surface antigen transgenic mice.
The latter develop a chronic necroinflammatory hep¬
atitis, with regenerative hyperplasia in high producer
lineages that leads eventually to development of he¬
patocellular carcinoma (39). ngj
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